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Summary 
Cellular growth is the accumulation of mass by a cell. This is required in order to 
ensure the maintenance of cell size upon cell division. As the majority of the dry 
mass of a cell is protein, protein synthesis is essential for cellular growth. RNA 
Polymerase III (Pol III) is crucial for protein synthesis as it transcribes the genes 
encoding 5S ribosomal RNA and the tRNAs – key components of the translation 
machinery. As a consequence, Pol III plays an important role on cell growth and 
proliferation. Pol III-mediated transcription is highly regulated. Cellular stress 
usually results in decreased Pol III-mediated transcription, while increased 
transcription occurs following exposure of cells to mitogens. Understanding how 
Pol III is regulated is particularly important as loss of regulation is associated 
with cancer, where Pol III-associated transcription factors and Pol III products 
are frequently found highly expressed. In this thesis, the role of p53, AP-1 and c-
Jun N-terminal kinases (JNKs) in the regulation of Pol III-mediated transcription 
in humans is examined. 
p53 is induced in response to stress and modulates the expression of a vast array 
of target genes. p53 represses Pol III-mediated transcription by binding to the 
Pol III-specific transcription factor TFIIIB and inhibiting polymerase recruitment 
to Pol III-target genes. In Chapter Three, it is demonstrated that repression of 
Pol III-mediated transcription is not the universal response to p53 upregulation. 
Treatment with the chemotherapeutic drug doxorubicin induces p53 robustly, 
and results in rapid reduction in tRNA levels but this is not dependent upon the 
presence of p53. Indeed, it is demonstrated that stress does not always result in 
the repression of Pol III-mediated transcription. Exposure of cells to ultraviolet 
light leads to an increase in tRNA levels. This demonstrates the complexity of 
the regulation of Pol III-mediated transcription in response to stress. 
Together, c-Jun and c-Fos produce one form of the transcription factor AP-1. AP-
1 mediates cell proliferation and cell death in response to mitogenic stimuli and 
stress via the binding and activation of target genes. c-Jun and c-Fos have been 
found binding Pol III target genes. In Chapter Four, their occupancy at tRNA 
genes is examined in detail and found to be associated with active genes. While 
AP-1 binding motifs are found at a subset of tRNA genes, this is not found to be 
associated with c-Jun or c-Fos occupancy. Instead, recruitment to tRNA genes 
 
 
3 
 
may occur via the association with Pol III-specific transcription factors that is 
observed. 
JNKs can regulate Pol III-mediated transcription by altering the level of the Pol 
III-specific transcription factor TFIIIB. JNKs also phosphorylate and activate c-Jun 
and other transcription factors, such as STAT1 and ATF2, found at Pol III target 
genes. The role of these transcription factors at tRNA genes has not been 
determined. However, in Chapter Five, it is demonstrated that JNKs may 
regulate Pol III-mediated transcription independently of regulating TFIIIB levels. 
Treatment of U2OS cells with a JNK inhibitor results in rapid reduction of tRNA 
levels resulting from reduced expression of tRNA genes. However, the levels of 
TFIIIB subunits TBP and Brf1 are unaffected. It is examined whether this effect 
may occur through a JNK target at tRNA genes or via another possible route, 
such as the phosphorylation of the Pol III machinery by JNK.  
Data in Chapters Four and Five suggest c-Jun and JNK may positively regulate Pol 
III-mediated transcription. This is consistent with their activation by mitogens, 
as more Pol III products are required for increased cell growth and proliferation. 
In conclusion, the data highlights the many pathways that converge to regulate 
Pol III-mediated transcription, and the complexity that arises as a consequence 
of this. 
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1 Introduction 
1.1 Transcription in eukaryotes  
Transcription is essential to convert information encoded in a genome to 
functional products. It is the process by which DNA is ‘read’ and an RNA copy is 
made. RNA is then translated to protein, which is required for all cellular 
processes, or RNA may function directly without a protein intermediary. 
Together, transcription and translation are the key steps of protein synthesis. In 
eukaryotes, transcription usually starts at a transcription start site (TSS) at the 
beginning of a gene. This transcription start site is defined by the DNA sequence 
and, with the assistance of additional factors, is recognised by a DNA-dependent 
RNA polymerase. Once correctly positioned, the polymerase can initiate 
transcription. Following initiation, transcription moves into the elongation 
phase, catalysing the incorporation of ribonucleotides complementary to the 
DNA being read, and is finally terminated at a defined site. The RNA product is 
then released from the polymerase. RNAs encoding proteins (mRNAs) are then 
transported from the nucleus to the cytoplasm where they can be translated. 
mRNAs are translated by the ribosome, where transfer RNAs (tRNAs) decode the 
mRNA to allow the incorporation of amino acids in the correct order to produce 
the protein. 
Prokaryotes have a single, multisubunit RNA polymerase. In eukaryotes, where 
the task of transcription has been divided, three major RNA polymerases (RNA 
Polymerases I, II and III) have evolved. These all contain subunits homologous to 
each of the five subunits of the bacterial RNA polymerase (Werner and 
Grohmann, 2011). RNA Polymerase II (Pol II) transcribes all protein-coding genes 
and most microRNA and snRNA (small nuclear RNA) genes [reviewed in (Baumann 
et al., 2010)]. RNA Polymerase I (Pol I) targets multiple copies of a single gene 
only, the ribosomal RNA gene that encodes 45S pre-rRNA which is then processed 
to produce three of the four RNA components of the ribosome, 28S, 18S and 5.8S 
[reviewed in (Russell and Zomerdijk, 2005, McStay and Grummt, 2008)]. RNA 
Polymerase III (Pol III) produces the fourth ribosomal RNA (5S rRNA), transfer 
RNAs (tRNAs) and a range of other short non-coding RNAs [reviewed in (White, 
2002, Schramm and Hernandez, 2002)]. In plants, two additional nuclear 
polymerases have been identified, RNA Polymerases IV and V (Haag and Pikaard, 
Chapter 1: Introduction   
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2011). These are related to RNA Polymerase II and produce non-coding RNA 
transcripts involved in gene silencing (Haag and Pikaard, 2011). In addition, 
eukaryotic cells contain a RNA polymerase responsible solely for transcription of 
the mitochondrial genome [reviewed in (Arnold et al., 2012)].  
1.2 Pol III targets and their roles in the cell 
The majority of genes transcribed by Pol III can be described as ‘housekeeper 
genes’. They play essential roles in the cell including translation, RNA processing 
and protein localisation. In total, their transcription is estimated to account for 
over 10% of transcription in the nucleus (White, 2001). However, the exact 
amount will vary depending upon the state of the cell. Pol III-transcribed genes 
are located throughout the human genome. All genes transcribed by Pol III 
encode non-coding RNAs, RNAs that do not encode a protein but are themselves 
structurally or catalytically functional. The majority of these RNAs are less than 
300nt in length (White, 2008). Below the Pol III products are described, focussing 
on those that we will encounter again later in this thesis. 
1.2.1 tRNAs 
tRNAs are essential components of the translation machinery, providing the link 
between the mRNA and the growing polypeptide. Their complex secondary 
structure is often visualised as a ‘cloverleaf’ structure (Figure 1.1). Further 
folding results in an L-shape tertiary structure. The anticodon loop contains the 
three bases that form the anticodon. This recognises a complementary codon in 
mRNA. The correct amino acid is loaded onto the acceptor stem of the tRNA by a 
tRNA synthetase. tRNAs are between 75 and 90bp in length and there are 516 
genes encoding functional tRNAs in the human genome (as annotated in the 
Genomic tRNA Database, hg18 (Chan and Lowe, 2009)). tRNAs are found on every 
chromosome except the Y chromosome. They can be divided into groups based 
on the amino acid they bind and the anticodon they contain. For example, a 
tRNA with the anticodon AAG and a tRNA with the anticodon CAG are of the 
same isotype as they both bind leucine. However, they are from different 
isoacceptor classes as they have different anticodons and thus recognise 
different codons (CUU and CUG respectively). There are tRNA genes representing 
51 isoacceptor classes in the human genome. The multiple genes present for 
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many isoacceptor classes add further complexity. These genes can have 
different internal sequences (despite having the same anticodon). Transcription 
of tRNA genes results in pre-tRNAs that require much additional processing to be 
functional. This includes removal of the 5’ and 3’ flanking sequences, addition of 
CCA to 3’ end and modification of multiple residues (Hopper and Phizicky, 2003). 
Some tRNA genes also have introns, adding an additional splicing step to their 
processing.  
 
 
Figure 1.1  The tRNA secondary structure  
Schematic of the secondary structure of a human tRNAi
Met.  The functional domains 
include the acceptor stem which binds to the amino acid and the anticodon which 
recognises the complementary codon in the mRNA. Predicted tRNA structure from 
Genomic tRNA Database (Chan and Lowe, 2009) 
1.2.2 5S ribosomal RNA 
5S rRNA is a component of the large subunit of the ribosome, and is thus 
required in equimolar quantities to the other ribosomal RNAs, 28S, 18S and 5.8S  
(produced by Pol I) (Phillips and McConkey, 1976). The ribosomal RNA carries out 
most of the structural and functional role of the ribosomes, while ribosomal 
proteins stabilise the ribosome core (Moore and Steitz, 2002). In humans, there 
are approximately 200-300 5S rRNA genes present in tandem repeats (Lander et 
al., 2001, Stults et al., 2008). They are highly conserved and have proved 
difficult to map accurately due to their repetitive nature (She et al., 2004). A 
role for 5S rRNA in ribosome biogenesis stress signalling has recently been 
identified (Li and Gu, 2011, Donati et al., 2013). 
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1.2.3 U6 snRNA 
U6 is one of the small nuclear RNAs (snRNAs) that form the RNA portion of the 
spliceosome, a ribonucleoprotein complex that is required to remove introns 
from mRNAs (‘splicing’) (Will and Lührmann, 2011). The other four small nuclear 
RNAs in the spliceosome, U1, U2, U4 and U5, are products of Pol II. Nine full-
length U6 genes exist in the human genome (Domitrovich and Kunkel, 2003).   
1.2.4 7SL 
7SL RNA forms the scaffold of the signal recognition particle (SRP) to which the 
six protein subunits of the SRP bind (Walter and Blobel, 1982). The SRP 
recognises the signal peptide in newly synthesised polypeptides and facilitates 
their insertion into the endoplasmic reticulum [reviewed in (Nyathi et al., 
2013)]. As such, it is essential for ensuring correct localisation of many proteins. 
Three 7SL genes are present in the human genome, all located on the long arm 
of chromosome 14. 
1.2.5 SINEs 
Short interspersed nuclear elements (SINEs) are DNA sequences derived from Pol 
III-transcribed genes. These elements became dispersed throughout the genomes 
of mammals via retrotransposition. The most abundant SINEs in humans are Alu 
family, derived from the 7SL gene (Jelinek et al., 1980). Over 1 million Alus are 
present in the human genome (Lander et al., 2001). Their number means that 
they are capable of sequestering a large pool of the Pol III machinery. Under 
normal conditions, Alus are transcribed at low levels, and this has been observed 
to increase following stress (Paulson and Schmid, 1986, Liu et al., 1995, Rudin 
and Thompson, 2001). Alus were originally considered to be ‘junk’ DNA, with no 
function. They have now been shown to have roles in the heat-shock response, in 
the regulation of alternative splicing, in translational control and in disease 
(Mariner et al., 2008, Sorek et al., 2002, Chu et al., 1998, Kaneko et al., 2011). 
Alus are unique to primates, however other SINEs are found in other organisms. 
For example, B1 and B2 elements, in mice, are derived from a 7SL and a tRNA 
gene respectively (Labuda et al., 1991, Daniels and Deininger, 1985). 
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1.2.6 Other Pol III-transcribed cellular genes 
There are many other Pol III-transcribed genes, in addition to those described 
above. H1 RNA is part of RNase P, a particle required for processing of the 5’ 
end of pre-tRNAs (Bartkiewicz et al., 1989). rRNA processing requires RNase MRP 
which contains with RNAse MRP RNA, a Pol III product (Gold et al., 1989). 
Another Pol III product is 7SK. 7SK regulates the elongation step of Pol II-
dependent transcription via its interaction with the elongation factor P-TEFb 
(Nguyen et al., 2001, Yang et al., 2001).  Vault RNAs are also Pol III transcribed. 
They form part of the large ribonucleoprotein vault complexes that are 
implicated in multidrug resistance (Mossink et al., 2003).  
1.2.7 Virus-encoded Pol III-transcribed genes  
Several viral genes have evolved to exploit the Pol III transcription machinery. 
These include those encoding VA-1 which is found in all adenovirus serotypes and 
EBER1 and EBER2 of the Epstein-Barr virus (EBV). VA-1 is approximately 160 
nucleotides long and promotes the translation of viral mRNA in late stages of 
viral infection, when it is highly expressed (Thimmappaya et al., 1982). The VA-1 
promoter has been frequently used as a reporter for in vitro Pol III activity 
studies. EBER1 and EBER2 are highly expressed following EBV infection of B 
lymphocytes (Arrand and Rymo, 1982). Like VA-1, EBER1 and EBER2 contribute to 
translation of the viral mRNA, subverting translation of host cell mRNA (Rosa et 
al., 1981).  
1.3 Mechanism of Pol III-mediated transcription 
Like all transcription, RNA Polymerase III-mediated transcription can be divided 
into initiation, elongation and termination steps. Initiation is dependent upon a 
promoter sequence to recruit Pol III-specific transcription factors, which can in 
turn recruit the polymerase. Elongation is the process of transcribing the 
remainder of the gene, which in Pol III is very short and hence this is not a 
lengthy step. Termination of transcription occurs when the polymerase reaches a 
short run of thymine residues. 
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1.3.1 Promoter types 
Pol III-transcribed genes in humans can be divided into three groups based on 
promoter type [reviewed in (White, 2002, Schramm and Hernandez, 2002, Dieci 
et al., 2007)]. The promoter sequences of type 1 and 2 promoters are within the 
transcribed region (Figure 1.2). Type 2 promoters are most common as they are 
found in all tRNA genes (except tRNASelCys) and other genes, including 7SL and 
VA-1. The type 2 promoter consists of conserved A and B boxes located 
downstream of the transcription start site (TSS), typically separated by 30-40bp. 
5S genes are the only genes with type 1 promoters, which also consist of pair of 
conserved motifs, A box and C box, with an additional sequence, the 
intermediate element (IE), between them. In contrast, type 3 promoters, such 
as that of U6, are more similar to protein-coding genes with an external 
promoter upstream of the TSS which includes a TATA-box, a proximal sequence 
element (PSE) and a distal sequence element (DSE). Variations exist within these 
three types, for example the EBER2 gene has a TATA box and A and B boxes.  
 
Figure 1.2  Promoter types of Pol III target genes 
The diagram above illustrates the main promoter types of genes transcribed by Pol III. 
Some variations on these promoter types have been described. Transcribed region of 
gene indicated by blue box. +1 denotes the transcription start site. TTTT represents the 
site of termination (the number of thymine residues is variable). Approximate positions 
of promoter elements are shown as coloured boxes with element name stated beneath. 
IE = intermediate element, DSE = distal sequence element, PSE = proximal sequence 
element, TATA = TATA box. Adapted from (Schramm and Hernandez, 2002). 
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1.3.2 Pre-initiation complex formation 
The promoter structure of a gene determines how the Pol III-specific basal 
transcription factors are recruited. Basal transcription factors, together with the 
polymerase, form the pre-initiation complex (PIC) at the transcription start site 
[reviewed in (Schramm and Hernandez, 2002, White, 2002)]. PIC formation is 
essential for transcription to begin. 
At type 1 and 2 promoters, PIC formation requires the recognition of the internal 
promoters by TFIIIC, a multisubunit basal transcription factor (Figure 1.3). In 
type 1 promoters, this recognition is aided by the binding of the zinc-finger 
protein TFIIIA to the intermediate element. Once TFIIIC is positioned on the 
DNA, it positions TFIIIB just upstream of the TSS. TFIIIB then recruits Pol III to 
the transcription start site. In type 3 promoters, a variant TFIIIB (see below), 
binds at the TATA box upstream of the transcription start site and a multisubunit 
complex, SNAPc, binds at the PSE. Together they recruit Pol III. Oct-1 and STAF 
bind at the distal sequence element (DSE) and promote PIC formation.  
TFIIIB All Pol III target genes require TFIIIB for successful polymerase 
recruitment. In vitro transcription can be driven from a minimal PIC of TFIIIB and 
Pol III alone at artificial promoters (Kassavetis et al., 1990), highlighting TFIIIB’s 
central role in Pol III-mediated transcription. TFIIIB is a complex of three 
independent subunits, TBP, Bdp1 and Brf1 or Brf2 (Figure 1.4). TBP, the TATA-
binding protein, is required for the activity of Pols I, II and III. However, binding 
to a TATA box is not always required. A TBP mutant that cannot bind the TATA 
box is still functional in Pol III-mediated transcription (Bryant et al., 1996). Brf1, 
TFIIB-related factor 1, is, as its name suggests, related to the Pol II basal 
transcription factor TFIIB. At genes with type III promoters, Brf2 is present 
instead of Brf1 in TFIIIB (Teichmann et al., 2000, Schramm et al., 2000). Similar 
to Brf1, it has an N-terminal zinc binding domain and a core domain related to 
TFIIB (Schramm and Hernandez, 2002). However, it lacks two conserved domains 
present in the C-terminus of Brf1. The third subunit of TFIIIB is Bdp1, B double 
prime 1. In yeast, it is only loosely bound to the stable TBP-Brf1/2 complex in 
the absence of a DNA template (Huet et al., 1994).  
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Figure 1.3  Pre-initiation complex formation at three Pol III promoters  
Different Pol III pre-initiation complexes (PIC) form at the three promoter types.  At 
type 1 promoters, TFIIIA binds to the promoter which includes the intermediate element 
(IE) and promotes TFIIIC recruitment. TFIIIB is then recruited, followed by recruitment 
of the polymerase. At type 2 promoters, TFIIIC binds directly to promoter sequence. 
This is followed by TFIIIB and Pol III recruitment as at type 2 promoters. At type 3 
promoters, TFIIIB binds the TATA box (TATA) and the SNAPc complex binds the proximal 
sequence element (PSE). Pol III is then recruited to the transcription start site (+1). Oct-
1 and STAF bind at the distal sequence element (DSE) and promote PIC formation.  
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TFIIIC TFIIIC consists of six subunits, TFIIIC220, TFIIIC110, TFIIIC102, TFIIIC90, 
TFIIIC63 and TFIIIC35 (Figure 1.4). Unlike TFIIIB, it has no direct relatives at 
other polymerases. It consists of two main subdomains, each recognising the A 
and B box, linked by a flexible linker (TFIIIC90) (Schramm and Hernandez, 2002). 
These subdomains contain TFIIIC220 which binds the B box and TFIIIC63 which 
binds the A box. TFIIIC102, TFIIIC90 and TFIIIC63 interact with TFIIIB. TFIIIC220, 
TFIIIC110 and TFIIIC90 have intrinsic histone acetyltransferase (HAT) activity 
which may contribute to gene activity (Hsieh et al., 1999a, Hsieh et al., 1999b, 
Kundu et al., 1999).  
 
Figure 1.4 The subunits of TFIIIB and TFIIIC in the pre-initiation complex 
The Pol III-specific transcription factors TFIIIB (dark blue) and TFIIIC (red) consist of 
multiple subunits with different binding and functional properties. Their relative 
positions at a type 2 promoter are depicted above. TFIIIC63 and TFIIIC220 bind to the A 
and B box motifs respectively. TFIIIC110 is associated with the terminator sequence 
(TTTTT) while TFIIIC90 acts as a flexible linker bridging the two subdomains of TFIIIC. 
TFIIIB subunits TBP, Brf1 and Bdp1 are positioned upstream of TFIIIC and recruit Pol III.  
Recent ChIP-seq analysis, chromatin immunoprecipitation followed by deep 
sequencing of the associated chromatin, has provided data for Pol III machinery 
occupancy at all annotated Pol III target genes in the human genome (Oler et 
al., 2010, Raha et al., 2010, Moqtaderi et al., 2010, Barski et al., 2010, Canella 
et al., 2012). It confirms PIC formation models at different promoter types, as 
determined originally in vitro, are correct. For example, Brf1 and Brf2 
occupancy is mutually exclusive, Brf1 occupying genes with type 1 and type 2 
promoters and Brf2 at type 3 promoters (Moqtaderi et al., 2010, Oler et al., 
2010). In Saccharomyces cerevisiae nearly all annotated Pol III target genes are 
occupied by Pol III (Moqtaderi and Struhl, 2004, Roberts et al., 2003, Harismendy 
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et al., 2003). However, in humans, many Pol III target genes are not occupied by 
Pol III, for example, in HeLa cells only approximately 50% of tRNA genes have Pol 
III present (Oler et al., 2010). TFIIIB occupancy and Pol III occupancy are highly 
correlated indicating TFIIIB recruitment is the rate-limiting step in PIC formation 
(Oler et al., 2010, Moqtaderi et al., 2010).  
1.3.3 Initiation 
Upon formation of the pre-initiation complex, transcription may begin. The 
polymerase unwinds the double stranded DNA, forming a transcription bubble in 
which the template strand is accessible (White, 2002). The polymerase then 
‘reads’ the template strand, incorporating ribonucleotides to begin a RNA 
molecule of complementary sequence.  While TFIIIB initially ensures Pol III is 
positioned correctly at the TSS, Pol III is released from TFIIIB as the transcription 
bubble moves along the gene (Kassavetis et al., 1990).  
1.3.4 Elongation and termination 
In comparison with PIC and transcription bubble formation, the rate-limiting 
steps in Pol III-mediated transcription, elongation and termination are very short 
and have minimal impact on the rate of Pol III-mediated transcription (White, 
2002).  Unlike Pols I and II, elongation requires no accessory factors, maybe 
because the transcribed region is so short (White, 2002). The end of the region 
to be transcribed is marked by a short run of thymine residues in the non-
template strand of the DNA at which the polymerase pauses. The mechanism of 
termination has only recently been determined (Nielsen et al., 2013). Once 
paused, Pol III backtracks until it reaches a hairpin in the newly synthesised RNA, 
at which point the RNA is released. The polymerase is then recycled back to the 
promoter, allowing repeated rounds of transcription that occur more quickly 
than the initial round (Dieci et al., 2013).  
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1.4 Regulation of Pol III-mediated transcription 
Cellular growth, or the accumulation of mass, is required with each cell cycle in 
order to maintain cell size. This includes the duplication of organelles, which is 
required to ensure two functional daughter cells are produced. The majority of a 
cell’s dry mass is protein and cell growth is directly proportional to protein 
synthesis (Baxter and Stanners, 1978). Consequently, cell proliferation is also 
proportional to protein synthesis, except in cases where cell growth and 
proliferation are uncoupled, such as in terminally differentiated neurons and 
muscle cells (Conlon and Raff, 1999). In order to increase the rate of cell 
growth, as occurs following mitogenic signals, more protein synthesis is 
required. This depends upon increased ribosome biogenesis, thus regulation of 
rRNA synthesis (by Pol I and Pol III) is important for cell growth (Camacho et al., 
1990, Ruggero and Pandolfi, 2003). Other Pol III products also play key roles in 
protein synthesis, including the tRNAs in translation and U6 and MRP RNA in 
mRNA and rRNA processing respectively. An increase in Pol III activity is, 
therefore, required for cell growth. Similarly, when growth is arrested, as occurs 
in times of reduced nutrient availability and other stresses, continued Pol III-
mediated transcription would waste vital resources. It is well established that 
serum induces Pol III-mediated transcription and reduced nutrients and 
mitogenic signals have the opposite effect (Clarke et al., 1996, Johnson et al., 
1974, Mauck and Green, 1974). Pol III activity also changes during the cell cycle, 
with reduced activity during mitosis and early G1 (Gottesfeld et al., 1994, White 
et al., 1995).  
In the past, the regulation of Pol III-mediated transcription has been considered 
to modulate the transcription of all Pol III target genes in unison, based upon the 
environment the cell finds itself in. This was a reasonable assumption to make, 
as the Pol III products have related functions and, as described below, several 
mechanisms by which they are regulated target factors shared by all, such as 
TFIIIB. However, with the advent of microarray, ChIP-seq and RNA-seq,  it has 
become apparent that more specific regulation of Pol III target genes may also 
occur (White, 2011). Differences in the promoter structure (and consequently 
the basal transcription factors involved) may account for this to some extent. 
However, it does not tell the whole story. In S. cerevisiae all 186 tRNA genes are 
occupied by Pol III, suggesting they are being actively transcribed (Harismendy 
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et al., 2003, Roberts et al., 2003, Moqtaderi and Struhl, 2004). However, in 
human cells approximately half are occupied by Pol III at any one time and the 
tRNA expression profiles vary between cell types (Raha et al., 2010, Moqtaderi 
et al., 2010, Oler et al., 2010, Barski et al., 2010, Dittmar et al., 2006).  
The regulation of Pol III-mediated transcription has been the subject of many 
studies because aberrant cell growth is associated with several diseases 
including, most notably, cancer. In cancer cells, normal control over cell 
proliferation is overcome, allowing cells to divide with reduced restraint. For 
this uncontrolled division to persist, cell growth is also required. Pol III products 
have been found upregulated compared to normal samples in many tumours. 
Winter et al. found increased tRNA levels in ovarian tumour samples, while Chen 
et al. found 7SL upregulated in 31 of 39 breast cancer tumours when compared 
to normal tissue (Winter et al., 2000, Chen et al., 1997). Staining of a tumour 
microarray for tRNAi
Met, the tRNA that binds the initiator methionine required to 
begin translation, showed that it was at high levels in breast tumours, lymphoma 
and other tumour types (Noor Nam, unpublished data). Many regulators of Pol III-
mediated transcription, as described below, are deregulated during cancer 
development. This may account for the high levels of Pol III products which 
contribute to the increased cell growth and proliferation in cancer cells 
compared to normal cells (White, 2008). It is currently unclear whether high Pol 
III products are a cause or a consequence of cancer. Further work to understand 
the regulation of Pol III-mediated transcription may provide a solution to this.  It 
will certainly contribute significantly to our understanding of cell growth and 
related diseases.  
1.4.1 Mechanisms of regulating Pol III-mediated transcription 
Pol III-mediated transcription is predominantly regulated at the initiation step as 
this is the rate-limiting step in transcription. Unlike Pol II target genes, the short 
length of Pol III genes and the lack of requirement for specific elongation factors 
mean the elongation step an inefficient target for regulation (Shilatifard, 2004). 
Regulation at the initiation step occurs through a variety of mechanisms and can 
involve many mediators.   
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1.4.1.1 Regulation of Pol III transcription machinery levels 
Pol III-mediated transcription requires sufficient levels of the specific Pol III 
transcription factors and the polymerase itself. As such, these levels must be 
modulated in accordance with the growth status of the cell. Producing the 
machinery when it is not required would be a large drain on the cell’s resources 
and, conversely, a lack of these proteins will impede cell growth. Increased 
TFIIIB and TFIIIC levels are frequently associated with increased Pol III activity 
(White, 2004). Increased levels of TFIIIC and TFIIIB subunits are found in cells 
infected with Epstein Barr Virus (EBV) and hepatitis B respectively (Felton-Edkins 
et al., 2006, Wang et al., 1995). Both of these viruses result in increased cell 
proliferation and Pol III activity. Likewise, high TFIIIB and TFIIIC protein levels 
are found in many tumours. Winter et al. found higher TFIIIC protein levels in 
ovarian carcinomas compared to normal tissue samples from the same patient 
(Winter et al., 2000). Pol III-specific transcription factor levels can be altered by 
changes in their gene expression or by changes in the stability of the protein. 
p53 induction has been shown to result in degradation of Brf1 in some cell types 
(Eichhorn and Jackson, 2001). High TFIIIB and TFIIIC mRNA levels are found in a 
wide range of cancers. These include colorectal and breast tumours where Brf1 
and TFIIIC220, respectively, were found significantly upregulated compared to 
healthy tissue samples [(Zhao et al., 2004, Hong et al., 2010) data mined from 
Oncomine]. Increased TFIIIB expression has also been found to correlate with 
more aggressive disease, for example, in two studies, Brf1 expression has been 
shown to be significantly higher in prostate cancer metastases than in primary 
prostate tumours [(Grasso et al., 2012, Varambally et al., 2005) data mined from 
Oncomine]. In addition, recent studies showed that c-Jun N-terminal kinases 
(JNKs) can regulate the expression of all three TFIIIB subunits (Zhong et al., 
2007, Zhong and Johnson, 2009). Clearly, regulating TFIIIB and TFIIIC levels has 
the potential to contribute to the overall regulation of Pol III-mediated 
transcription.  
1.4.1.2 Phosphorylation of Pol III transcription machinery 
TFIIIB can be phosphorylated by multiple kinases. Phosphorylation alters its 
ability to interact with other components of Pol III machinery in pre-initiation 
complex formation. For example, ERK, a mitogen-activated protein kinase 
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(MAPK), phosphorylates Brf1 in response to serum (Felton-Edkins et al., 2003) 
(Figure 1.5). This phosphorylation was shown to contribute to the subsequent 
activation of Pol III-mediated transcription, possibly by increasing TFIIIB’s 
affinity for TFIIIC. Plk1 and CK2 also regulated Pol III activity by phosphorylating 
TFIIIB (Hu et al., 2004, Fairley et al., 2012). Phosphorylation is a faster 
mechanism of relaying a signal than alteration of protein levels and may be 
important in fine-tuning Pol III activity in response to changes in cellular 
environment.   
1.4.1.3 Regulator binding to Pol III transcription machinery 
The third mechanism by which initiation of Pol III-mediated transcription is 
regulated is through regulatory proteins binding to the Pol III machinery (Figure 
1.5). As with phosphorylation, TFIIIB is the main target of these regulators, 
probably due to its rate-limiting role in initiation. Regulators act by either 
sequestering machinery away from Pol III target genes or altering interactions 
between components of the PIC while present at the gene. 
Retinoblastoma protein (RB) RB is a global repressor of the level of Pol III-
mediated transcription (White et al., 1996, Gjidoda and Henry, 2013). RB can 
bind to TFIIIB, preventing its recruitment to Pol III target genes by inhibiting its 
interaction with TFIIIC (Larminie et al., 1997, Chu et al., 1997). RB binding also 
prevents TFIIIB interaction with Pol III. This, along with RB interaction with 
SNAPC, allows RB to repress genes with the type III promoters that do not recruit 
TFIIIC (Hirsch et al., 2000). RB activity is regulated through its phosphorylation 
by cyclin-dependent kinase/cyclin complexes, cdk4/cyclin D and cdk2/cyclin E. 
Phosphorylation of RB reduces its affinity for TFIIIB, thus Pol III-mediated 
transcription increases at the end of G1 (Scott et al., 2001). TFIIIB can also be 
bound and repressed by RB-related proteins p107 and p130 (Sutcliffe et al., 
1999). 
p53 p53 represses Pol III-mediated transcription (Chesnokov et al., 1996, Cairns 
and White, 1998).  TFIIIB is bound by p53, which prevents TFIIIB’s recruitment to 
Pol III target genes by interfering with its interaction with TFIIIC (Chesnokov et 
al., 1996, Cairns and White, 1998, Crighton et al., 2003). Like RB, p53 prevents 
TFIIIB from interacting with Pol III, ensuring the repression of target genes, like 
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U6, that do not recruit TFIIIC (Crighton et al., 2003). p53 regulation of Pol III-
mediated transcription is described in more detail below. 
c-Myc c-Myc interacts with TFIIIB and binds at Pol III target genes (Gomez-Roman 
et al., 2003). When bound at these genes, c-Myc recruits the histone 
acetyltransferase (HAT) GCN5 and promotes gene expression (Kenneth et al., 
2007). Histone acetylation is associated with a chromatin environment 
permissive for Pol III-mediated transcription (White, 2011). It is currently 
unclear whether c-Myc promotes the recruitment of TFIIIB or vice versa. c-Myc is 
activated in response to mitogenic factors and induces cell growth and 
proliferation through regulating expression of many target genes (Grandori et 
al., 2000). During proliferation, Pol III products, such as 5S rRNA and tRNAs, are 
required at higher levels to meet demands for increased protein synthesis and c-
Myc activity may contribute to these higher levels. 
Maf1 Maf1 was originally identified as a global negative regulator of Pol III-
mediated transcription in S. cerevisiae (Pluta et al., 2001, Upadhya et al., 
2002). This function is conserved in mammals, where Maf1 activity is associated 
with reduced PIC formation at Pol III target genes (Reina et al., 2006, Johnson et 
al., 2007, Goodfellow et al., 2008). Maf1 associates with Pol III and TFIIIB and 
can be found at Pol III target genes (Moir and Willis, 2013). When Maf1 is 
phosphorylated, it is no longer able to repress Pol III-mediated transcription. 
Maf1 is the target of multiple kinases and phosphatases, including mTORC1 (Shor 
et al., 2010, Kantidakis et al., 2010). This contributes to the regulation of Pol III-
mediated in response to nutrient availability. 
1.4.2 Transcription-independent regulation of Pol III products 
The most efficient route to regulate Pol III product levels is by regulating their 
transcription. However, they may also be manipulated by transcription-
independent mechanisms. The levels of Pol III products may be altered via 
changes in their stability. The rapid tRNA degradation (RTD) pathway contributes 
to tRNA levels in S. cerevisiae (Wichtowska et al., 2013). At present, no 
equivalent pathway has been identified in humans. Transcripts produced by Pol 
III require processing to produce functional products. In tRNAs, this is extensive 
(Hopper and Phizicky, 2003). Perturbation of any processing step will reduce the 
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level of functional products and, consequently, has the potential to disrupt cell 
growth.   
 
 
Figure 1.5  Regulators of Pol III-mediated transcription 
The diagram above illustrates how regulators can act at a gene with a type 2 promoter. 
For simplicity, not all known regulators are included. Repression or activation can be 
mediated by a single regulator. a) Repression of a gene can be mediated by p53, RB or 
Maf1. p53 and RB prevent pre-initiation complex formation by binding to TFIIIB, 
preventing its recruitment by TFIIIC. Unphosphorylated Maf1 binds Pol III, preventing its 
recruitment to the transcription start site (+1). b) Activation of a gene can be mediated 
by c-Myc, ERK or inactivation of repressors. c-Myc binds at promoters, interacting with 
TFIIIB and promoting transcription. ERK phosphorylates TFIIIB, probably increasing its 
affinity for TFIIIC. Phosphorylation of Maf1 and RB prevent their association with Pol III 
and TFIIIB respectively.  Adapted from (White, 2008). 
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1.4.3 Comparing regulation of Pols I, II and III 
p53, RB and c-Myc regulate transcription by Pols I, II and III. This shared 
regulation may have evolved to allow tight regulation of ribosome biosynthesis 
and core housekeeping processes (White, 2008). Despite this shared regulation, 
it was thought that the majority of Pol II transcriptional regulators were specific 
to Pol II target genes (Raha et al., 2010). However, over the past few years, 
many transcription factors normally associated with Pol II genes, including c-Jun, 
c-Fos, STAT-1 and Elk1, have been found at Pol III target genes (Raha et al., 
2010, Oler et al., 2010, Zhong et al., 2011). Their function at Pol III target genes 
remains to be determined.  
Recently, it has been shown that chromatin at Pol III target genes has similar 
modification patterns to that at Pol II target genes (Barski et al., 2010, Oler et 
al., 2010). As at Pol II-transcribed genes, acetylated histones are associated with 
active transcription and deacetylation is associated with repression of 
transcription. Many histone methylation events are also shared between Pol II- 
and Pol III-transcribed genes. It is unclear at the moment whether the activity of 
Pol III target genes is a cause or a consequence of the chromatin environment 
(White, 2011). 
In addition, Pol II itself has been found bound upstream of many Pol III target 
genes (Raha et al., 2010, Oler et al., 2010, Barski et al., 2010). While not 
required for Pol III-mediated transcription, it may contribute to a permissive 
chromatin environment. Together, these findings hint at a further complexity to 
regulation of Pol III-mediated transcription than is currently understood.    
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1.5 p53 
 p53 is a transcription factor that activates and represses a vast range of genes 
in many functional classes, including Pol III-transcribed genes. Initially identified 
in 1979, p53 was soon found to be a key figure in the cell’s response to stress 
and, due to its role in protecting the cell from accruing DNA damage, it was 
dubbed ‘the guardian of the genome’ (Lane, 1992). Upon stress, p53 can induce 
cell cycle arrest, senescence or apoptosis (Figure 1.6). p53’s role, however, 
extends beyond this; it has been identified to regulate DNA repair, cellular 
metabolism, and remodelling of the extracellular matrix, among other functions 
(Vousden and Prives, 2009). p53 is activated by stimuli including DNA damage, 
hypoxia, oncogenic stress and ribonucleotide depletion (Horn and Vousden, 
2007). It is particularly well studied due to its role as a tumour suppressor. The 
loss or mutation of p53, or the disruption of other p53 pathway components, is 
required for the development of many tumours in humans (Lozano and Elledge, 
2000). Many p53 mutations found in cancer are so-called ‘gain of function’ 
mutations, converting p53 from a tumour suppressor to an oncogene (Muller and 
Vousden, 2013).  
          
Figure 1.6  The p53 pathway 
The p53 pathway is depicted above, in a simplified form. Some of the stresses capable 
of inducing p53 activity are highlighted in purple. These result in the stabilisation and 
post-translational modification of p53 by a range of mechanisms (not shown). p53 
mediates responses including growth arrest and apoptosis via the routes shown in green. 
Adapted from (Levine and Oren, 2009). 
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1.5.1 Structure and regulation of p53  
The transcriptional activity of p53 is mediated primarily by interaction of the 
transcription activation domains (TAD I and II) at p53’s N-terminus with other 
proteins (Ko and Prives, 1996, Laptenko and Prives, 2006). The core DNA-binding 
domain, between residues 98 and 303, recognises and binds specific DNA motifs 
present upstream of many target genes. p53 binds as a tetramer which is formed 
via its oligomerisation domain located towards its C-terminus (aa 323-363). 
p53 activity is regulated primarily through its stability and post-translational 
modification (Kruse and Gu, 2009). Normally in the cell, p53 is maintained at a 
low level by MDM2 which binds and ubiquitinates it, marking it for proteasomal 
degradation. Upon stress, this degradation pathway can be overcome by the 
inhibition of MDM2. p53 can be phosphorylated, acetylated and methylated at 
multiple sites in all protein domains (Meek and Anderson, 2009, Dai and Gu, 
2010). The exact post-translational modifications that occur depend upon the 
stimulus and can alter p53 stability, activity and the target genes it associates 
with. For example, p53 is phosphorylated at Serine 15 by ATM and ATR following 
DNA damage, decreasing p53’s association with MDM2 and increasing its 
association with its coactivator p300/CBP (Shieh et al., 1997, Lambert et al., 
1998). Also, phosphorylation of p53 at Serine 46 is required for induction of 
proapoptotic genes but not involved in regulating cell cycle genes (Oda et al., 
2000).  
1.5.2 p53 response 
p53 is stabilised following stress, whose identity and strength contribute to 
determining the outcome of p53 induction (Horn and Vousden, 2007, Murray-
Zmijewski et al., 2008). p53 mediates this outcome by differential regulation of 
target genes. 
1.5.2.1 Cell cycle arrest 
Transient cell cycle arrest allows time for repair before DNA replication and 
mitosis, thus preventing the transfer of damaged DNA to daughter cells. p53 
induces cell cycle arrest primarily through activating transcription of its target 
gene CDKN1A, which encodes for the cell cycle regulator p21 (Vogelstein et al., 
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2000). p21 binds to Cyclin E/Cdk2 and Cyclin D/Cdk4 complexes, preventing 
them from phosphorylating RB. Unphosphorylated RB can bind to E2F 
transcription factors, preventing them from activating the expression of their 
target genes. These genes are required for cell cycle progression. Thus, when 
p21 is present, the cell cycle remains arrested in G1. p53 can also induce G2 
arrest by p21 activation. p21 represses Cdc2 activity, which is required for 
progression into mitosis. GADD45 and 14-3-3, whose genes are also direct targets 
of p53, also contribute to G2 arrest (El-Deiry, 1998).  
1.5.2.2 Senescence 
Senescence, an irreversible cell cycle arrest, can also be mediated by p53. As in 
transient cell cycle arrest, p21 is key to this p53-induced response (Brown et al., 
1997). Senescence can be induced by stress, including irreparable DNA damage 
and oncogene overexpression. Indeed, evidence suggests that induction of 
senescence may be a key tool in p53’s ability to suppress tumour development 
following oncogene activation (Vousden and Prives, 2009).  
1.5.2.3 Apoptosis 
In some instances, p53 causes the cell to undergo apoptosis (a form of 
programmed cell death). This may occur if repair of DNA damage is not 
successful or if the stress inducing p53 is particularly strong. p53 directly induces 
the expression of many pro-apoptotic factors, including Puma, Noxa, Bax and Bid 
(Fridman and Lowe, 2003). In addition, p53 can repress transcription of pro-
survival factors Bcl-2, Bcl-xL and Survivin. p53 can also regulate apoptosis 
independently of transcription, binding to Bak and promoting cytochrome C 
release from the mitochondria (Yee and Vousden, 2005). 
1.5.3 Mechanism of regulating transcription 
p53 activates or represses the transcription of its target genes. Several different 
pathways for this have been identified (Beckerman and Prives, 2010). However, 
the mechanisms by which p53 regulates its target genes are not fully 
understood. This is especially true of gene repression. 
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1.5.3.1 Gene activation 
Nearly all genes directly activated by p53 have a p53 response element (p53 RE) 
nearby. This DNA motif usually consists of two ‘half sites’ separated by a spacer 
region of 0-21 base pairs. The half site is 5’-RRRCWWGYYY-3’ where R is a 
purine, W is adenine or thymine and Y is a pyrimidine (el-Deiry et al., 1992). p53 
binds at this site and recruits basal transcription factors and coactivators to 
induce transcription (Laptenko and Prives, 2006). Coactivators include the 
histone acetyltransferases (HATs) CBP, p300 and PCAF which can acetylate local 
histones making the environment more conducive to transcription.  
1.5.3.2 Gene repression 
While it is a paradigm mediator of transcription activation, p53 represses many 
genes via several mechanisms (Beckerman and Prives, 2010, Rinn and Huarte, 
2011). In those genes with a p53 RE, p53 may recruit negative regulators to the 
promoter. For example, at Nanog and c-Myc genes, HDAC1 is recruited via p53’s 
interaction with mSin3a, thus resulting in an environment less conducive to 
transcription (Ho et al., 2005, Lin et al., 2005). Alternatively, the binding of p53 
to its binding motif can prevent/displace the association of positive regulators 
with their binding motifs nearby. However, many repressed genes do not have a 
p53 RE nearby. Repression of these genes may occur due to loss of 
transcriptional activators to p53-bound genes, so-called ‘squelching’. 
Alternatively in these cases, p53 may interact with other proteins present at the 
genes and recruit negative regulators. For example, p53 has been shown to 
interact with NF-Y, a transcription factor, at the cyclin B2 promoter and recruit 
HDAC1 (Imbriano et al., 2005). As described below, the mechanism by which p53 
represses Pol III-mediated transcription is different again. 
1.5.4 Regulation of Pol III-mediated transcription by p53 
1.5.4.1 Establishing p53 as a regulator of Pol III-mediated transcription 
A range of evidence supports a role for p53 in Pol III regulation. MEFs from p53 
knockout mice have higher Pol III activity than MEFs from their wild type 
littermates (Cairns and White, 1998). In fibroblasts from humans with Li 
Fraumeni syndrome, an inherited mutation in p53, Pol III activity is higher than 
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in individuals without a mutation (Stein et al., 2002a). A direct effect of p53 on 
Pol III-mediated transcription was established using in vitro and cellular assays. 
In in vitro transcription assays (IVTs), addition of p53 was found to repress 
expression of Pol III target genes (Chesnokov et al., 1996, Cairns and White, 
1998). These genes were from all three Pol III promoter types, including tRNA, 
5S, U6, Alu and VA-1, establishing p53 as a general repressor of Pol III-mediated 
transcription. Similarly, p53 overexpression in p53-null cells repressed VA-1 
expression and this effect could be overcome by cotransfection with plasmids 
encoding E6 or Mdm2, known inhibitors of p53 (Stein et al., 2002a). Several 
mutated forms of p53 have lost the ability to repress Pol III-mediated 
transcription (Stein et al., 2002a). Indeed, the most common p53 mutation in 
human tumours, R175H, converts p53 from a repressor to an activator of VA-1 
transcription in SAOS2 cells (Stein et al., 2002a). Interestingly, p53 with a R175P 
mutation shows reduced ability to repress Pol III-mediated transcription but can 
still cause growth arrest (Stein et al., 2002a, Crook et al., 1994). This 
demonstrates that Pol III-repression is not a secondary result of p53-induced cell 
cycle arrest. 
1.5.4.2 Mechanism 
p53 is known to interact with TBP at Pol II promoters (where TBP is a subunit of 
TFIID) (Ko and Prives, 1996). This interaction also appears to be important for 
the regulation of Pol III-mediated transcription by p53. p53 interacts with TFIIIB, 
preventing the recruitment of TFIIIB to TFIIIC at Pol III target genes (Chesnokov 
et al., 1996, Cairns and White, 1998, Crighton et al., 2003). p53 does not bind to 
Pol III-transcribed genes, with the exception of U6 (Gridasova and Henry, 2005). 
By binding to TFIIIB, p53 also prevents TFIIIB’s interaction with Pol III (Crighton 
et al., 2003). This may account for p53’s ability to repress U6 and other genes 
with type 3 promoters. Alternatively, repression of this subset of Pol III target 
genes may occur through a different mechanism. p53 presence correlates with 
HDAC occupancy of these genes and p53 can also interact with another 
component of the PIC at type 3 promoters, SNAPC (Gridasova and Henry, 2005).  
p53 mutant studies have shed further light onto the p53-TFIIIB interaction. These 
show that both N and C termini of p53 are required to repress Pol III activity at 
genes with type 2 promoters (Stein et al., 2002b). This supports the hypothesis 
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that p53 interacts with TBP in TFIIIB, as these regions of p53 are required for 
p53-TBP interactions (non Pol III-specific) (Horikoshi et al., 1995). Unexpectedly 
for a repression mechanism that does not appear to require p53 binding at target 
gene promoters, point mutations in the DNA binding domain prevent Pol III 
repression (Stein et al., 2002a).   
Eichhorn and Jackson showed that Brf1 is degraded following p53 induction in 
the human fibroblast cell line TR9-7, suggesting an additional route by which p53 
may regulation Pol III-mediated transcription (Eichhorn and Jackson, 2001).  
1.5.4.3 Regulation of p53 regulation of Pol III-mediated transcription 
It is unclear whether p53 can always repress Pol III-mediated transcription or 
only under certain conditions, for example when it is modified at a specific site. 
The former is supported by the observation that Pol III activity is higher in p53-
null MEFs than wild type MEFs (Cairns and White, 1998). This suggests that basal 
levels of p53 (without a stress-induced modification) are sufficient to repress Pol 
III. However, while oncogenic stress induces p53-dependent repression of Pol III-
mediated transcription (Morton et al., 2007), DNA damage by methyl 
methanesulfonate (MMS) induces p53 but the repression of Pol III-mediated 
transcription observed is independent of p53 (J. Morton and R. White, 
unpublished). This suggests that repression of Pol III-mediated transcription may 
not be a universal response to p53 induction. This is examined further in Chapter 
Three. 
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1.6 AP-1  
AP-1 is a dimeric transcription factor with a complex array of roles in 
proliferation, apoptosis, differentiation and invasion. Its activity is regulated by 
multiple upstream factors, which are activated in response to extracellular and 
intracellular signals including growth factors, cytokines and stress (Shaulian and 
Karin, 2001). Most notable of these upstream factors are the mitogen-activated 
protein kinases (MAPKs). However, other regulators include casein kinase II (CK2) 
and glycogen synthase kinase 3 (GSK-3) (Boyle et al., 1991, Karin and Hawkins, 
1996). Upon activation, AP-1 regulates transcription of an array of target genes 
by RNA Polymerase II (Shaulian and Karin, 2002). Among these are the genes 
encoding the components of TFIIIB, TBP and Brf1 (Fromm et al., 2008, Zhong et 
al., 2011). This provides the potential for AP-1 to modulate Pol III-mediated 
transcription. Recent studies have also identified the presence of AP-1 at many 
Pol III-transcribed genes, suggesting AP-1 may not be a Pol II-specific regulator 
of transcription (Raha et al., 2010, Zhong et al., 2011).   
1.6.1 AP-1 structure  
AP-1 (activator protein 1) consists of two proteins from the JUN, FOS, ATF and 
MAF families. The JUN family members are c-Jun, JunD and JunB. The FOS 
family includes c-Fos, FosB and Fra-1. ATF2 is a member of the ATF family. AP-1 
composition varies depending upon the levels of these proteins in the cell and 
the ability of the proteins to interact with one another (Table 1.1) [reviewed in 
detail in (Chinenov and Kerppola, 2001)]. Not all combinations of proteins are 
possible, for example c-Jun can form a heterodimer with c-Fos (c-Jun/c-Fos) and 
a homodimer (c-Jun/c-Jun) but a c-Fos/c-Fos dimer is not possible. AP-1 
proteins each contain a basic leucine zipper (bZIP) domain through which 
dimerization occurs (Landschulz et al., 1988). Dimerization brings the DNA 
binding domains of the proteins together, allowing them to bind at target genes 
(Ellenberger et al., 1992). Binding usually occurs at AP-1 binding motifs located 
upstream of target genes. AP-1 binding motifs include the TPA-responsive 
element (TRE, TGACTCA) and the cAMP-response element (CRE, TGACGTCA) 
sites. The binding strength of AP-1 to these sites depends upon the dimer 
composition of AP-1 (Table 1.1). TRE is the most common binding site for the c-
Chapter 1: Introduction   
39 
 
Jun/c-Fos dimer, while CRE is the most common for c-Jun/ATF2 (Nakabeppu et 
al., 1988, Hai and Curran, 1991).  
Once bound at target genes, gene expression is regulated through the 
transactivation domains of the AP-1 proteins. AP-1 proteins can undergo post-
translational modification. For example, the phosphorylation of c-Jun at Serine 
63 and Serine 73 in its transactivation domain by c-Jun N-terminal kinase (JNK) 
promotes its transactivational function (Hibi et al., 1993, Derijard et al., 1994). 
The transcriptional activity of c-Fos and ATF2 is also enhanced by 
phosphorylation (Chen et al., 1993, Chen et al., 1996, Gupta et al., 1995). 
Exactly how AP-1 modulates the transcription of its target genes is not fully 
defined. Its ability to interact with basal transcription machinery and 
coactivators, including TBP and p300/CBP, may contribute to regulation 
(Ransone et al., 1993, Arias et al., 1994).  Moreover, c-Jun has recently been 
shown to recruit the nucleosome remodelling and histone deacetylation (NuRD) 
repressor complex to the gene encoding stem cell marker lgr5 in a 
phosphorylation-dependent manner (Aguilera et al., 2011).   
 
Table 1.1  AP-1 dimers and their binding preferences 
The table above shows some of the proteins that can form AP-1 dimers with c-Jun or c-
Fos. Their preference for binding to specific AP-1 binding motifs is described in the third 
column. TRE = TPA-responsive element, CRE = cAMP-response element. For simplicity, 
AP-1 proteins not discussed in the main text are not included. Adapted from (Eferl and 
Wagner, 2003) 
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1.6.2 AP-1 function 
The cellular outcome of AP-1 activity is dependent upon which of its target 
genes it regulates. This is determined by dimer composition (itself determined 
by levels of the AP-1 proteins), post-translational modification of the AP-1 
proteins and the binding motifs present at the target genes. While binding motifs 
are constant at a single gene, protein levels and post-translational modification 
are subject to regulation by multiple upstream pathways and, thus, AP-1 is 
regulated in response to the cellular environment (Shaulian and Karin, 2001). For 
example, c-Fos expression is upregulated by ERK following 12-O-
tetradecanoylphorbol-13-acetate (TPA) treatment, while JNK phosphorylates c-
Jun in response to UV (Whitmarsh et al., 1995, Hibi et al., 1993, Derijard et al., 
1994). However, it is the combination of proteins making up the AP-1 dimer that 
appears to be most important in determining the target gene recognised (van 
Dam and Castellazzi, 2001). The multiple possible dimer combinations account 
for the complexity of AP-1 function, for example it has both pro- and anti-
proliferative roles (Shaulian and Karin, 2002). c-Jun and c-Fos have undergone 
the most extensive functional analysis and it is these AP-1 factors whose 
function will be addressed here, as they have been identified at tRNA genes and 
other Pol III-transcribed genes (Raha et al., 2010). Historically, despite their 
known requirement to form a dimer, each protein’s function has been studied 
separately due to the difficulty in determining the role of a transient dimer.  
1.6.2.1 Proliferation 
AP-1 dimers have both pro- and anti-proliferative effects dependent primarily 
upon their composite proteins. c-Jun has pro-proliferative effects. c-Jun null 
mouse embryonic fibroblasts (MEFs) are unable to proliferate (Schreiber et al., 
1999, Wisdom et al., 1999). As part of AP-1, c-Jun can activate Cyclin D1, 
allowing the G1-S phase transition (Wisdom et al., 1999). It also inhibits p53 
expression and, thus, prevents p21-induced arrest (Schreiber et al., 1999). The 
role of JunB and JunD in proliferation is less well defined. However, evidence 
suggests JunB has a negative impact on proliferation, while the impact of JunD is 
context-dependent (Eferl and Wagner, 2003). c-Fos null fibroblasts are able to 
proliferate normally, as are FosB null fibroblasts (Brusselbach et al., 1995, Gruda 
et al., 1996). However, when both c-Fos and FosB are depleted, proliferation is 
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significantly reduced (Brown et al., 1998). This suggests an ability to functionally 
compensate for one another to some degree. 
1.6.2.2 Apoptosis 
AP-1 has both pro– and anti-apoptotic activity. c-Jun can positively regulate Bim, 
a pro-apoptotic protein, and it may be this that contributes to c-Jun’s ability to 
drive apoptosis in neuronal cells (Whitfield et al., 2001). Apoptosis may also be 
induced by Fas ligand (FasL), expression of which can be induced by the c-Jun/c-
Fos dimer (Kasibhatla et al., 1998). On the other hand, c-Jun can repress p53 
activity and thus prevent p53-induced apoptosis (Schreiber et al., 1999).  
1.6.2.3 Other functions 
AP-1 activity contributes to many other cellular processes including 
angiogenesis, development, invasion and differentiation. They have been 
described in detail elsewhere (Jochum et al., 2001, Shaulian and Karin, 2002, 
Ozanne et al., 2006). 
1.6.3 AP-1 and cancer 
With functions in a number of processes known to contribute to cancer 
development upon deregulation, it is not surprising that AP-1 is implicated in 
tumour development (Young et al., 2003, Jochum et al., 2001). But with its 
complex role in these processes, its role in cancer is equally complex. c-Jun and 
c-Fos were first identified due to their constitutively active mutants found in the 
Finkel–Biskis–Jinkins osteosarcoma virus and avian sarcomavirus 17 respectively, 
v-Jun and v-Fos (Vogt, 2002). These proteins are capable of the transforming the 
infected cell. c-Jun and c-Fos also have oncogenic capacity. c-Jun activation is 
important in skin and liver tumour development, while c-Fos is required for 
osteosarcoma development in mice (Young et al., 1999, Eferl et al., 2003, Wang 
et al., 1991, Grigoriadis et al., 1993). c-Fos deletion cannot prevent 
development of skin tumours in a mouse tumour model, but it does prevent 
progression to malignancy (Saez et al., 1995). c-Fos also functions as a tumour 
suppressor. Rhabdomyosarcomas arise when c-Fos is deleted in p53 null mice, 
possibly resulting from impaired apoptosis (Fleischmann et al., 2003). JunB has 
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an anti-oncogenic capacity that could derive from its competition with c-Jun  
(Eferl and Wagner, 2003). 
1.7 JNKs 
The c-Jun N terminal kinases (JNKs) are one subfamily of the mitogen-activated 
protein kinase (MAPK) family (Johnson and Lapadat, 2002). The MAPK family also 
includes the ERK and p38 subfamilies. MAPKs are one component of signalling 
cascades by which extracellular stimuli can be relayed through the cell to 
influence cellular processes. These processes include proliferation, cell growth, 
differentiation, migration and apoptosis. The MAPKs are highly conserved from 
yeast to humans, highlighting their important role in cellular function (Widmann 
et al., 1999). JNKs can regulate Pol III-mediated transcription by regulating the 
expression of TFIIIB subunits (Zhong et al., 2007, Zhong and Johnson, 2009, 
Zhong et al., 2011). 
1.7.1 Structure and regulation of JNKs 
The human genome contains three JNK genes. JNK1 and JNK2 are expressed 
ubiquitously, while JNK3 expression is limited to the brain, heart and testis 
(Mohit et al., 1995). The functional roles of JNK1 and JNK2 have not been fully 
differentiated. It seems they have some shared roles, particularly in 
development, and some protein specific roles (Bode and Dong, 2007, Chen et al., 
2009). JNK1 and JNK2 are each expressed as four different isoforms through 
alternative splicing, adding further complexity to JNK activity within the cell 
(Gupta et al., 1996). JNK1α1 and JNK1β1 are both 46kDa and share the same 
final exon but each has a different exon 6 (one has exon 6α and the other exon 
6β). JNK1α2 and JNK1β2 are 54kDa and share an alternative final exon, but again 
differ in exon 6. JNK2 undergoes similar splicing. The importance of different 
isoforms has not been determined. JNKs are activated by mitogenic factors, 
cytokines and stress signals and influence proliferation, development and 
apoptosis through phosphorylation of a range of targets (Davis, 2000, 
Bogoyevitch and Kobe, 2006). Stimuli include TNFα and UV light (Rosette and 
Karin, 1996). JNK kinase activity requires its ATP-binding pocket, catalytic loop 
and substrate binding site. JNKs are activated by dual phosphorylation at a Thr-
X-Tyr motif in the activation loop of JNK by MKK4 (mitogen-activated protein 
Chapter 1: Introduction   
43 
 
kinase kinase 4) and MKK7 (Lawler et al., 1998). These kinases specifically 
phosphorylate JNK and can be activated by multiple MAPKKKs (MAPK kinase 
kinase) (Figure 1.7) (Davis, 2000). MAPKKK activity is stimulus-dependent. Some 
stimuli may activate MAPKKKs that can phosphorylate MKK4/7, while other 
stimuli may not activate these MAPKKKs. Hence, JNK activation is dependent 
upon the stimuli present.  
 
Figure 1.7  The JNK pathway 
The diagram above illustrates the JNK pathway, from extracellular stimuli to biological 
response, in simplified form. Extracellular signals activate MAPKKKs (intermediate 
pathway not shown). These phosphorylate MKK4 and MKK7, resulting in the 
phosphorylation of JNKs. Once activated, JNK phosphorylates target proteins, including 
c-Jun and ATF2. The activity of the target protein is altered and can, in turn, alter the 
transcription of its target genes. This mediates the biological response. Possible 
biological responses include proliferation and apoptosis. Adapted from (Wagner and 
Nebreda, 2009) 
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1.7.2 JNK substrates 
JNK has many phosphorylation targets, including both nuclear and cytoplasmic 
proteins, that have roles in many processes. They have been reviewed in detail 
elsewhere (Bogoyevitch and Kobe, 2006). Highlighted below are those that have 
known links with Pol III-mediated transcription. 
1.7.2.1 c-Jun 
JNKs were first identified because of their ability to phosphorylate c-Jun (Hibi et 
al., 1993, Derijard et al., 1994). Phosphorylation occurs at serines 63 and 73 and 
threonines 91 and 93 and a JNK binding domain in c-Jun is required for 
phosphorylation to occur (Hibi et al., 1993, Derijard et al., 1994, Morton et al., 
2003). Phosphorylation of c-Jun at serines 63 and 73 promotes its ability to 
activate a range of target genes, many involved in cell proliferation and 
apoptosis (see Section 1.6.2). JNK1 and JNK2 appear to have different roles in 
regulating c-Jun.  JNK1 is most efficient at phosphorylating c-Jun, while JNK2 
has been described as a negative regulator of c-Jun (Gupta et al., 1996, 
Sabapathy et al., 2004). It promotes c-Jun degradation when bound to c-Jun in 
its unphosphorylated form (Sabapathy et al., 2004). Jun family members JunD 
and JunB are also JNK substrates (Yazgan and Pfarr, 2002, Li et al., 1999). Like 
c-Jun, phosphorylation increases their transcriptional activity. 
1.7.2.2 ATF2 
ATF2 is another AP-1 protein targeted for phosphorylation by JNK. It is 
phosphorylated at Thr69 and Thr71 in its transactivation domain, enhancing its 
transactivational activity (Gupta et al., 1995). As part of an AP-1 dimer, ATF2 
plays an important role in the regulation of cell development, proliferation and 
death (Lau and Ronai, 2012). 
1.7.2.3 p53 
p53 can be phosphorylated by JNK at Thr81 in rat cells (Buschmann et al., 2001). 
This modification stabilises p53 and, thus, upregulates its activity. The authors 
suggest that phosphorylation at this site is required for p53 stabilisation. More 
Chapter 1: Introduction   
45 
 
recently, JNK1 has been shown to negatively regulate p53 (Tafolla et al., 2005). 
The function of p53 is described in detail above (Section 1.5) 
1.7.2.4 c-Myc 
JNK phosphorylates c-Myc at Ser61 and Ser71 (Noguchi et al., 1999). This 
phosphorylation is associated with an increase in c-Myc-mediated apoptosis and 
appears to be primarily carried out by JNK1 (Noguchi et al., 1999). c-Myc 
contributes to apoptosis in addition to its key role in inducing proliferation 
(Grandori et al., 2000). 
1.7.2.5 Elk1 
Elk1 is a member of the Ets family of transcription factors (Sharrocks, 2001). 
Two sites in it transactivation domain, Ser383 and Ser389, are phosphorylated by 
JNK (Whitmarsh et al., 1995, Yang et al., 1998). Phosphorylation increases the 
transcriptional activity of Elk1, whose targets genes include TFIIIB subunits TBP 
and Brf1 (Zhong et al., 2007, Zhong and Johnson, 2009).   
1.7.2.6 STAT1 
JNK activation can also result in the phosphorylation  and activation of STAT1 at 
Ser727 (Zhao et al., 2005). Another member of the STAT family member, STAT3, 
is phosphorylated by JNK (Zhang et al., 2001). STAT proteins are activated in 
response to growth factors and cytokines and contribute to the regulation of 
many cellular processes including differentiation, proliferation and apoptosis 
(Calo et al., 2003).   
1.7.2.7 TIF-IA 
TIF-IA is a Pol I-specific transcription factor. It binds to the TBP-containing 
factor SL1 on the promoter of 45S rRNA gene and recruits Pol I (White, 2008). 
Following JNK activation by stress, JNK phosphorylates TIF-IA at Thr200 (Mayer 
et al., 2005). This reduces TIF-IA’s interaction with SL-1 and Pol I, resulting in 
reduced Pol I-mediated transcription and, thus, reduced rRNA levels (Mayer et 
al., 2005). 
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1.7.3 JNK and cancer 
JNK mutations are uncommon in cancers, however JNK activation has been found 
in several human tumour types, including in breast cancer, osteosarcoma and 
hepatocellular carcinoma (HCC) (Wang et al., 2003, Papachristou et al., 2003, 
Hui et al., 2008, Chang et al., 2009). They play a complex role in cancer, acting 
in both positive and negative roles depending on cancer type (Bode and Dong, 
2007). In HCC, two independent studies found that more than 50% of HCC 
samples had upregulated JNK1 (but not JNK2) activity (Hui et al., 2008, Chang et 
al., 2009). Knockout of JNK1 in mice results in reduced size and number of 
chemically-induced mouse liver tumours, compared to the wild type (Hui et al., 
2008). In addition, JNK1 was recently identified as an important kinase in 
tobacco-induced lung cancer in mice (Takahashi et al., 2010). Conversely, JNK1 
may have a tumour suppressive role in TPA-induced skin carcinogenesis, where 
JNK1-/- mice are more susceptible to tumour development than their WT or 
JNK2-/- littermates (She et al., 2002). JNK activity may be required for c-Jun’s 
transforming activity, for example JNK activation and c-Jun phosphorylation 
have been demonstrated to be required for transformation by oncogenic Ras in 
mouse models (Smeal et al., 1991, Behrens et al., 2000). 
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1.8 PhD Objectives 
Regulation of Pol III-mediated transcription is essential to ensure a cell has 
sufficient Pol III products and to prevent the transcription of Pol III target genes 
from consuming too much of the cell’s resources. 5S rRNA and tRNAs contribute 
significantly to protein synthesis, alongside other Pol III products. Protein 
synthesis is essential for cell growth and, consequently, cell proliferation. Pol III-
mediated transcription is regulated by many proteins, however how these 
regulators work is not fully understood and further regulators remain to be 
identified. Understanding the regulation of Pol III-mediated transcription is given 
further importance by the increase in Pol III-mediated transcription that is 
associated with cancer. 
The aim of this thesis was to investigate the regulation of Pol III-mediated 
transcription by three proteins, all with a known association to cancer. In 
Chapter Three, the role of p53 in regulating Pol III activity in response to DNA 
damage is investigated. Chapter Four analyses the occupancy of c-Jun and c-Fos 
at tRNA genes and investigates whether they may contribute to Pol III-mediated 
transcription. In Chapter Five, the objective was to determine whether JNK may 
directly regulate Pol III-transcribed genes, independently of its ability to 
regulate TFIIIB levels.   
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2 Materials and Methods 
2.1 Cell culture 
U2OS cells (a human osteosarcoma cell line) were grown in Dulbecco's Modified 
Eagle Medium (DMEM) (4.5g/l glucose, 110mg/l sodium pyruvate) (Gibco, Life 
Technologies) supplemented with 10% foetal bovine serum (FBS) (PAA 
Laboratories), 20mM L-Glutamine (Gibco, Life Technologies), 100U/ml penicillin 
and 100μg/ml streptomycin (Pen Strep, Life Technologies) in a humid incubator 
at 37°C with 5% CO2. NARF2 cells were provided by Prof. Gordon Peters, London 
Research Institute. These are U2OS cells expressing human p14ARF from an IPTG-
regulated promoter (Stott et al., 1998). NARF2 were maintained in the 
supplemented media described above, with 300µg/ml G418 sulphate solution 
(Formedium) and 150µg/ml Hygromycin B (Life Technologies) to maintain 
selection. U2OS-pRS-Scr, U2OS-pRS-p53, RKO-pRS-Scr, RKO-pRS-p53, MCF7-pRS-
Scr and MCF7-pRS-p53 were provided by Prof. Kevin Ryan, Beatson Institute 
(Crighton et al., 2006, Crighton et al., 2007). These cells stably express non-
silencing shRNA or an shRNA targeting p53 under a constitutive promoter. 
Reselection was carried out approximately once a month by addition of 1ug/ml 
puromycin to the media. c-Jun-null mouse embryonic fibroblasts (MEFs) stably 
expressing c-Jun or c-Jun mutants (c-Jun S63/73A, c-Jun Δ284-286, v-Jun, 
TAM67-GFP) from a pBabe vector were provided by Prof. David Gillespie, 
Beatson Institute (MacLaren et al., 2004) and cultured in supplemented media as 
described above.  
Passaging of cells was carried out every 2-3 days. Media was removed and 
replaced with 0.25% trypsin (Gibco) in PBS-EDTA to disengage cells from plate. 
Once this was complete, trypsin was quenched by addition of fresh media. Cells 
were then transferred to new tissue culture dishes. 
Cryofreezing of cells was carried out for long-term storage. Trypsinised cells 
were pelleted and resuspended in 1ml freezing media (70% FBS, 20% DMEM 
without supplements, 10% dimethyl sulfoxide (DMSO)) per near confluent T75 
tissue culture flask. Cells were transferred to cryo-vials in a cryo-freezing 
container containing room temperature isopropanol. This was placed in at -80°C 
overnight. Vials were then transferred to a liquid nitrogen freezer. To thaw 
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cells, they were placed at 37°C. Cells were then added to fresh media and 
pelleted by centrifugation. The supernatant was discarded and pellet was 
resuspended in fresh media.  
2.1.1 UV exposure 
Cells were grown to approximately 80% confluency in tissue culture dishes, then 
washed with PBS. PBS was removed and plates placed in UV irradiator without 
lids. 50J/m2 UVB (312nm) (UV Crosslinker XL-1000, Spectronics Corporation) or 
50J/m2 UVC (254nm) (UV Crosslinker CL-E508, UVITEC Cambridge) was used. 
Fresh media was added directly after UV exposure. Cells were harvested 8 hours 
later.  
2.1.2 Chemical compound addition 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) (Sigma) was dissolved in sterile 
water to 1M and stored at 4°C. ARF expression was induced in NARF2 cells by 
treatment with 1mM IPTG for 24 hours.  Doxorubicin (Adriamycin, Merck 
Millipore) was dissolved in H2O to stock concentration of 10mg/ml. Final 
concentrations used as described in text. SP600125 (JNK Inhibitor II, Merck 
Millipore) was dissolved in DMSO to make a 20mM stock solution and stored at -
20°C.  Used at final concentration as described in the text. JNK-IN-8 (JNK 
inhibitor XVI, Merck Millipore) was dissolved in DMSO to make a 100mM stock 
solution and stored -20°C. Before treatment of cells, it was further diluted in 
DMSO for each concentration required, so that 3μl of DMSO was added per 1ml of 
media. 
2.1.3 Transient transfection  
5x105 U2OS cells were plated in 10cm dishes 48 hours before transfection. 
pEGFP-C3 (empty vector) and pEGFP-C3-TAM67 were transfected using 
Lipofectamine 2000 (Life Technologies). 20μl of Lipofectamine 2000 and 5μg of 
plasmid were incubated separately in 1.5ml warm DMEM (no supplements) for 5 
minutes at room temperature. These were then combined and incubated for a 
further 20 minutes to allow complex formation. The media on the plates of cells 
to be transfected was replaced with 7ml of DMEM (10% FBS, 1% L-glutamine, no 
antibiotics). The transfection complex containing media was then added. 24 
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hours later GFP was observed in 50-80% of cells and cells were harvested for 
protein. 
2.2 Protein extract preparation 
Cells were washed twice with cold PBS. They were then scraped into a small 
volume of PBS, transferred to a microcentrifuge tube and centrifuged to pellet 
cells (2min, 400g, 4°C). The pellet was resuspended in low salt microextraction 
buffer (20mM HEPES, 150mM NaCl, 0.2mM EDTA, 25% glycerol, 1x Halt Protease 
and Phosphatase Inhibitor Cocktail (Thermo Scientific), 0.5% Triton X-100) of 
approximately equal volume to the pellet and incubated on ice for 10 minutes. 
The sample was then freeze-thawed 3-4 times to mechanically disrupt the cells. 
The extracts were then centrifuged at 16,000g at 4°C for 15 minutes to pellet 
any cell debris. Supernatant was collected. The protein concentration of the cell 
extract was determined by spectrophotometry (Biophotometer, Eppendorf) using 
Bio-Rad Protein Assay reagent (Bio-Rad). A standard curve was produced using 
BSA and protein extract absorbance was compared to this to determine 
concentration. Extracts were used for western blot or immunoprecipitation 
experiments. 
2.3 SDS-PAGE gel electrophoresis 
Protein samples were separated according to size using SDS-polyacrylamide gel 
electrophoresis. 12% vertical polyacrylamide gels (resolving gel: 375mM Tris pH 
8.8, 0.1% SDS, stacking gel: 125mM Tris pH6.8, 0.1% SDS) were poured and run 
with mini-Protean gel system (Bio-Rad). Electrophoresis was performed in SDS 
running buffer (76.8mM glycine, 10mM Tris pH8.3, 0.1% SDS). Alternatively, 12% 
or 4-12% Novex Bis-Tris precast gels were used with Novex NuPAGE SDS-PAGE Gel 
System (Life Technologies). For these gels, electrophoresis was carried out in 1x 
MOPS SDS Running Buffer (Life Technologies). 
10μg of protein extract was denatured by addition of 5μl of 4x SDS-PAGE loading 
buffer (125mM Tris pH6.8, 4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.04% 
bromophenol blue) and heating for 2 minutes at 100°C. The sample was then 
loaded into gel and electrophoresis performed at 180V until required separation, 
as determined by Full-Range rainbow ladder RPN800E (GE Healthcare).  
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2.4 Western blotting 
Protein was transferred from polyacrylamide gel to nitrocellulose membrane 
using BioRad wet transfer system. Transfer was carried out in transfer buffer 
(76.8mM glycine, 10mM Tris pH8.3, 20% methanol) at 4°C for 2 hours at 100V or 
overnight at 30V. Nitrocellulose was then blocked with blocking reagent, TBS-T 
(32.5mM Tris, 150mM NaCl, 0.2% Tween) with 5% milk or 5% BSA (when probing 
for phosphorylated proteins) for a minimum of 30 minutes. Primary antibody 
(Table 2.1) was added in 1% milk or 5% BSA for a minimum of 1 hour at room 
temperature. Blots were then washed three times with TBS-T to remove 
unbound antibody. An appropriate HRP-labelled secondary antibody (Dako) was 
added for a minimum of 1 hour at room temperature. For Western blots carried 
out with immunoprecipitated samples, HRP-labelled light chain specific-
secondary antibodies (Jackson) were used. Following incubation with secondary 
antibody, membrane was washed with TBS-Tween (3x5 minutes, 2x15 minutes) 
and TBS (1x 5 minutes). The presence of secondary antibody was visualised by 
enhanced chemiluminescence using Western Lightening ECL reagents (Perkin 
Elmer), followed by exposure of membranes to autoradiograph film. 
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Table 2.1 Primary antibodies used for western blot analysis 
  
Protein recognised Supplier Antibody Dilution 
HSP70 Santa Cruz Biotechnology sc-24 1:2000 
Tubulin Sigma-Aldrich T-9026 1:10,000 
Actin Santa Cruz Biotechnology sc-1615 1:5000 
p53 Santa Cruz Biotechnology sc-126 1:1000 
Phospho-p53(Ser9) Cell Signalling Technology #9288 1:1000 
Phospho-p53(Ser15) Cell Signalling Technology #9284 1:1000 
Phospho-p53(Ser20) Cell Signalling Technology #9287 1:1000 
Phospho-p53(Ser46) Cell Signalling Technology #2521 1:1000 
Phospho-p53(Ser392) Cell Signalling Technology #9251 1:1000 
Acetyl-p53 (Lys305) Biolegend 614102 1:1000 
Acetyl-p53 (Lys373) Millipore 06-916 1:50,000 
Acetyl-p53 (Lys382) Cell Signalling Technology #2525 1:1000 
Acetyl-p53 (Lys386) Abcam ab52172 1:500 
p14ARF Non-commercial (K. Vousden) 4037 1:1000 
Brf1 Non-commercial (R. White) 482 1:1000 
Phospho-Brf1 (Thr145) Non-commercial (R. White) SK2839 1:1000 
TBP Abcam ab818 1:3000 
TFIIIC110 Santa Cruz Biotechnology sc-81406 1:1000 
c-Jun (DNA binding domain) Santa Cruz Biotechnology sc-44 1:1000 
c-Jun (aa1-79) Santa Cruz Biotechnology sc-1694 1:1000 
c-Jun (N-terminal) Cell Signalling Technology #9165 1:1000 
Phospho-c-Jun (Ser 63) Santa Cruz Biotechnology sc-822 1:1000 
Phospho-c-Jun (Ser 63/73) Santa Cruz Biotechnology sc-16312 1:1000 
c-Fos Santa Cruz Biotechnology sc-447 1:1000 
c-Fos Santa Cruz Biotechnology sc-52 1:1000 
JNK Santa Cruz Biotechnology sc-474 1:1000 
JNK Cell Signalling Technology #9252 1:1000 
Phospho-JNK (Thr183/Tyr185) Cell Signalling Technology #9251 1:1000 
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2.5 Protein Immunoprecipitation 
The method of immunoprecipitation chosen was dependent whether cross-linking 
of antibody to beads was required. 
2.5.1 IP with crosslinking  
30μl of Protein A or G coated magnetics beads (Dynabeads, Life Technologies) 
were incubated with 5μg of antibody or appropriate IgG to a total volume of 
255μl in PBS/NP-40 (PBS, 0.015% NP-40) for a minimum of 1 hour at room 
temperature. The beads were then washed three times with conjugation buffer 
(20mM Sodium Phosphate, 0.15M NaCl (pH 7-9)) and incubated in 150μl of 5mM 
BS3 (bissulfosuccinimidyl suberate, Thermo Scientific) for 30 minutes at room 
temperature to crosslink antibody to beads. The crosslinking reaction was then 
quenched by addition of 7.5μl of Tris(pH 7.5). Subsequently, the beads were 
washed 3 times with PBS/NP40 and resuspended in 200μl PBS/NP40. 250-500μg 
of protein and 100x protease and phosphatase inhibitor cocktail (PPIC, to a final 
concentration of 1x, Fisher Scientific) were added. Following 3 hour incubation 
on a rotating wheel at 4°C, beads were washed with PBS/NP40 4 times. Bound 
protein was eluted by incubation in 2xSDS-PAGE loading buffer at 80°C for 5 
minutes in shaking incubator. Samples were then applied to magnet (to separate 
the beads) and supernatant removed to fresh tubes. 10% of input protein extract 
was taken and an equal volume of 4x SDS-PAGE loading buffer was added 
followed by heating at 80°C for 5 minutes in shaking incubator. IP and input 
samples were then heated at 100°C for 2 minutes and analysed by gel 
electrophoresis and western blotting. 
2.5.2 IP without crosslinking 
When no crosslinking was required, 5μg of primary antibody (Table 2.2) was 
incubated with 250-500μg protein extract and PPIC (to 1x concentration) for 3 
hours at 4°C on rotating wheel. 30μl Protein A or G magnetic beads (Dynabeads, 
Life Technologies) were washed 3 times with PBS/NP40 (PBS, 0.015% NP-40) and 
blocked in 50μl 1mg/ml BSA (made up in PBS/NP-40) for 15 minutes. Blocking 
buffer was then removed and antibody/protein complexes were added to beads. 
Following 2 hour incubation at 4°C on rotating wheel, beads were washed 4 
times with PBS/NP40 and the bound protein was eluted by incubation in 2xSDS-
Chapter 2: Materials and Methods    
54 
 
PAGE loading buffer at 80°C for 5 minutes in shaking incubator. 10% of input 
protein extract was taken and an equal volume of 4x SDS-PAGE loading buffer 
was added followed by heating at 80°C for 5 minutes in shaking incubator. IP 
and input samples were then heated at 100°C for 2 minutes and analysed by gel 
electrophoresis and western blotting.  
Protein recognised Supplier Antibody 
IgG (mouse) Sigma-Aldrich  
IgG (rabbit) Sigma-Aldrich  
c-Jun (DNA binding domain) Santa Cruz Biotechnology sc-44 
TFIIIC110 Santa Cruz Biotechnology sc-81406 
GFP Life Technologies A6455 
JNK Santa Cruz Biotechnology sc-474 
Table 2.2 Antibodies used for immunoprecipitation 
 
2.6 RNA extraction 
Cells were washed 2-3 times with cold PBS and scraped into 1ml TRIzol (Life 
Technologies) (per 10cm plate). Samples in TRIzol were then snap frozen and 
stored at -80°C until time of RNA extraction. At this time, samples were thawed 
at room temperature and 200μl chloroform was added per 1ml TRIzol. Sample 
was vortexed thoroughly and allowed to stand briefly before centrifugation at 
16,000g for 15min at 4°C. Of the resulting three phases of liquid, the top phase 
was carefully removed to a fresh eppendorf tube. To this, 0.5ml isopropanol was 
added (per 1ml of TRIzol) and mixed gently by inverting tube several times. The 
sample was then centrifuged for 10min at 16,000g at 4°C and supernatant was 
discarded. The remaining pellet was washed with 1ml 75% ethanol. The tube was 
then centrifuged for 5min at 9000g at 4°C. The ethanol was removed and pellet 
allowed to air dry. As soon as pellet went transparent,  it was resuspended in 20-
50μl of DEPC-treated water and placed at 55°C in shaking incubator for 15 
minutes to ensure complete rehydration. RNA was quantified using a Nanovue 
spectrophotometer (GE Healthcare) and stored at -80°C.   
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2.7 cDNA preparation 
Two alternative reverse transcription methods were used to prepare cDNA from 
RNA. SuperScript III (Life Technologies) was used for Figure 3.4. QuantiTect 
Reverse Transcription kit (Qiagen) was used for all other reverse transcription. 
SuperScript III 200ng of RNA and 2μl of 10x hexanucleotide mix (Roche) were 
combined and total volume made up to 25μl with nuclease-free water. This was 
then incubated at 80°C for 10min and transferred directly onto ice. 8μl First 
Strand Buffer (Life Technologies), 4μl 0.1M DTT, 2μl 10mM dNTP mix and 1μl 
SuperScript III reverse transcriptase (RT) were then added and the reaction 
mixture was incubated at 50°C for 1 hour. RT inactivation was carried out by 
incubation at 70°C for 15min. Alongside, cDNA was also prepared from 400ng of 
RNA (to analyse whether reaction was quantitative). To determine whether the 
RNA was contaminated with genomic DNA, reactions lacking RT were also carried 
out. cDNA was stored at -20°C. 
Quantitect Reverse Transcription Reverse transcription was carried out 
according to manufacturer’s instructions. 10ng of RNA was used for each sample. 
In addition, reverse transcription of 20ng and 5ng of RNA was carried out to test 
whether the reaction was quantitative. No RT controls were used to check for 
genomic DNA contamination of RNA samples. cDNA was stored at -20°C. 
2.8 Chromatin Immunoprecipitation 
Cells were grown to about 80% confluency in 10cm dishes and crosslinking of 
chromatin was carried out by addition of formaldehyde to the media to a final 
concentration of 1% and incubation for 7-10 minutes at room temperature. To 
quench crosslinking reaction, glycine was added to the final concentration of 
0.125M at room temperature for 5 minutes. Plates were placed on ice and most 
of the media was discarded. Cells were scraped into remaining media while 
maintained on ice. Cells in the resulting suspension were then pelleted by 
centrifugation at 400g for 5 minutes at 4°C. This pellet was washed by 
resuspension in PBS + 0.5% NP-40, followed by centrifugation. This wash step was 
repeated once more and pellet was snap frozen and stored at -80°C until 
required. 
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Cell pellet was thawed and washed once with PBS + 0.5% NP-40 and spun down 
(400g for 5 minutes at 4°C). Pellet was then resuspended in cold high salt buffer 
(PBS, 1M NaCl, 0.5% NP-40) and incubated for 30 minutes on ice. This was then 
centrifuged at 400g for 5 minutes at 4°C and the resulting pellet washed once 
with PBS + 0.5% NP-40 as above. It was then resuspended in low salt buffer (LSB) 
(0.1M NaCl, 10mM Tris, 1mM EDTA, 0.1% NP-40) and incubated for 30 minutes on 
ice. The cells were then pelleted, supernatant discarded and resuspended in 
600μl LSB. This suspension was then passed through a 26G needle three times. 
The volume was then made up to 2.7ml with LSB and was mixed with 300μl of 
20% (w/v) N-laurylsarcosine sodium salt. The suspension was then transferred to 
a 50ml Falcon tube containing 40 ml LSB/100mM sucrose, carefully to ensure the 
suspension sat at the top. This was then centrifuged at 4000g for 10 min at 4°C. 
Following this, the pellet was resuspended in 2ml TE (10mM Tris pH8, 1mM 
EDTA) and passed through another sucrose cushion. The pellet was then 
resuspended in 2ml TE and mixed with 200μl of 11x NET buffer (550mM Tris 
pH7.4, 1.65M NaCl, 5.5mM EDTA, 5.5% NP-40). This was then sonicated at 4°C in 
a water bath sonicator (Biorupter, Diagnode) for 10 minutes (30sec on/30sec 
off). Ice was replaced and this was repeated a further two times. The resulting 
suspension was centrifuged at 16000g for 15min at 4°C to pellet the cellular 
debris. 
The supernatant (containing sonicated chromatin) was aliquoted evenly into 
microcentrifuge tubes, according to the number of IPs to be carried out. 10% of 
the volume of an aliquot was taken for the 10% input sample. 2-5μg of antibody 
(Table 2.3) was added to each tube and they were incubated overnight at 4°C on 
a rotor wheel. The following day, 50μl protein G sepharose beads (for Pol III and 
histone ChIPs) or 30μl protein G magnetic beads (other ChIPs) were washed three 
times in 1xNET buffer (made up with TE) and added to each IP. These were 
incubated for 2 hours at 4°C. The beads were then washed twice with cold RIPA 
buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-
40), twice with cold LiCl buffer (10mM Tris-HCl pH8.0, 250mM LiCl, 0.5% 
deoxycholate, 0.5% NP-40, 1mM EDTA) and twice with cold TE. For elution from 
sepharose beads, the beads were incubated in 400µl of TE/1%SDS for 10 minutes 
at room temperature. 10% input was made up to 400μl with TE/1%SDS. 20μg of 
RNase A (Life Technologies) was added to all samples and they were then 
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incubated at 37°C for 1 hour. Proteinase K was added to the concentration of 
0.125mg/ml and samples incubated at 42°C overnight. DNA was purified using 
Qiagen PCR Purification kit (according to manufacturer’s instructions). For 
elution from magnetic beads and DNA purification (adapted from (Nelson et al., 
2006)), 50μl of 10% Chelex 100 (BioRad) was mixed with beads or 10% input and 
heated at 95°C for 15 minutes. Samples were cooled and treated with 
0.125mg/ml Proteinase K for 30 minutes at 55°C in heated shaker. Samples were 
then heated to 95°C for a further 10 minutes to inactivate Proteinase K. Samples 
were made up to 250μl total volume with H2O (Milli-Q purified), vortexed for 10 
seconds and centrifuged at 4°C for 1min at 12000g. 100μl of supernatant was 
carefully removed to a fresh tube and the remaining supernatant and pellet was 
discarded. All ChIP samples were stored at -20°C before analysis by qPCR.   
 
 
Protein recognised Supplier Antibody 
TAF I 48 Santa Cruz Biotechnology sc-6571 
RPC155 (Pol III subunit) Non-commercial (R. White) 1900 
Brf1  Non-commercial (R. White) 127 
TBP Abcam ab818 
Histone H3 Abcam ab1791 
HDAC1 Santa Cruz Biotechnology sc-7872 
HDAC2 Santa Cruz Biotechnology sc-7899 
Acetyl-histone H3 (pan) Millipore 06-599 
Phospho-histone H3 (Ser10) Santa Cruz Biotechnology sc-8656 
JNK Santa Cruz Biotechnology sc-474 
Table 2.3 Antibodies used in chromatin immunoprecipitation 
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2.9 qPCR 
Gene expression analysis (RT-qPCR) and ChIP analysis (qPCR) were carried out in 
96 well plates using C1000 Thermocycler CFX96 Real Time System (Bio-Rad). 
Total reaction volume per well of 10μl. For gene expression analysis, 5μl 
PerfeCTa SYBR Green Fast Mix (Quanta BioSciences), 0.25µl of 10µM forward 
primer, 0.25µl of 10µM reverse primer, 0.5μl cDNA and 4μl Milli-Q filtered H2O. 
For ChIP analysis, 0.5μl of DNA was used after purification by Qiagen Purification 
kit or 2.5μl of sample was used after purification by Chelex (H2O volume altered 
to maintain 10μl reaction volume). For gene expression analysis, a two-step 
protocol was used, 5 min at 95°C followed by 35 cycles of [95°C for 30sec, 60°C 
(58°C for c-Jun primers)  for 20sec]. For ChIP analysis, a three step protocol was 
used, 5 min at 95°C followed by 35 cycles of [95°C for 30 sec, 60°C for 20 sec, 
72°C for 10 sec]. Samples were tested in duplicate and a standard curve made 
with combined samples (cDNA analysis) or input DNA (ChIP analysis) was used to 
determine efficiency of the PCR reaction in each sample. A well containing no 
sample (no template control, NTC) was included for each primer set to test for 
primer dimer formation. Data was collected and analysed in BioRad CFX Manager 
software (Version 2.1.1022.0523). Further analysis was carried out in Microsoft 
Excel. In gene expression analysis, the average starting quantity (SQ) of 
duplicates was determined and normalised to the average of loading control 
(ARPP P0). For ChIP samples, the signal was quantified as percentage of signal in 
input. % input was calculated with the formula [(IP/input)x100] – [(TAFI48 
IP/input)x100]. 
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Target cDNA Primer sequences 
ARPP P0 
F GCACTGGAAGTCCAACTACTTC 
R TGAGGTCCTCCTTGGTGAACAC 
tRNALeu 
F ATGGCGAGTGGTCTAAGG 
R ACCAGAAGACCCGAACACAG 
tRNATyr 
F CCTTCGATAGCTCAGCTGGT 
R CGACCTAAGGATGTCCACAAAT 
tRNAIle 
F GGCGGCCGGTTAGCTCAG 
R CCCGTACGGGGATCGAAC 
tRNAiMet 
F AGAGTGGCGCAGCGGAAG 
R GAGGATGGTTTCGATCCATC 
tRNAPro 
F GCTCGTTGGTCTAGGGGT 
R CTCGTCCGGGATTTGAAC 
5S rRNA 
F GGCCATACCACCCTGAACGC 
R CAGCACCCGGTATTCCCAGG 
Brf1 
F TGGCCCACGTGATTGCTGCC 
R CAGCAGGTGCGCAAAGCGTG 
TBP 
F CTCAGGGTGCCATGACTCCCG 
R TTGTTGTTGCTGCTGCTGCCTTTG 
Bdp1 
F GATCAGAGCAAGGAAGGCAAGCCAGAAG 
R CAACTGAAGATGGTGAATTATCTACTACAG 
c-Jun 
F CCCCAAGATCCTGAAACAGA 
R CCGTTGCTGGACTGGATTAT 
Table 2.4 Primer sequences for RT-qPCR 
 
Target gene Primer sequences 
tRNALeu 
F ATGGCGAGTGGTCTAAGG 
R ACCAGAAGACCCGAACACAG 
tRNATyr 
F CCTTCGATAGCTCAGCTGGT 
R CGACCTAAGGATGTCCACAAAT 
tRNAVal 
F TGTAGCTCAGTGGTAGAGC 
R GAAACGAAATGTTCAACGATAG 
tRNAThr 
F GTGGCCAAGTGGTAAGGCGTC 
R ACCCGACTTCCCCACAGCC 
tRNALeu 
(inactive) 
F CTTGAAACTTGCCCCAGTCA 
R TTCGCGTACTTTTTAAATGCTG 
Table 2.5 Primers sequences used in qPCR analysis of ChIP samples 
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2.10 Cell Cycle Analysis 
Following treatment, cells were trypsinised (approximately 2.5x105 cells per 
treatment) and transferred to 15ml Falcon tube. They were then centrifuged at 
180g for 5 minutes at room temperature and washed once in PBS. Next, the cell 
pellet was resuspended in 300μl PBS and 700μl of 100% ethanol was added 
dropwise while vortexing. Then placed at -20°C for a minimum of 1hr. Once 
fixed, tubes centrifuged directly from freezer. Cell pellet was then washed once 
in PBS and resuspended in 300μl of PBS containing 10μg/ml propidium iodide (PI) 
and 250μg/ml RNase A. Incubated in dark at room temperature for 30 minutes. 
Samples were then stored at 4°C until analysis by flow cytometry on a BD 
Biosciences FACSCalibur. Cell cycle profiles determined using Cell Quest Pro (BD 
Bisosciences.    
2.11 Bioinformatics and data analysis  
ChIP-seq data downloaded from GEO database, accession number: 
GSE19551(Raha et al., 2010) and GSE25533 (Tiwari et al., 2011) 
ChIP-seq data downloaded from: http://genome.ucsc.edu/cgi-
bin/hgTrackUi?db=hg18&g=wgEncodeYaleChIPseq (Moqtaderi et al., 2010)   
List of tRNAs in the human genome from the Genomic tRNA Database 
(http://lowelab.ucsc.edu/GtRNAdb/) (Chan and Lowe, 2009) 
ChIP-seq data mined by Damian Graczyk. All ChIP-seq peaks mined had a p-value 
of less than 0.05. TRE/CRE and CCAAT motif searches carried out by Ann Hedley. 
Upon receiving the data from ChIP-seq and motif search, I carried out all of the 
data analysis myself.  
All data analysis was carried out using Microsoft Excel. All graphs were created 
using Microsoft Excel, with the exception of Venn diagrams which were created 
using Google Charts. All error bars represent standard deviation from the mean. 
Student T-test was used to determine significance where indicated. Chi-squared 
test was used to analyse the association between binding motifs and/or protein 
occupancy at tRNA genes. 
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3 Regulation of RNA Polymerase III-mediated 
transcription by p53 
3.1 Introduction 
p53 was first shown to regulate Pol III-mediated transcription over a decade ago 
(Chesnokov et al., 1996, Cairns and White, 1998). Since then, the mechanism for 
this repression has been determined: p53 sequesters TFIIIB, preventing its 
recruitment to the promoter, as described in Chapter 1 (Cairns and White, 1998, 
Crighton et al., 2003). However, little is understood about when p53 regulates 
Pol III-mediated transcription following p53 activation in vivo. How is p53’s 
regulation of Pol III-mediated transcription regulated? In a cell, p53 can be 
activated by many different stimuli and can result in a range of different 
outcomes including cell cycle arrest, DNA repair, senescence, apoptosis, 
induction of autophagy and changes in metabolism (Vogelstein et al., 2000, 
Vousden and Prives, 2009). It is possible that repression of Pol III-mediated 
transcription may be beneficial in some intended outcomes of p53 activation but 
not others. For example, after cell cycle arrest, Pol III repression may contribute 
to the slowing of growth that is required to maintain cell size when division 
stops. In contrast, upon induction of apoptosis there may be little selection for 
the repression of Pol III-mediated transcription because the cell is going to die 
anyway. In this chapter, I will address whether repression of Pol III–mediated 
transcription is a universal response to p53 activation or is dependent upon the 
activating signal and the desired outcome.  
The clearest example of p53 repression of endogenous targets of Pol III as part of 
a stress response was described by Morton and colleagues in 2007 (Morton et al., 
2007). They showed that induction of ARF in U2OS osteosarcoma cells resulted in 
reduced tRNA expression and this was dependent upon ARF’s ability to induce 
p53 activity. ARF induction is a model for oncogenic stress, as ARF is the central 
mediator of the oncogenic stress response (Lowe and Sherr, 2003). ARF 
(otherwise known as p14ARF in humans and p19ARF in mice) is induced through 
increased expression and stabilisation by E2F1, Myc and Ras overexpression (Gil 
and Peters, 2006, Sherr, 2006). Once induced, ARF binds to MDM2 and prevents 
it from binding p53. p53 is, therefore, no longer targeted for degradation and 
thus p53 is stabilised. ARF is central to p53 induction that occurs following 
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oncogenic stress. Morton and colleagues found that E2F1 overexpression resulted 
in Pol III repression and attributed this to the activation of p53 by ARF. Upon 
oncogenic stress, p53 causes cell cycle arrest and may induce senescence or 
apoptosis (Sherr, 2006). This prevents a cell’s continued proliferation following 
the damage that may be inflicted by oncogene overexpression.   
Hypoxia, ribonucleotide depletion and DNA damage can all result in Pol III 
repression (Ernens et al., 2006, Crighton et al., 2003, Gridasova and Henry, 
2005). In rat cardiomyocytes, hypoxia (1% oxygen) did not result in p53 induction 
and repression of Pol III-mediated transcription was attributed to the increased 
binding of RB, and reduced binding of c-Myc and ERK, to TFIIIB (Ernens et al., 
2006). Ribonucleotide depletion was carried out by mycophenolic acid (MPA) 
treatment, which prevents guanine synthesis, inducing p53 by causing nucleolar 
stress (Sun et al., 2008). Repression of Pol III-mediated transcription was 
observed following MPA treatment of U2OS cells (T. Kantidakis and R. White, 
unpublished). However, in cells in which p53 had been knocked down, MPA had 
the same Pol III repressive effect, suggesting p53 was not required for the 
repression observed. Methyl methanesulfonate (MMS) causes DNA damage by 
methylation of DNA (Wyatt and Pittman, 2006). This damage induces p53 in HeLa 
cells and suppresses Pol III-mediated transcription (Crighton et al., 2003). 
However, the repression of Pol III-mediated transcription is independent of p53 
(J. Morton and R. White, unpublished). DNA damage is also induced by UV 
exposure (Latonen and Laiho, 2005). Interestingly, Gridasova and Henry found 
that the Pol III products U6 and 5S rRNA showed different responses to UVC 
exposure, 5S levels increased and U6 levels decreased in the MCF7 breast cancer 
cell line upon exposure to UVC (Gridasova and Henry, 2005). Further 
investigation suggested that these changes may be p53 dependent. As Pol III 
transcribes U6 and 5S rRNA from different promoters, this provides an intriguing 
hint that p53 regulation may occur by different mechanisms at different Pol III 
promoter structures.  It also provides the first indication that p53 may repress 
Pol III-mediated transcription in vivo following a stimulus other than oncogenic 
stress. Clearly, repression of Pol III-mediated transcription is a frequent outcome 
of stress. However, activation of p53 does not always lead to p53-induced 
repression of Pol III-mediated transcription. 
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The physiological outcome of p53 induction is the result of the integration of 
many factors influenced by the nature and magnitude of the stress and the 
cellular environment (Murray-Zmijewski et al., 2008, Espinosa, 2008). p53 
interacts with many proteins that contribute to its activity (Beckerman and 
Prives, 2010). It is also targeted for multiple post-translational modifications 
which can alter its stability and its ability to interact with cofactors and DNA 
(Meek and Anderson, 2009, Dai and Gu, 2010). Thus, in two different cell types, 
the same stress can cause different outcomes to p53 induction. Conversely, two 
different stimuli can induce the same outcome to p53 induction. Pol III 
repression by p53 has been studied in a diverse range of cell types so far. It is 
therefore difficult to conclude if differences in the effect of p53 on Pol III-
mediated transcription are due to inherent differences in the stimuli involved or 
due to differences in cell type. For this reason, in this chapter, the response of 
Pol III-mediated transcription to stress is examined in U2OS only. U2OS were 
chosen as they are the parental cell of the ARF-inducible (NARF2) cells in which 
repression of Pol III-mediated transcription following ARF induction was shown to 
be p53 dependent and they have a functional p53 pathway (with the exception 
of ARF) (Morton et al., 2007).  
The conflicting results from MMS and UVC treatment suggest that the type of 
DNA damage inflicted may play a role in determining how Pol III-mediated 
transcription is regulated (Crighton et al., 2003, Gridasova and Henry, 2005). 
p53 induction by DNA damage occurs via two main pathways, however cross-talk 
is likely to exist (Vogelstein et al., 2000). In one, double-stranded DNA breaks 
cause ATM induction and this induces p53 via Chk2. Other types of DNA damage, 
such as DNA crosslinking, induce p53 via ATR and Chk1.  ATM and ATR induce 
different post-translational modifications of p53, allowing the outcome of p53 
induction to be tailored to the stimulus (Meek, 2009). As p53 represses Pol III-
mediated transcription by interacting with TFIIIB, we hypothesise that a likely 
route by which this interaction may be regulated is through the post-
translational modification of p53. In this model, upon stress, p53 is induced but 
this only causes repression of Pol III-mediated transcription if a specific post-
translational modification of p53 occurs, promoting its interaction with TFIIIB. In 
this chapter, the post-translational modification of p53 is examined following 
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several stresses to determine if there is a correlation between modification and 
p53’s ability to repress Pol III-mediated transcription.      
In this chapter, the effect of UVC and doxorubicin on Pol III-mediated 
transcription is examined. UVC was chosen in order to extend the study by 
Gridasova and Henry, in which they show that U6 and 5S rRNA respond 
differently to 50J/m2 UVC treatment (Gridasova and Henry, 2005). UVC 
(<280nm) is absorbed by the DNA resulting in the formation of pyrimidine 
photodimers. These, in turn, can result in double-stranded breaks (Latonen and 
Laiho, 2005). UV can also induce DNA-independent effects on the cell, such as 
through the activation of JNK and p38 kinases. Doxorubicin (Adriamycin) was 
chosen as it is a common chemotherapeutic drug that causes robust p53 
induction. It is a topoisomerase inhibitor and, like UV, causes double-stranded 
breaks. The concentration of doxorubicin used was chosen as it resulted cell 
cycle arrest rather than cell death. p53 activation will often result in cell cycle 
arrest following DNA damage, allowing the cell time to repair damage before 
damage is transferred to the daughter cells. Cell death may be induced following 
stronger damage. Repression of Pol III-mediated transcription will contribute to 
the repression of protein synthesis following cell cycle arrest (Ruggero and 
Pandolfi, 2003). Whether regulation of Pol III-mediated transcription is 
advantageous during cell death is unclear. 
In this chapter, the effect of two alternative DNA damage stimuli on Pol III-
mediated transcription and on p53 induction is examined. The post-translational 
modification of p53 that occurs following these treatments is compared to those 
following ARF induction to examine whether any of these modifications may 
contribute to p53’s ability to repress Pol III-mediated transcription. Whether 
basal levels of p53 may also regulate Pol III-mediated transcription is also 
addressed. 
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3.2 Results 
3.2.1 Doxorubicin causes p53-independent repression of tRNA 
transcription 
To examine the cellular response to DNA damage, U2OS expressing a scrambled 
(Scr) or p53 shRNA were treated with 200ng/ml of doxorubicin. This is a low 
dose, resulting in no detectable cell death by the time of harvest (data not 
shown). Cells were harvested 1 hour and 6 hours after treatment. A large 
increase in p53 levels was observed in the Scr shRNA expressing cells after 6 
hours, as determined by western blot (Figure 3.1). Phosphorylation of p53 at 
Serine 15 was also detectable by this time point. This modification is indicative 
of activation of the DNA damage response. In the cells expressing p53 shRNA, 
basal levels of p53 were lower and p53 levels, while increasing upon doxorubicin 
treatment, did not reach the levels seen in the Scr shRNA–expressing cells 
(Figure 3.1). Likewise, little p53 phosphorylated at serine 15 was detectable. 
Treatment of U2OS Scr shRNA cells with doxorubicin resulted in a 50-80% 
reduction in tRNATyr, tRNALeu and tRNAi
Met levels compared to control treated 
(Figure 3.2). The reduction in tRNA levels was also observed in p53 shRNA-
expressing cells when treated with doxorubicin, suggesting that repression of 
tRNA levels following doxorubicin treatment is independent of p53 (Figure 3.2). 
 
Figure 3.1  Doxorubicin treatment increases p53 protein levels 
Analysis by western blot of p53 and phospho-p53(Ser15) protein levels in U2OS stably 
expressing shRNA targeted to a scrambled sequence or p53, and treated with 200ng/ml 
doxorubicin or H2O. Cells were harvested 1hr or 6hr post-treatment. HSP70 used as a 
loading control. n=1 
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Figure 3.2  A non-lethal dose of doxorubicin results in p53-independent repression 
of tRNA transcription 
Analysis by RT-qPCR of tRNALeu, tRNAi
Met and tRNATyr levels in U2OS stably expressing 
shRNA targeted to a scrambled sequence or p53, and treated with 200ng/ml doxorubicin 
or H2O. Cells were harvested 6hr post-treatment. Expression was normalised to ARPP P0 
mRNA levels. n=3  
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3.2.2 UVC upregulates Pol III-mediated transcription 
U2OS cells were exposed to 50J/m2 UVC and were harvested for protein and RNA 
eight hours later. This resulted in minimal increase in p53 levels, according to 
western blot analysis (Figure 3.3, Figure 3.5). However, the proportion of p53 
phosphorylated at Serine 15 rose dramatically (Figure 3.3). UVC treatment 
resulted in a small but significant increase in tRNAi
Met, tRNALeu and 5S rRNA levels 
(Figure 3.4a). This is consistent with the increase in 5S rRNA levels observed in 
MCF7 cells following UVC treatment (Gridasova and Henry, 2005). Interestingly, 
levels of mRNA for the TFIIIB subunits, TBP, Brf1 and Bdp1, are reduced 
following UVC treatment (Figure 3.4b). This is not reflected in the protein levels 
of TBP and Brf1, which appear to remain unchanged (Figure 3.3). In future 
studies, it will be interesting to examine whether the increased tRNA and 5S 
rRNA levels are dependent upon p53. If they are, they are unlikely to be due to 
p53’s established repressive effect on Pol III-mediated transcription through 
binding to TFIIIB.  
 
Figure 3.3  Exposure to UVC induces p53 activation 
Analysis by western blot of p53, phospho-p53(Ser15), Brf1 and TBP protein levels in 
U2OS (stably expressing scrambled shRNA) 8hr after exposure to 50J/m2 UVC. Tubulin 
used as a loading control. n=1 
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Figure 3.4  Exposure to UVC induces Pol III-mediated transcription 
Analysis by RT-qPCR of a) tRNAi
Met , tRNALeu and  5S rRNA levels (n=4) and b)TBP, Brf1 
and Bdp1 mRNA levels (n=3) in U2OS (stably expressing scrambled shRNA) 8hr after 
exposure to 50J/m2 UVC. The expression was normalised to ARPP P0 mRNA levels. 
*p<0.05, ***p<0.01 ***p<0.001 
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3.2.3 p53 modification following oncogenic stress and DNA 
damage  
I hypothesised that p53 repression of Pol III-mediated transcription may require a 
specific post-translational modification of p53, allowing it to interact with 
TFIIIB. A difference in modification status could explain why p53 represses Pol III 
following oncogenic stress but not doxorubicin treatment. Therefore, western 
blotting was employed to probe for different post-translational modifications of 
p53 following UVC treatment and doxorubicin treatment in U2OS and ARF 
induction in NARF2 cells. The NARF2 cells were induced with IPTG according to 
the protocol of Morton et al. (Morton et al., 2007). Induction of ARF and 
increased p53 levels were detectable following IPTG treatment (Figure 3.5b). In 
addition, reduced tRNATyr and 5S rRNA levels were detected by semi-quantitative 
RT-PCR following ARF induction (data not shown). Cells were also treated with 
UVB (50J/m2), however the effect of UVB on Pol III-mediated transcription 
remains to be determined. Doxorubicin and ARF induction resulted in very 
similar total p53 levels, while UVC-exposed cells only showed weak p53 
induction (Figure 3.5a). An increase in phosphorylation of p53 at Serine 9 and 
Serine 15 was apparent in UVB, UVC and doxorubicin treated cells compared to 
their respective controls (Figure 3.5a). A slight increase in Serine 15 
phosphorylation and no increase in Serine 9 phosphorylation was detectable in 
NARF2 cells when ARF was induced.  Phosphorylation at Serine 20 and Serine 46 
was detectable at low levels but did not change with ARF induction. Slight 
increases in Serine 20 and Serine 46 phosphorylation occurred in both UVB and 
UVC treated cells compared to control. While, with doxorubicin treatment 
Serine 46 phosphorylation was slightly reduced. Phosphorylation at Ser20 does 
not change with doxorubicin treatment. Interestingly, an increase in 
phosphorylation at Serine 392 occurred with all treatments. It was highest 
following doxorubicin treatment, while p-p53(Ser392) levels were lower 
following ARF induction and lower still following UV exposure.  
Acetylation of p53 was also examined. Acetylation of p53 at Lysine 382 was 
undetectable in NARF2 cells (Figure 3.6). Acetylation at Lysine 305, Lysine 373 
and Lysine 386 was detectable and may have reduced slightly with ARF 
induction. Only acetylation at Lysine 382 changed with doxorubicin treatment. 
Following treatment, an additional band was detectable below the band present 
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in the untreated cells. This is indicative of acetylation, as proteins usually 
migrate faster when acetylated. There may be a slight increase in acetylation at 
all sites examined following both UVB and UVC treatment. However as this is 
very subtle, further examination is necessary. Overall, changes in p53 
modification were very limited compared to changes in total p53 levels 
observed, with the exception of phosphorylation at Serines 15 and 392. In 
particular, there was no evidence of p53 modification in ARF-induced cells that 
distinguishes it from the other treatments and could account for p53’s ability to 
repress Pol III-mediated transcription following this treatment. This does not 
rule out the possibility that modification of p53 is required for p53 to interact 
with TFIIIB and, as a result, repress Pol III-mediated transcription. This remains 
an interesting hypothesis for future studies. 
 
 
Figure 3.5  Analysis of p53 phosphorylation following DNA damage and ARF-induction 
a) Analysis by western blot of total p53 protein level and levels of p53 phosphorylated 
at Ser9, Ser15, Ser20, Ser46 or Ser392 in U2OS, following 50J/m2 UVB (harvested 8hr 
post-treatment), 50J/m2 UVC (harvested 8hr post-treatment), 580ng/ml doxorubicin or 
H2O (harvested 24hr post-treatment), and NARF2, -/+ 1mM IPTG to induce expression 
ARF (harvested 24hr post-induction). HSP70 used as a loading control. n=1 b) Analysis by 
western blots of p14ARF and p53 protein levels in NARF2 cells following induction by IPTG 
for 24 hours. Tubulin used as a loading control. 
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Figure 3.6  Analysis of p53 acetylation following DNA damage and ARF-induction 
Analysis by western blot of total p53 protein level and levels of p53 acetylated at 
Lys305, Lys373, Lys382 or Lys386 in U2OS U2OS, following 50J/m2 UVB (harvested 8hr 
post-treatment), 50J/m2 UVC (harvested 8hr post-treatment), 580ng/ml doxorubicin or 
H2O (harvested 24hr post-treatment), and NARF2, -/+ 1mM IPTG to induce expression 
ARF (harvested 24hr post-induction). HSP70 protein level is a loading control. n=1 
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3.2.4 Basal p53 levels do not influence tRNA levels in RKO and 
MCF7 cell lines  
Having examined the role of p53 in regulating Pol III-mediated transcription 
under stress conditions, I wanted to determine whether basal levels of p53 could 
influence Pol III activity. To examine this, RKO (colon cancer cell line with wild- 
type p53) and MCF7 (breast cancer cell line with wild type p53) cells stably 
expressing a scrambled shRNA or a shRNA targeting p53 were cultured and 
harvested. Western blotting showed that p53 shRNA expression resulted in 
reduced p53 levels in both cell types (Figure 3.7). However, no significant 
differences in tRNALeu, tRNAIle and tRNAi
Met levels were observed between cells 
expressing the scrambled and p53 shRNA, when examined by RT-qPCR (Figure 
3.8). Returning to Figure 3.2, in untreated U2OS expressing the same shRNAs, 
tRNATyr and tRNAi
Met levels did not differ between shRNA. However, tRNALeu 
levels were significantly higher in U2OS in which p53 had been knocked down, 
than in the Scr shRNA-expressing U2OS. Overall, these finding suggests that basal 
levels of p53 may regulate Pol III-mediated transcription but this regulation is 
likely to be subtle and, potentially, cell type dependent.   
 
 
Figure 3.7  p53 protein level is reduced in cells stably expressing p53 shRNA 
Analysis by western blot of p53 protein levels in RKO and MCF7 cells stably expressing 
shRNA targeted to a scrambled sequence or p53. HSP70 protein level is a loading 
control. n=3 
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Figure 3.8  Stable knockdown of p53 in RKO and MCF7 cells does not alter tRNA 
levels 
Analysis by RT-qPCR of tRNALeu, tRNAIle and tRNAi
Met levels in a) RKO cells stably 
expressing shRNA targeted to a scrambled sequence or p53 and b) MCF7 cells stably 
expressing shRNA targeted to a scrambled sequence or p53. The expression was 
normalised to ARPP P0 mRNA levels. Student t-tests showed no significant differences. 
n=3 
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3.3 Discussion 
Following stress, a cell usually undergoes arrest. Subsequently, it may re-enter 
the cell cycle, it may undergo senescence, or cell death may occur (Vousden and 
Prives, 2009). Cell cycle arrest allows the cell to recover and repair any damage 
done by the stress before the next cell division. When a cell arrests, it is 
essential that cell growth (accumulation of cellular mass) is also arrested in 
order to maintain a constant cell size. Ribosome biogenesis is rate limiting for 
growth and protein synthesis is key to cell growth as the majority of dry cellular 
mass is protein (Ruggero and Pandolfi, 2003). It has been demonstrated that 
repression of Pol III activity is part of this cell growth arrest (Goodfellow and 
White, 2007). This is not a surprising finding as Pol III-mediated transcription is 
responsible for producing 5S rRNA, tRNAs and other important components of the 
protein synthesis machinery (Dieci et al., 2007). In mammals, p53 is the key 
initiator of cell cycle arrest and cell death in response to stress (Vogelstein et 
al., 2000). p53 can also repress Pol I and Pol III-mediated transcription which 
together produce the RNA components of the ribosome (Chesnokov et al., 1996, 
Cairns and White, 1998, Budde and Grummt, 1999). However, as demonstrated 
in this chapter, repression of Pol III activity in response to stress does not always 
require p53. Furthermore, the results following UVC treatment demonstrate that 
Pol III repression may not be a universal response to stress. 
Gridasova and Henry found that 5S rRNA transcription increased upon exposure 
of MCF7 cells to 50J/m2 of UVC (Gridasova and Henry, 2005). I found that this 
also occurs in U2OS cells (Figure 3.4a). And tRNA levels, which were not studied 
by Gridasova and Henry, also increased. It is interesting that similar effects are 
observed in 5S rRNA and tRNA levels as tRNA and 5S rRNA genes share a similar 
promoter structure (Type 2 and Type 1 respectively) (Figure 1.2). They bind 
TFIIIC and TFIIIB is then recruited. In contrast, U6 exhibited reduced levels 
following UVC exposure (Gridasova and Henry, 2005). This has a more disparate 
promoter structure (type 3) and TFIIIC is not part of the PIC at this promoter and 
the TFIIIB recruited contains Brf2 rather than Brf1. It is likely that targeting of a 
shared feature in PIC formation is responsible for the increases in 5S rRNA and 
tRNA levels seen. Gridasova and Henry found that overexpression of p53 in HeLa 
cells resulted in an increase in 5S rRNA levels. As a result, they concluded that 
the increase in 5S rRNA levels following UVC treatment in MCF7 cells was also 
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likely to be p53 dependent. However, the effects of UVC treatment and p53 
overexpression are not comparable so this conclusion should be treated 
cautiously. Unfortunately, time restrictions prevented the determination of p53 
dependency of the Pol III activity in the UVC treatment of U2OS cells. However, 
if p53 is required, it is unlikely to act through its known mechanism of regulating 
Pol III activity. In this mechanism, active p53 binds to TFIIIB and prevents its 
recruitment to target genes and, thus, reduces their transcription (Cairns and 
White, 1998, Crighton et al., 2003). Following UVC treatment, p53 is activated 
yet Pol III-mediated transcription increases. This could, for example, be a 
secondary effect of p53 induction rather than a direct effect. The increase in Pol 
III activity following exposure to UVC is interesting and could provide useful 
information about the regulation of Pol III activity following stress, given further 
study.    
The increase in 5S rRNA and tRNA levels following UVC is not the expected 
outcome of cell cycle arrest, as upon cell cycle arrest a cell has reduced 
requirement for protein synthesis. The cell cycle status of U2OS following UVC 
requires further examination, however it is possible that this unexpected 
response is due to the non-physiological nature of the experiment. UVC does not 
penetrate the ozone layer except where the ozone layer has been damaged 
(Latonen and Laiho, 2005). Also, U2OS cells are bone-derived cells, which would 
never be exposed to UV under normal conditions. Nevertheless, UVC causes 
damage that can be caused by other treatments (including UVB) and thus 
activates appropriate pathways in response to this damage. However, there has 
been no evolutionary pressure to develop a suitable ‘whole cell’ response to 
UVC. UVC activates other pathways in addition to p53  and one of these could 
contribute to the regulation of Pol III-mediated transcription (Healy et al., 
2013). For example, c-Jun N-terminal kinase (JNK) is activated by UV, allowing it 
to phosphorylate its targets, such as c-Jun (Bogoyevitch and Kobe, 2006). JNK 
activity is known to promote Pol III-mediated transcription and c-Jun also has a 
potential positive influence (see Chapters 4 and 5) (Zhong and Johnson, 2009, 
Raha et al., 2010). It is, therefore, possible that JNK activation may contribute 
to the increased Pol III products seen. Indeed, increased levels of phospho-c-Jun 
were observed following UVC treatment (data not shown). To determine if JNK 
could contribute, cells were pre-treated with a JNK inhibitor before exposing to 
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UVC. It was found that this prevented the increase in Pol III transcription seen 
after UVC treatment (data not shown). However, as JNK inhibitor alone resulted 
in a decrease in Pol III-mediated transcription in U2OS (Figure 5.5), these results 
were not conclusive. In future studies, it will be interesting to examine whether 
JNK contributes to the increase in Pol III-mediated transcription observed 
following UVC treatment.  
Doxorubicin treatment results in substantial p53 activation and significant 
repression of Pol III-mediated transcription (Figure 3.1, Figure 3.2). However, 
unlike following ARF induction (Morton et al., 2007), these are not linked. p53 is 
not required for the repression of Pol III-mediated transcription following 
doxorubicin treatment (Figure 3.2). So, what may account for difference 
between oncogenic and DNA damage response with regards to p53’s role in Pol III 
activity?  
The first possibility I considered was that a specific p53 modification was 
required for its Pol III repression activity and this modification occurred 
following ARF induction but not doxorubicin treatment. The most obvious way a 
modification may affect p53’s activity (with regard to Pol III) is by altering its 
interacting surface with TFIIIB. The most noticeable conclusion from Figure 3.5 
and Figure 3.6 is that ARF induction results in very few post-translational 
modifications of p53, while following DNA damage they are more common. This 
is supported by the literature where ARF activity is generally ascribed to its 
ability to stabilise p53 (through ARF’s ability to bind with MDM2) while 
modification of p53 is associated with DNA damage (Sherr, 2006). One exception 
to this, demonstrated in this chapter, is Ser392 phosphorylation. This has been 
described previously, where the authors concluded this phosphorylation was a 
universal outcome of p53 induction (Cox and Meek, 2010). Moreover, as it is 
observed following all treatments it is difficult to foresee how this would result in a 
response specific to ARF induction. Acetylation at Lysine 120 has been found to be 
associated with p53 activation by ARF (Mellert et al., 2007). Lysine 120 is in the DNA 
binding domain of p53 and this domain is required for p53 to regulate Pol III activity, 
despite DNA binding of p53 appearing to be unnecessary (Stein et al., 2002b). Given 
more time, it would be very interesting to examine whether this acetylation is 
required for Pol III regulation by p53. This could be most directly examined by 
looking at whether p53, mutated so it cannot be acetylated at this site, can bind to 
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TFIIIB, the described mechanism of action in Pol III repression. It would be best to 
investigate by this route as the acetylation may be necessary for other functions of 
p53 after stress. These could also impact Pol III-mediated transcription. This route 
of investigation will be more specific than previous studies that looked at the 
regions of p53 required for repression of Pol III activity (Stein et al., 2002b, 
Gridasova and Henry, 2005). The whole of p53, except for residues 13-19 and 364-
392, is required for repression of Pol III-mediated transcription (Stein et al., 2002b). 
The only exception is for the U6 gene, where only the C-terminus of p53 is required 
for repression (Gridasova and Henry, 2005). In conclusion, these experiments did not 
demonstrate a likely candidate of a post-translational modification that promotes 
the interaction between p53 and TFIIIB. However, further studies may prove fruitful 
as there are many modifications that could not be examined in this chapter. 
Another mechanism by which post-translational modification of p53 could regulate 
p53’s regulation of Pol III should be considered. One of the modifications that occurs 
following DNA damage could prevent p53’s interaction with TFIIIB, either by altering 
the interaction surface so that the interaction can no longer occur or because it 
promotes a stronger association with another protein. As Pol III-mediated 
transcription can be repressed independently of p53, as demonstrated following 
doxorubicin treatment, this would probably not be evolutionarily negative. This 
model of regulation deserves further examination.  
Post-translational modification of p53 is not the only potential model that would 
result in p53 being able to regulate Pol III activity following some stresses but not 
others. I propose two alternative models: 1) a specific cofactor may be required 
and/or 2) a specific modification of TFIIIB may be required. p53 recruits cofactors, 
including histone acetyltransferases GCN5 and CBP/p300, to modify the activity of 
the target genes it binds to (Beckerman and Prives, 2010). It is not unreasonable to 
suppose that a cofactor is also involved in p53 sequestering of TFIIIB away from the 
Pol III machinery. The location of the p53-TFIIIB interaction in the cell is not known, 
but a cofactor could, for example, ensure that it is held in a particular location. 
Alternatively, a cofactor may be necessary to sterically block the binding of TFIIIB 
to TFIIIC or to modify TFIIIB to either allow the interaction with p53 or prevent the 
interaction with TFIIIC. To determine if a cofactor is present, one could 
immunoprecipitate TFIIIB (using an antibody recognising Brf1) and carry out mass 
spectrometry on the complexes pulled down with it. Post-translational modification 
of polymerase machinery is a common mechanism for modulating its activity. For 
Chapter 3: Regulation of Pol III-mediated transcription by p53   
78 
 
example, Brf1 is phosphorylated by ERK and CK2, promoting TFIIIB recruitment to 
Pol III target gene promoters. TFIIIB may undergo modification following ARF 
induction (but not DNA damage) allowing it to interact with p53. 
 Where possible, this study has attempted to remove the possibility of genetic 
background contributing to differences in the stress response. The ARF induction 
experiments by Morton et al. were carried out using NARF2 cells, U2OS with 
inducible ARF. I used U2OS cells for my DNA damage experiments to keep the 
background as similar as possible. However, these have been grown separately over 
time, so it is possible that genetic differences between the parental U2OS and the 
NARF2 cells may now exist. The only definitive difference is that U2OS cells do not 
express ARF. There is some evidence that ARF may be activated downstream of DNA 
damage (Khan et al., 2000). If this is the case, it may be that DNA damage can 
regulate p53-dependent repression of Pol III in cell types other than U2OS. Though 
U2OS are considered more ‘normal’ than many tumour cell lines, it would be 
beneficial to repeat these stress studies in untransformed, primary cell lines. This 
may give us more evidence about what happens to Pol III in an untransformed cell, 
as Pol III-mediated transcription is subject to regulation by many proteins that are 
modulated cancer.   
Another possible reason for the disparity in the DNA damage and oncogenic 
stress responses is that a threshold p53 level may be required before p53 can 
have an impact on Pol III activity. This seems unlikely as total p53 levels are 
similar between doxorubicin-treated and ARF-induced cells (Figure 3.5a). The 
level of Pol III activity is a balance between positive and negative regulators. 
There do not appear to be more positive regulators active following doxorubicin 
treatment (which might increase the p53 activity threshold compared to 
oncogenic stress), as Pol III activity goes down following treatment. However, 
there is a possibility that different positive regulators are activated in each 
instance and, due to its mechanism of action, p53 is not able to overcome those 
induced by doxorubicin treatment. This hypothesis highlights a further 
possibility: that redundancy exists in the pathways regulating Pol III activity 
following stress. Maybe following doxorubicin treatment, p53 and another 
regulator act to repress Pol III transcription, and when p53 is knocked down the 
other regulator is able to act sufficiently alone. Yet this alternative regulator is 
not activated in response to ARF induction. To investigate this one would first 
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have to find this regulator and then repeat the doxorubicin experiment in its 
absence. The most probable candidates are Maf1 and RB. RB acts very much like 
p53, binding to TFIIIB and preventing its recruitment to Pol III target genes 
(White et al., 1996, Sutcliffe et al., 2000). Upon p53 induction, it is activated 
via the p53 target gene p21 and may therefore contribute to Pol III repression 
during cell cycle arrest following stress. Maf1 is also an interesting possibility. 
When unphosphorylated, it binds to Pol III, inhibiting Pol III-mediated 
transcription. In yeast, it is key to Pol III regulation following stress, but its role 
following stress has not been well studied in humans (Boguta, 2013, Moir and 
Willis, 2013). In addition, it will be interesting to examine whether p53 family 
members p63 and p73 may regulate Pol III activity. The complex response of Pol 
III-mediated transcription to p53 induction may be attributed to redundancy in 
the regulation of Pol III activity. If this is the case, it would demonstrate the 
importance of repressing Pol III activity following stress. 
p53 is present in cells at low levels in non-stressed conditions and this basal 
level of p53 contributes to cellular function (Vousden and Prives, 2009). p53 null 
MEFs have higher Pol III product levels than the wild type control, suggesting 
that basal levels of p53 may contribute to regulation of Pol III activity. In this 
chapter, I addressed this further. Knockdown of p53 with a short hairpin RNA did 
not have an effect on Pol III product levels in RKO or MCF7 cells (Figure 3.8). And 
knockdown of p53 in U2OS cells only resulted in a significant increase in the 
level of one of the tRNAs examined (Figure 3.2). This suggests that if basal p53 
does repress Pol III-mediated transcription, it may be a promoter-specific and 
cell type-specific effect. However, it is also possible that these cells have 
adapted to the reduced p53 levels. Pol III has many regulators and these may 
continue to act to ensure Pol III activity is at the optimal level, despite reduced 
levels of p53. An inducible hairpin system would be more suitable to determine 
basal p53’s role. Pol III activity could be measured directly after p53 knockdown, 
before the cell has time to adapt. It will also be interesting to look in animal 
models, for example, when p53 knockout is induced in a particular organ of a 
mouse. At present, p53’s role in the regulation of Pol III-mediated transcription 
in unstressed cells is unclear. 
Further study of the p53-TFIIIB interaction will be key to understanding how p53 
repression of Pol III-mediated transcription is regulated. I attempted to visualise 
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this interaction by co-immunoprecipitation (coIP) and by proximity ligation assay 
(PLA), but failed. This interaction is, however, shown by coIP by Crighton and 
colleagues (Crighton et al., 2003). We hypothesise that the p53-TFIIIB complex is 
only formed following stresses, such as ARF induction, that induce p53-
dependent repression of Pol III activity. In this case, visualising this interaction 
would provide an accurate marker for whether Pol III was being repressed by 
p53. Alternatively, p53-TFIIIB complex formation may occur whenever p53 is 
induced, even when p53 is not required to repress Pol III activity, such as 
following doxorubicin treatment. This would suggest that further regulators are 
required for the Pol III repression, either to contribute additionally to the p53 
repressive mechanism (such as by modifications or as a cofactor) or to repress 
Pol III by an alternative pathway. In either case, once we can visualise this 
interaction successfully, studies can be carried out to determine the domains of 
p53 and TFIIIB involved in this interaction. And, through studies in which this 
interaction is disrupted, we could determine whether Pol III repression by p53 
contributes to p53’s tumour suppressive function. If it did, this would be a 
fascinating discovery. p53 pathway function is lost in many tumours and Pol III 
activity is high in many cancers (White, 2008). This would suggest that high Pol 
III product levels may not merely be a consequence of cancer, but could 
contribute to tumour development. 
The findings in this chapter, together with previously published and unpublished 
data, suggest that p53 may not be important in repressing Pol III-mediated 
transcription in response to DNA damage (Figure 3.9). Repression of Pol III does 
appear to be the standard response to most stresses, as predicted. It will be 
interesting to determine whether p53 repression of Pol III is associated with one 
cellular outcome in particular, be it cell cycle arrest, senescence or apoptosis. 
Looking at stresses beyond oncogenic stress and DNA damage will tell us more 
about the importance of Pol III regulation following cellular stress. Studying Pol 
III-mediated transcription following disruption of the ribosome biogenesis 
pathway may be particularly interesting as Pol III produces 5S rRNA, a key 
component of the ribosome, and 5S rRNA itself has been shown to contribute to 
the induction of p53 following disruption (Chakraborty et al., 2011, Donati et 
al., 2013)  Overall, p53 repression of Pol III-mediated transcription appears to be 
particularly associated with the oncogenic stress response. This is particularly 
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interesting as evidence suggests that p53’s tumour suppressor activity may be 
more dependent upon its oncogenic function than p53’s ability to respond to 
DNA damage (Christophorou et al., 2006). It is, therefore, possible that 
regulation of Pol III-mediated transcription could be an important part of p53’s 
wide spectrum of activities.  
 
Figure 3.9 Model for regulation of Pol III-mediated transcription in response to stress 
Stress often results in reduced Pol III-mediated transcription. Following oncogene 
overexpression, ARF is induced and binds to MDM2, stabilising p53 and resulting in p53-
dependent repression of Pol III-mediated transcription. In the current model for this 
repression, p53 binds to TFIIIB preventing its recruitment to the Pol III target gene, and 
consequently preventing polymerase recruitment. Upon doxorubicin treatment, p53 
levels rise, probably via the ATM/ATR DNA damage pathways, however the reduction in 
Pol III-mediated transcription that is observed occurs independently of p53. One 
possible model is that p53 cannot bind TFIIIB following doxorubicin treatment. The 
mediators of repression of Pol III-mediated transcription upon doxorubicin treatment 
have not been defined. Dashed lines indicate the existence of intermediate steps in the 
pathway.  
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4 Regulation of RNA Polymerase III-mediated 
transcription by AP-1 
4.1 Introduction 
Over the past decade it has become increasingly apparent that transcription by 
RNA Polymerases I, II and III can be regulated by shared factors (White, 2008). 
While initially unexpected, it provides an efficient mechanism for the regulation 
of translational machinery, where the products of all three polymerases are 
required in unison. p53, as described in Chapter 3, is one example. p53 represses 
45S rRNA expression by inhibiting Pol I-mediated transcription and also regulates 
many Pol II target genes (Zhai and Comai, 2000, Vousden and Prives, 2009). And, 
by sequestering TFIIIB away from promoters and preventing the formation of a 
complete pre-initiation complex (PIC), active p53 reduces transcription of all Pol 
III target genes (Cairns and White, 1998, Crighton et al., 2003). However, 
‘shared’ regulators can also be found interacting with the Pol III machinery at 
promoters. For example, c-Myc binds to TFIIIB and enhances transcription of Pol 
III-transcribed genes (Gomez-Roman et al., 2003). Recently, the employment of 
ChIP-seq technology has identified Ets1, Stat1 and the AP-1 proteins, c-Jun and 
c-Fos, at multiple Pol III target genes (Oler et al., 2010, Raha et al., 2010, Zhong 
et al., 2011). These transcription factors are more commonly associated with 
regulating Pol II-transcribed genes and their function at Pol III-transcribed genes, 
if they have one, is undetermined.  
AP-1 is a dimeric transcription factor and AP-1 proteins include c-Jun, c-Fos and 
ATF2. It has been shown that AP-1 can regulate Pol III-mediated transcription via 
altering levels of Pol III machinery available (Zhong et al., 2011, Felton-Edkins et 
al., 2006). Ethanol treatment of HepG2-ADH cells (a hepatocellular carcinoma 
cell line stably-expressing alcohol dehydrogenase (ADH) to allow alcohol 
metabolism) results in the induction of tRNALeu, 5S rRNA and 7SL expression 
which appears to be dependent upon the increased TFIIIB levels that are also 
observed (Zhong et al., 2011). c-Jun binds at the promoters of TBP and Brf1 
genes (Fromm et al., 2008, Zhong et al., 2011). Its occupancy increases between 
2- and 4-fold following ethanol treatment (Zhong et al., 2011). The authors 
conclude that c-Jun is required for the increase in TBP and Brf1 mRNA levels 
following ethanol treatment. (Zhong et al., 2011). However, the mechanism of 
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this regulation has not been fully defined (including which AP-1 dimer is 
involved). Recent data from our lab has shown that transformation of TIFFs 
(telomerase-immortalised foreskin fibroblasts) by v-Fos expression results in a 4- 
to 8-fold increase in tRNAi
Met and tRNATyr when compared to TIFFs transfected 
with an empty vector (unpublished results, Joanna Birch). This may occur via the 
increase in TBP and TFIIIC220 that is also observed, however further 
investigation is required. Like the TBP gene, TFIIIC220 has an AP-1 binding site 
81-88bp upstream of transcription start site (+1). This site is required for the 
higher level of TFIIIC220 mRNA seen in EBV (Epstein Barr Virus) infected HeLa 
cells compared to uninfected HeLas (Felton-Edkins et al., 2006). The higher 
mRNA level probably accounts for the higher TFIIIC220 protein level that, with 
other TFIIIC subunits, may contribute to the increased Pol III-mediated 
transcription seen in infected cells. ATF2 and, possibly, c-Jun bind at the 
TFIIIC220 gene (Felton-Edkins et al., 2006). This binding does not appear to be 
different between EBV-infected and uninfected cells. However, EBV infection 
can promote ATF2 phosphorylation by activating MAPK pathways and the authors 
suggest this increase in ATF2 phosphorylation may account for the increased 
TFIIIC220 expression. These examples demonstrate that Pol III-specific 
transcription factors are subject to upregulation by AP-1. 
The presence of AP-1 at Pol III-transcribed genes suggests a further mechanism 
of regulating Pol III machinery. AP-1 often binds at its target genes via an AP-1 
binding motif, such as TRE (TGACTCA) or CRE (TGACGTCA), situated nearby. The 
first example of AP-1 near Pol III-transcribed genes came from Alu elements, a 
class of short interspersed nuclear elements (SINEs) derived from a 7SL gene and 
transcribed by Pol III. A TRE motif is present upstream (-33) of the EPL Alu, an 
Alu that gave rise to a whole subfamily of Alus in primates (Chesnokov and 
Schmid, 1996). Upon deletion or mutation of this motif, the expression of this 
Alu is significantly reduced in vivo (Chesnokov and Schmid, 1996). While 
technically unable to explore this finding further in vitro, the authors did 
propose that the AP-1 site may have contributed to its ability to produce a whole 
subfamily of Alus where other Alus did not. Retrotransposition requires 
transcription of the gene, so genes that are more highly transcribed are more 
likely to be retrotransposed, a key advantage in producing an Alu subfamily. CRE 
motifs have been identified upstream of the 7SL gene and the EBER genes, 
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EBER1 and EBER2, from the Epstein-Barr virus that recruit Pol III machinery for 
their transcription in infected cells. The CRE motifs promote transcription of 
these genes in vitro and in vivo (Howe and Shu, 1989, Bredow et al., 1990, 
Felton-Edkins et al., 2006). The CRE motifs at the EBER genes were found to be 
occupied by ATF2 and ATF2 was not detected at 5S rRNA genes (which do not 
have CRE motifs) (Felton-Edkins et al., 2006). EBV infection activates MAPKs, 
promoting ATF2 phosphorylation and this may promote EBER gene transcription 
(Young and Rickinson, 2004, Felton-Edkins et al., 2006). More recently, ChIP-seq 
experiments have identified c-Jun and c-Fos at 76% and 86% of Pol III-bound 
genes respectively (Raha et al., 2010). The exact genes bound were not 
described in detail. In contrast, JunD, another c-Jun family member, was only 
present at 15% of Pol III-bound genes (Raha et al., 2010). Zhong and colleagues 
also identified c-Jun at a tRNALeu gene and found the first evidence of 
dynamicity to this association (Zhong et al., 2011). Upon treatment of cells with 
ethanol, c-Jun occupancy and tRNA expression increased, although the 
requirement for c-Jun in increased tRNA expression was not proven. 
In summary, AP-1 can regulate Pol III-mediated transcription by the regulation of 
Pol III basal transcription factor levels and may also contribute to Pol III activity 
directly by binding at Pol III target genes. In this chapter, the presence of AP-1 
at Pol III target genes will be investigated further, with a specific focus on tRNA 
genes. 
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4.2 Results 
4.2.1 c-Jun and c-Fos occupy tRNA genes  
c-Jun and c-Fos are frequently present at Pol III target genes, as identified by 
Raha and colleagues in K562 cells (a human chronic myeloid leukaemia cell line) 
using ChIP-seq (Raha et al., 2010). This data was subsequently made publically 
available in the Gene Expression Omnibus (GEO) database (accession number 
GSE19551). We utilised this data for a more in-depth study of c-Jun and c-Fos 
occupancy at tRNA genes. Occupancy at 631 human tRNA genes was analysed 
(tRNA genes from hg18 Genomic tRNA Database (Chan and Lowe, 2009)). This 
total includes 109 predicted pseudogenes and 6 other tRNA of undetermined 
function. These were included in the analysis as they may help identify features 
of tRNA genes required for c-Jun and c-Fos recruitment. Of the 631 tRNA genes, 
c-Jun was found at 115 (18%) and c-Fos was found at 222 (35%) (Figure 4.1). Only 
three pseudogenes were occupied, two by c-Fos only and one by c-Jun and c-
Fos. 86% of tRNA genes with c-Jun also had detectable c-Fos occupancy. The 
correlation of c-Jun and c-Fos binding at tRNA genes was found to be significant; 
a chi-squared test gave a p value of less than 0.001. This suggests that c-Jun and 
c-Fos may be present as a dimer. 
 
 
 
Figure 4.1  c-Jun and c-Fos occupy many tRNA genes 
Venn diagram displaying the occupancy by c-Jun and c-Fos at tRNAs in K562 cells. ChIP-
seq data mined from (Raha et al., 2010). Chi-squared test: p<0.001 for association 
between c-Jun and c-Fos binding.  
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To explore how widespread the occupancy of c-Jun and c-Fos is at tRNA genes, 
their presence was classified by tRNA isoacceptor. For example, tRNALeu exists as 
five different isoacceptors, each with a different DNA anticodon but all charged 
with leucine. Most isoacceptors have multiple genes (Chan and Lowe, 2009). 
Figure 4.2 shows that for most isoacceptors, there is at least one gene with both 
c-Jun and c-Fos present. There are four isoacceptors at which only either c-Jun 
or c-Fos is present. There are no genes encoding tRNAIle-GAT, tRNATyr-ATA and 
tRNAAsn-ATT that have c-Jun and/or c-Fos present. However, c-Jun and c-Fos are 
present at genes that encode tRNAs specific for every amino acid.   
 
 
Figure 4.2  c-Jun and c-Fos are detected at genes encoding the majority of tRNA 
isoacceptors 
Codon table highlighted according to c-Jun and c-Fos occupancy at genes encoding the 
tRNA with the complimentary anticodon. For example, if highlighted in blue, at least 
one gene for this isoacceptor class has both c-Jun and c-Fos present. *UGA - usually a 
stop codon, in a small number of proteins codes for selenocysteine. #Stop codon does 
not require tRNA. However, tRNA genes have been identified with the corresponding 
anticodons and are described as ‘suppressor tRNAs’. ChIP-seq data mined from (Raha et 
al., 2010).  
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4.2.2 c-Jun and c-Fos occupancy correlates with occupancy of 
Pol III subunit RPC155 
Presence of Pol III at tRNA genes is often used as a marker of actively 
transcribed genes. A ChIP-seq dataset from K562 cells is available for RPC155, a 
subunit of Pol III, from a different study (Moqtaderi et al., 2010). Of all tRNAs, 
58% have Pol III bound (data displayed as Venn diagram Figure 4.3a). 53% of 
these Pol III occupied tRNA genes are also occupied by c-Jun and/or c-Fos 
(Figure 4.3b). Only 18% of tRNA genes occupied by c-Jun and/or c-Fos are not 
also occupied by Pol III. A Chi-squared test shows significant association between 
c-Jun/c-Fos occupancy and Pol III occupancy. However, 47% of Pol III-occupied 
genes do not have c-Jun and/or c-Fos bound. This suggests that, while c-Jun and 
c-Fos are associated with active tRNA genes, c-Jun and c-Fos recruitment is not 
simply a by-product of tRNA activity. 
 
Figure 4.3  c-Jun and c-Fos occupancy correlates with Pol III occupancy  
a) Venn diagram displaying the occupancy Pol III subunit RPC155 at tRNA genes in K562 
cells. b) Venn diagram displaying the occupancy by RPC155 and c-Jun and c-Fos at tRNA 
genes in K562 cells. RPC155 ChIP-seq data from (Moqtaderi et al., 2010). c-Jun and c-
Fos ChIP-seq data from (Raha et al., 2010). Chi-squared test gives p<0.001 for 
association between Pol III and c-Jun/c-Fos occupancy.   
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4.2.3 c-Jun and c-Fos occupancy at tRNA genes is not associated 
with the presence of a consensus AP-1 binding site nearby 
To determine how c-Jun and c-Fos are recruited to tRNA genes, we examined 
the human genome for the incidence of AP-1 binding motifs TRE (TGACTCA) and 
CRE (TGACGTCA) within 1000bp and 250bp of tRNA genes. 12% of tRNA genes 
were found to have an AP-1 consensus site nearby (Figure 4.4) However, the 
presence of these sites at a gene was not associated with the occupancy of c-Jun 
and/or c-Fos (Figure 4.4a,b). Only 13% of tRNA genes with c-Jun and 9.5% with c-
Fos also had an AP-1 motif nearby. This data suggests that c-Jun and c-Fos are 
not recruited to tRNA genes through binding to consensus binding motifs. 
 
 
Figure 4.4  c-Jun and c-Fos occupy tRNA genes independently of AP-1 binding motifs 
Venn diagram displaying tRNA genes with a TRE or CRE motif within 1kb and the 
occupancy by a) c-Jun and b) c-Fos at tRNAs in K562 cells. TRE/CRE incidence analysis in 
human genome carried out. ChIP-seq data mined from (Raha et al., 2010). Association 
between c-Jun binding and CRE/TRE motif presence and c-Fos binding and CRE/TRE 
presence is not significant according to Chi-squared analysis.  
4.2.4 c-Jun associates with TFIIIC 
To further explore the presence of c-Jun and c-Fos at tRNA genes, protein 
immunoprecipitation was employed to test for interactions with components of 
the Pol III pre-initiation complex. Coimmunoprecipitation of the TFIIIC subunit 
TFIIIC110 was detected when U2OS (a human osteosarcoma cell line) protein 
lysate was incubated with a c-Jun specific antibody, suggesting that c-Jun and 
TFIIIC can exist in the same protein complex (Figure 4.5a). This association was 
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confirmed in nuclear extract from HeLa cells (Figure 4.5b). In preliminary 
experiments, the reverse co-immunoprecipitation was also possible. c-Jun was 
associated with TFIIIC following immunoprecipitation using an anti-TFIIIC 
antibody (Figure 4.5c). Association with TFIIIC63 (another subunit of TFIIIC) was 
also detectable, however background level of antibody binding was high (data 
not shown). c-Jun interaction with the TFIIIB subunit Brf1 was also detected 
(data not shown). This data clearly demonstrates that c-Jun can associate with 
the Pol III machinery.  
 
Figure 4.5  c-Jun associates with TFIIIC  
Anti-c-Jun antibody used to immunoprecipitate c-Jun from a) U2OS whole cell protein 
extract and b) HeLa nuclear extract. Western blot analysis carried out on precipitate 
with antibodies against TFIIIC110 and c-Jun. c) Anti-TFIIIC110 antibody used to 
immunoprecipitate TFIIIC110 from U2OS whole cell protein extract. Western blot 
analysis carried out on precipitate with antibodies against TFIIIC110 and c-Jun. IgG used 
as control for non-specific binding. 
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4.2.5 c-Jun association with TFIIIC is independent of DNA 
As both TFIIIC and c-Jun are known to bind DNA, it was important to determine 
whether their association may occur only via DNA rather than in a common 
protein complex. U2OS cell lysates were treated with DNase and then c-Jun was 
immunoprecipitated. As seen in Figure 4.6, the amount of TFIIIC110 co-
immunoprecipitated in the DNase-treated sample (lane 6) was equal to that 
detected in the sample that was not subjected to DNase treatment (lane 5). 
Thus indicating that the association of c-Jun with TFIIIC110 does not occur 
through DNA but by protein-protein interaction.  
 
Figure 4.6  c-Jun association with TFIIIC is DNA-independent  
U2OS protein extract incubated with DNase I (or mock) for 1hr at 37°C before 
immunoprecipitation with anti-c-Jun antibody. Followed by western blot analysis for 
TFIIIC110. IgG used as control for non-specific binding. 
4.2.6 N-terminal deletion mutant of c-Jun (TAM67) can associate 
with TFIIIC 
To begin to map the association between TFIIIC110 and c-Jun, an N-terminal 
deletion mutant of c-Jun, TAM67, was utilised. This mutant is missing amino 
acids 3-122 which includes the entire transactivation domain (Figure 4.7a). 
Lysates were made from U2OS cells that had been transiently transfected with a 
plasmid containing a gene encoding GFP-TAM67. Good protein expression was 
achieved as can be seen by comparing lanes 1 and 2 of Figure 4.7b. When GFP-
TAM67 was immunoprecipitated using an antibody that recognises GFP, TFIIIC110 
was present in the associated complexes (Figure 4.7b, lane 6). However, as GFP-
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TAM67 can form a dimer with wild-type c-Jun, it is possible that this association 
is occurring via the full-length protein (Brown et al., 1993). To determine if the 
N-terminus of c-Jun is required for its interaction with the Pol III machinery, a c-
Jun null cell line would be required. If c-Fos alone is capable of interacting with 
Pol III machinery then a c-Jun c-Fos double knockout cell line would be required. 
Alternatively, in vitro analysis could be carried out. 
 
Figure 4.7  N-terminal deletion mutant of c-Jun (TAM67) can associate with TFIIIC 
a) Diagram illustrating the domains of c-Jun (top) and TAM67 (bottom), a mutant of c-
Jun lacking the N-terminus (including the transactivation domain). b) Anti-GFP antibody 
used to immunoprecipitate GFP-TAM67 from protein lysates from U2OS harvested 24 
hours after transfection with pEGFP-C3-TAM67 or empty vector. Western blot analysis 
carried out on precipitate with antibodies against TFIIIC110 and c-Jun. Endogenous c-
Jun (arrow) and GFP-TAM67 are detectable (brackets). IgG used as control for non-
specific binding. 
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4.2.7 c-Fos may associate with TFIIIC 
As c-Jun and c-Fos are both found at tRNA genes it seemed likely that they are 
present together in the form of an AP-1 heterodimer. On the basis of the 
experiments with c-Jun, as described above, it would be predicted that c-Fos 
would also associate with TFIIIC110. Indeed, preliminary data shows c-Fos can 
associate with TFIIIC110 in U2OS lysate (Figure 4.8).  
 
Figure 4.8  c-Fos may associate with TFIIIC 
Anti-TFIIIC110 antibody used to immunoprecipitate TFIIIC110 from U2OS whole cell 
protein extract. Western blot analysis carried out on precipitate with antibodies against 
TFIIIC110 and c-Fos. IgG used as control for non-specific binding.  
4.2.8 Phosphorylation of c-Jun at Serine 63/73 does not alter its 
association with TFIIIC 
c-Jun is transcriptionally activated when phosphorylated at Serine 63 and Serine 
73 in its transactivation domain. It is reasonable that this modification may also 
play a role in any function of c-Jun at tRNA genes. To test whether 
phosphorylation of c-Jun at Serine 63/73 alters interaction with TFIIIC, I 
repeated the co-immunoprecipitation experiments in lysates from cells that had 
been harvested 8 hours after treatment with UVC (50J/m2). UVC treatment 
resulted in increased phosphorylation of c-Jun at Serine 63/73 (compare lanes 1 
and 2 in Figure 4.9). However, under these conditions c-Jun association with 
TFIIIC110 did not alter (compare lanes 5 and 6).  
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Figure 4.9  Phosphorylation of c-Jun at Serine 63/73 following UVC treatment does 
not alter c-Jun-TFIIIC association 
Anti-c-Jun antibody used to immunoprecipitate c-Jun from protein lysate from U2OS 
exposed to UVC (50J/m2) and harvested 8 hours later.  Western blot analysis carried out 
on precipitate with antibodies against TFIIIC110, c-Fos and phospho-c-Jun (Ser63/73). 
IgG used as control for non-specific binding. 
An alternative procedure to alter phosphorylation of c-Jun at Serines 63 and 73 
was also used. Treatment with 20μM SP600125 (JNK inhibitor) for 1 hour resulted 
in reduced levels of phospho-c-Jun (Ser63/73) (compare lanes 1 and 2 in Figure 
4.10). As was seen with UVC treatment, the altered levels of p-c-Jun (Ser63/73) 
had no effect on the association between c-Jun and TFIIIC110 (compare lanes 5 
and 6). Technical difficulties prevented blotting of c-Jun directly following 
immunoprecipitation. It is therefore possible that the amount of c-Jun 
immunoprecipitated by the anti-c-Jun antibody alters with treatment, most 
likely due to changes in total protein level. This is unlikely following SP600125 
treatment as the total c-Jun protein level does not change (Figure 5.1). 
However, whether c-Jun protein levels change following the UVC treatment 
remains to be determined. The amount of c-Fos co-immunoprecipitated with c-
Jun does not appear to change with UVC treatment suggesting the amount of c-
Jun immunoprecipitated may possibly also remain unchanged. These 
experiments suggest the association between c-Jun and TFIIIC does not alter 
with c-Jun phosphorylation at Serine 63/73, however further studies are 
required to confirm this.  
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Figure 4.10  Dephosphorylation of c-Jun at Serine 63/73 following treatment with a 
JNK inhibitor does not alter c-Jun - TFIIIC association 
Anti-c-Jun antibody used to immunoprecipitate c-Jun from protein lysate from U2OS 
following 1 hour treatment with JNK inhibitor SP600125 (20μM).  Western blot analysis 
carried out on precipitate with antibodies against TFIIIC110 and phospho-c-Jun 
(Ser63/73). IgG used as control for non-specific binding. 
4.2.9 Altered expression of TFIIIB protein components in c-Jun 
null cells stably expressing c-Jun or mutant c-Jun  
In order to explore the functional role of c-Jun at tRNA genes, I first analysed 
the Pol III machinery and Pol III-mediated transcription in c-Jun null mouse 
embryonic fibroblasts (MEFs) stably transfected with plasmids encoding wild type 
c-Jun and c-Jun mutants (MacLaren et al., 2004). The mutants included: c-Jun 
S63/73A, in which the serine residues at positions 63 and 73 were replaced with 
alanine so they could not be phosphorylated – thus preventing transactivation by 
JNK; c-Jun Δ284-286 which is lacking amino acids 284-286 resulting in a non-
functional DNA binding domain; TAM67-GFP, the N-terminal deletion mutant as 
described previously, and v-Jun, the oncogenic c-Jun mutant isolated from avian 
sarcoma virus - this does not require JNK mediated phosphorylation for it to be 
transcriptionally active. Levels of the TFIIIB subunits, Brf1 and TBP, were 
analysed by western blot as their expression is known to be regulated by c-Jun 
(Fromm et al., 2008, Zhong et al., 2011). Preliminary findings show slightly 
increased levels of Brf1 but not TBP in MEFs expressing wild type c-Jun 
compared to those expressing the vector alone (Figure 4.11, compare lanes 1 
and 2). In MEFs expressing the S63/73A mutant, TBP protein levels were 
markedly reduced while Brf1 levels appeared similar to the empty vector control 
(compare lanes 1 and 3). TBP levels were also reduced in the Δ284-286 and 
TAM67 mutants, however Brf1 levels were higher than in cells expressing wild-
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type c-Jun or vector only. In the MEFs expressing v-Jun, TBP were similar to 
those in the empty vector and wild-type c-Jun cells while Brf1 levels were higher 
than in empty vector cells and similar to wild-type c-Jun expressing cells. 
Therefore Brf1 and TBP levels are differentially regulated in response to c-Jun 
mutants. As TBP and Brf1 are often limiting factors in Pol III-mediated 
transcription, changes in their protein levels may contribute to differences in 
tRNA levels that may be seen in these cells, independently of c-Jun presence at 
tRNA genes.  
 
Figure 4.11  Altered expression of TFIIIB protein components in c-Jun null MEFs 
stably expressing c-Jun or mutant c-Jun 
Analysis by western blot of c-Jun, TBP and Brf1 protein levels in c-Jun null MEFs stably 
expressing empty vector (EV), c-Jun, c-Jun S63/73A (phosphorylation site mutant), c-
Jun Δ284-286 (DNA binding site mutant), TAM67-GFP (lacking N-terminus (including 
transactivation domain)) and v-Jun. Two antibodies against c-Jun were used: 1 raised 
against N-terminus, 2 raised against DNA binding domain. HSP70 used as a loading 
control. *Protein sample from c-Jun S63/73A expressing cells harvested at different 
time to other samples. 
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4.2.10 tRNA expression in c-Jun null cells stably expressing 
c-Jun or mutant c-Jun  
tRNA levels in the c-Jun null MEFs were determined by qRT-PCR. Preliminary 
data shows that tRNA levels that do not correspond entirely with either Brf1 or 
TBP levels (Figure 4.12). tRNA levels are higher in cells expressing wild-type c-
Jun compared to those expressing empty vector alone (and therefore containing 
no c-Jun). Of particular note, tRNA levels are highest in cells expressing the 
S63/73A mutant, despite these cells containing the lowest TBP level. tRNA 
expression in these cells appears to be dependent upon the amount of the 
mutant expressed. In cells harvested at a different time, when expression of the 
mutant was lower, tRNA levels were also lower and TBP levels slightly higher. 
Expression of c-Jun and c-Jun mutants in these cells are having an effect upon 
tRNA expression, however the mechanism for this is uncertain as other effects, 
such as the changes in TFIIIB expression described above, may contribute to the 
tRNA levels observed. Thus, these cells are not the best model for determining 
the role of c-Jun at tRNA genes.  
 
Figure 4.12  tRNA expression differs in c-Jun null MEFs stably expressing c-Jun or 
mutant c-Jun 
Analysis by RT-qPCR of tRNAIle and tRNAPro in c-Jun null MEFs stably expressing empty 
vector (EV), c-Jun, c-Jun S63/73A (phosphorylation site mutant), c-Jun Δ284-286 (DNA 
binding site mutant), TAM67-GFP (lacking N-terminus (including transactivation 
domain)) and v-Jun. The expression was normalised to ARPP P0 mRNA levels. n=1 *RNA 
sample from c-Jun S63/73A expressing cells harvested at different time to other 
samples. 
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4.3 Discussion 
Several studies have identified AP-1 proteins occupying Pol III target genes 
(Chesnokov and Schmid, 1996, Felton-Edkins et al., 2006, Raha et al., 2010, 
Zhong et al., 2011). The data presented by Raha et al. is especially enlightening 
as, through the employment of ChIP-seq technology, it provides a global view of 
c-Jun and c-Fos occupancy. Using this data as a basis, in this chapter I have 
explored AP-1 occupancy at tRNA genes. 
c-Jun and c-Fos occupy a large proportion of tRNA genes (Figure 4.1). Nearly all 
those with c-Jun present also had c-Fos bound, suggesting they may be present 
as a c-Jun/c-Fos heterodimer. As ChIP-seq does not confirm that c-Jun and c-Fos 
are on the exact same gene in a single cell (mutually exclusive binding could 
give the same results), ChIP re-ChIP studies will be required to further support 
their presence as a dimer. As c-Jun and c-Fos are only present in cells as dimers, 
the only possibility that would not be excluded by ChIP re-ChIP is that two AP-1 
dimers are present, one containing c-Jun and the other c-Fos. While this seems 
unlikely, it cannot be ruled out. 
Interestingly, c-Fos occupies nearly twice as many tRNA genes as c-Jun. This 
could be due to a more sensitive c-Fos antibody: c-Jun could also be present on 
these genes but below detectable level. Alternatively, c-Fos could be paired 
with another protein. c-Fos can form dimers with the other JUN family members 
and various ATF and MAF family members (Eferl and Wagner, 2003). JunD can be 
ruled out as a likely partner at Pol III target genes, as it was only found at 15% of 
Pol III-bound genes (Raha et al., 2010). It will be interesting to examine other 
potential c-Fos partners in the future.  
For overall regulation of tRNA activity, c-Jun and c-Fos would need to ensure 
changes in the expression of tRNAs that recognise all possible codons. c-Jun and 
c-Fos together occupy at least one gene for each tRNA isoacceptor, with a few 
exceptions (Figure 4.2). These exceptions are three isoacceptors with genes at 
which either only c-Jun or c-Fos is present and five isoacceptors with neither c-
Jun nor c-Fos. For the former, it seems likely AP-1 is present as c-Jun and c-Fos 
cannot function except as part of AP-1. Either the AP-1 dimer present is not c-
Jun/c-Fos or, simply, the other subunit was below the level of detection.  Of 
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those isoacceptors with neither c-Jun nor c-Fos, two recognise codons that are 
usually stop codons. Stop codons do not require recognition by a tRNA, however 
genes have been identified encoding tRNAs with the corresponding anticodon. 
These are possible ‘suppressor’ tRNAs and their role, if they have one, is 
unknown (Beier and Grimm, 2001).  Of the other three isoacceptors with neither 
c-Jun nor c-Fos, two, tRNATyr-ATA and tRNAAsn-ATT, have only one gene in the 
human genome (hg18) while tRNAIle-GAT has eight genes. However, in all cases 
the other isoacceptors for that amino acid can also recognise the corresponding 
codon according to ‘wobble’ rules – where a codon may be recognised by an 
anticodon despite the third base not being complementary according to 
traditional rules of base pairing. Thus, all codons encoding amino acid 
incorporation can potentially be recognised by a tRNA encoded by a gene with 
AP-1 present. 
Excluding SINEs, tRNA genes make up the largest proportion of Pol III-transcribed 
genes in the human genome. Pol III occupancy is associated with gene activity 
and in S. cerevisiae all 286 tRNA genes are occupied by Pol III (Moqtaderi and 
Struhl, 2004, Harismendy et al., 2003, Roberts et al., 2003). In humans and 
mice, however, only a subset of tRNA genes is occupied (Moqtaderi et al., 2010, 
Oler et al., 2010, Barski et al., 2010). Microarray analysis has shown that tRNA 
levels vary with human tissue type (Dittmar et al., 2006). For example, tRNATrp-
CCA is present in spleen tissue at significantly higher levels than brain tissue, 
while tRNAGlu-TTC is higher in brain than spleen tissue. This is supported by ChIP-
seq analysis which shows that there are differences in Pol III occupancy at tRNA 
genes, suggesting different tRNA genes are expressed, in different cell types 
(Barski et al., 2010, Raha et al., 2010, Oler et al., 2010). In a comparison of 
HeLa cells and CD4+ T cells, 26% of tRNAs were occupied by Pol III in one cell 
type but not the other (Barski et al., 2010). How tRNA genes are regulated 
independently of one another is unclear as promoters are highly similar and 
regulators often target the Pol III machinery which has a more general effect on 
Pol III-mediated transcription. It is likely to require the recruitment of a 
regulator to some genes but not others, such as we see with c-Jun and c-Fos. 
Determining whether c-Jun and c-Fos may contribute to this will be very 
interesting.  
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 AP-1 occupancy is highly associated with Pol III occupancy suggesting that c-Jun 
and c-Fos may activate or support the activation of tRNA genes (Figure 4.3). 
There are also many Pol III-occupied tRNA genes that do not have AP-1 present. 
This observation makes it unlikely that active tRNA genes passively recruit c-
Jun/c-Fos simply because they are active. Instead, there must be a 
distinguishing feature between these two groups of Pol III-bound genes that 
results in AP-1 recruitment. This may be a binding motif or a protein with which 
AP-1 can interact. Whether AP-1, once recruited, contributes to gene regulation 
cannot be resolved with this data. An alternative viewpoint is that Pol III 
occupancy may not be associated directly with active transcription in this cell 
type. Instead it could indicate that the polymerase is ‘poised’, ready to 
transcribe but not yet transcribing. The data for this cell type (K562) is unclear, 
Moqtaderi et al. conclude that Pol III occupancy is associated directly with tRNA 
expression while Raha et al. support the poised hypothesis (Moqtaderi et al., 
2010, Raha et al., 2010).  Whichever is correct, AP-1 has definite association 
with ‘active’ genes. Pol III-mediated transcription has many regulators. It is 
therefore not surprising that ‘active’ tRNA genes exist that do not have AP-1 
present, even if AP-1 does prove to promote transcription.  
AP-1 has pro-proliferative activity (Shaulian and Karin, 2001, Eferl and Wagner, 
2003). Therefore, it seems most likely that if it does regulate Pol III-mediated 
transcription it will be towards the outcome of increased protein synthesis (i.e. 
increased 5S, increased tRNAs) which is required for growth and proliferation. 
The association of c-Jun and c-Fos occupancy with Pol III occupancy supports 
this. The presence of c-Jun and c-Fos at many but not all tRNAs also provides an 
indication that they do indeed have a positive rather than negative effect on 
tRNA expression. It would theoretically be possible to support increased 
translation by increasing the transcription of a limited proportion of tRNA genes, 
as long as tRNAs were produced that could read all possible codons. However, 
repressing just a proportion of those already active would be unlikely to have a 
significant effect on translation, as it would simply result in increased 
availability of Pol III machinery at non-repressed genes. It is certainly not the 
most efficient method for repression. Well-established repressors of Pol III-
mediated transcription, p53 and pRb, act by targeting Pol III machinery, thus 
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having a general effect on the transcription of Pol III target genes (Cairns and 
White, 1998, Crighton et al., 2003, Sutcliffe et al., 2000). 
So, how are c-Jun and c-Fos recruited to some tRNA genes but not others? Two 
possible models exist: these genes have either an AP-1 binding motif nearby or a 
protein present at the gene to which AP-1 can bind. Flanking sequences are 
known to be important for optimal transcription of Pol III-transcribed genes 
despite their internal promoters (Dieci et al., 2007). We identified the consensus 
TRE (TGACTCA) and CRE (TGACGTCA) AP-1 binding motifs one kilobase up or 
downstream of 73 tRNA genes. However their presence was not associated with 
c-Jun or c-Fos occupancy at the nearby gene (Figure 4.4). Of those tRNA genes 
with TRE or CRE nearby, at only 20 genes was the motif within 250bp of the gene 
(data not shown). As AP-1 binding motifs are often 100-200bp upstream of their 
target genes (Conkright et al., 2003), the positioning of the motifs near tRNA 
genes would therefore be unusual if the tRNA gene was the target gene. It is, 
therefore, not unexpected that these AP-1 binding motifs do not account for AP-
1 occupancy at tRNA genes. However, it is possible that these AP-1 motifs may 
have AP-1 present (ChIP-seq was not analysed for these sites) but this does not 
correlate with AP-1 occupancy at tRNA genes. Raha et al. found that c-Jun and 
c-Fos occupancy peaked at the transcription start site of Pol III-transcribed 
genes, where Pol III occupancy is also at its peak (Raha et al., 2010). This 
provides further evidence that the feature promoting AP-1 occupancy must be 
near the promoter site. The TRE motif is the AP-1 binding motif to which c-Jun 
and c-Fos dimers bind with the highest affinity, followed by the CRE motif 
(Nakabeppu et al., 1988). However, it remains possible that alternative 
consensus binding motifs may be responsible for AP-1 occupancy at tRNA genes. 
Given more time, it would be interesting to take the flanking regions from tRNAs 
of the three main groups (those with AP-1 and Pol III bound, those with Pol III 
only and those with neither) and carry out a motif search. This would identify 
any non-consensus or novel motifs that could be associated with AP-1 occupancy 
at tRNA genes. However, it is possible that an AP-1 binding motif is not required 
for recruitment of AP-1 to tRNA genes. There is precedent for this in the 
regulation of Pol III-mediated transcription. Though E-boxes (Myc binding motifs) 
are present near many Pol III target genes and c-Myc is also present at a 
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proportion of Pol III target genes, E-box presence does not correlate with c-Myc 
occupancy (Raha et al., 2010) (Kirsteen Campbell and R.J. White, unpublished). 
Further clues as to how AP-1 may be recruited to tRNA genes come from the 
association observed between c-Jun and TFIIIC (Figure 4.5). This association was 
not dependent on DNA (Figure 4.6) and this is consistent with the previous 
finding that DNA binding sites may not be required for AP-1 occupancy (Figure 
4.4). However, one can envision a scenario where AP-1 is recruited through 
binding to a motif and, once bound, can interact directly with the Pol III 
machinery. In this way, a motif may be required for complex assembly in the 
first instance but not required for complex maintenance. Coimmunoprecipitation 
experiments will detect association between c-Jun and TFIIIC anywhere in the 
cell, so it is possible that the association detected is not occurring on tRNA 
genes. However, the presence of c-Jun on tRNA genes suggests that this 
interaction is most likely to occur at target genes. In addition, preliminary 
observations suggest Brf1 is also present in complex with c-Jun. ChIP-seq 
experiments have shown that TFIIIC frequently occupies sites in the human 
genome independently of TFIIIB (Oler et al., 2010, Moqtaderi et al., 2010). 
Consequently, a complex containing c-Jun, TFIIIB and TFIIIC is most likely to be 
found at tRNA genes or other Pol III-transcribed genes rather than elsewhere in 
the cell. 
Further studies are required to determine exactly which part of the Pol III 
machinery c-Jun is bound to and to determine the residues of c-Jun involved in 
this interaction. TBP, a component of TFIIIB, is already known to interact with c-
Jun and c-Fos (Ransone et al., 1993). However, TBP is also part of the Pol I and II 
transcriptional apparatus, so this observation is not specific to Pol III. The 
finding that Brf1 may associate with c-Jun suggests that c-Jun and TBP may 
interact in the TFIIIB context. The association with TFIIIC could therefore occur 
via this known interaction with TBP. The N-terminus and bZIP domain of c-Jun 
interact with TBP (Franklin et al., 1995). It will be interesting to examine 
whether these regions are required for its association with the Pol III machinery.   
Phosphorylation of c-Jun at Serine 63 and Serine 73 promotes its transactivation 
function (Meng and Xia, 2011). The phosphorylation status of c-Jun at these sites 
did not appear to alter its interaction with TFIIIC110 (Figure 4.9, Figure 4.10). 
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This suggests, if c-Jun transactivation function plays a role at tRNA genes, 
activity and localisation of c-Jun are independent of one another.   
Pol II has been found upstream of many Pol III-transcribed genes (Oler et al., 
2010, Barski et al., 2010, Raha et al., 2010). This was an unexpected finding and 
the reasons for its presence there are still not fully understood. It appears to 
promote Pol III-mediated transcription but is not required for Pol III-mediated 
transcription. Interestingly, Raha and colleagues found that c-Jun occupancy at 
tRNA genes resembled Pol III occupancy more than Pol II occupancy (which was 
further upstream of the TSS) (Raha et al., 2010). However, it is possible that Pol 
II may promote the recruitment of AP-1 (which is more typically a regulator of 
Pol II transcription). It will be interesting to further analyse the ChIP-seq data to 
see if an association exists between Pol II occupancy and c-Jun/c-Fos occupancy 
at tRNA genes.  
In this chapter, it has been demonstrated that c-Jun and c-Fos occupancy is a 
common but not universal feature of tRNA genes. Therefore, AP-1 has the 
potential to regulate tRNA expression at two levels, as shown in Figure 4.13. It 
will be interesting to examine the occupancy of c-Jun and c-Fos at other Pol III 
target genes. The associated occupancy of these proteins suggests they may be 
present as a c-Jun/c-Fos AP-1 dimer. However, this dimer is not recruited to 
tRNA genes by the TRE and CRE binding motifs. Instead, it may occur through 
direct interaction with Pol III machinery. c-Jun and c-Fos occupancy is associated 
with active tRNA genes, suggesting it may contribute to the activation of tRNA 
expression. This is consistent with AP-1’s role in the cell.  
 AP-1 is regulated in response to environmental stresses, growth factors and 
cytokines and contributes to the cell’s response to these stimuli by regulating 
the expression of genes involved in many processes, most predominantly 
proliferation and cell death (Shaulian and Karin, 2001). The mitogen-activated 
kinases, ERK, JNK and p38, are the main mediators of c-Jun and c-Fos activation 
(Shaulian and Karin, 2001). Interestingly, ERK and JNK have both already been 
shown to positively regulate Pol III-mediated transcription (Felton-Edkins et al., 
2003, Zhong and Johnson, 2009). The regulation of AP-1 activity at Pol III target 
genes may provide an additional route for the regulation of Pol III-mediated 
transcription by these kinases. The upregulation of Pol III-mediated transcription 
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in response to mitogenic factors is required for increased ribosome biogenesis, a 
prerequisite for cell growth (Ruggero and Pandolfi, 2003). In Chapter Five, I will 
examine whether JNK may regulate tRNA gene expression via phosphorylation of 
c-Jun at tRNA genes. The mechanism by which c-Jun could mediate changes in 
tRNA expression is also examined. 
  
Figure 4.13 Model for regulation of Pol III-mediated transcription by AP-1 
The diagram above represents possible routes by which AP-1 may regulate Pol III-
mediated transcription. AP-1 subunits c-Jun and ATF2 have been identified bound at 
genes encoding TFIIIB and TFIIIC subunits (Zhong et al., 2011, Felton-Edkins et al., 2006) 
providing an indirect route for regulation of Pol III-mediated transcription via regulation 
of the availability of Pol III-specific transcription factors. AP-1 is also found at Pol III 
target genes including many tRNA genes, where its recruitment is independent of TRE 
and CRE AP-1 binding motifs. Instead it may be recruited through its association with 
the Pol III machinery, as described in this chapter. AP-1 occupancy at tRNA genes 
correlates with active transcription, suggesting AP-1 may promote Pol III-mediated 
transcription directly. 
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5 Regulation of RNA Polymerase III-mediated 
transcription by c-Jun N-terminal kinases (JNKs) 
5.1 Introduction 
Protein synthesis is required for nearly all cellular activities. The overall 
requirement for protein synthesis changes with the state of the cell. In highly 
proliferating cells, there are higher levels than during quiescence or in cells 
arrested due to checkpoint activation (Clarke et al., 1996, Johnson et al., 1974, 
Mauck and Green, 1974). It would be wasteful to produce Pol III products at high 
levels in the latter cases, but they would be required at high levels in the former 
case. JNKs are interesting cellular effectors as they can be activated by signals 
that promote each state (Davis, 2000). They are activated by mitogens and 
contribute to the highly proliferative state. But they are also activated in 
response to many stress signals. Interestingly, JNKs have been identified as 
regulators of Pol III-mediated transcription and could, therefore, contribute to 
changes in Pol III activity in these conditions (Zhong and Johnson, 2009, Zhong et 
al., 2011).   
Recent work by Zhong and colleagues has shown that JNK can regulate Pol III-
mediated transcription by altering the expression of components of the Pol III-
specific transcription factor TFIIIB (Zhong and Johnson, 2009). In JNK1-null MEFs, 
the expression of tRNALeu and 7SL was half that of wild type MEFs, suggesting 
JNK1 has a positive effect on Pol III-mediated transcription. JNK2 appears to 
have an opposing effect as, in JNK2-null MEFs, tRNALeu and 7SL are significantly 
higher than in the wild-type cells. These changes in expression corresponded 
with changes in TBP and Brf1 mRNA and protein levels. Elk1, a JNK-targeted 
transcription factor, can occupy TBP and Brf1 gene promoters (Zhong et al., 
2007, Zhong and Johnson, 2009). This occupancy alters with JNK activity and the 
authors suggest that Elk1 mediates JNK-dependent changes in TBP and Brf1 
expression. Zhong and Johnson also show Bdp1 expression is regulated by TBP 
protein level and, thus, all three subunits of TFIIIB are coregulated. In converse 
experiments, the authors activate JNK using anisomycin and examine the Pol III 
output. Anisomycin is a bacterially-derived compound that can activate JNKs and 
another MAPK, p38 (Hazzalin et al., 1998). This treatment resulted in a 2-fold 
increase in expression of a tRNA gene reporter in wild-type and JNK2-null MEFs, 
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but no change in JNK1-null MEFs was observed. This suggests JNK1 is required for 
the increased expression. The authors do not further explore the changes in Pol 
III-mediated transcription that occur following anisomycin treatment. However, 
it is interesting to note that expression was measured only 30 minutes after 
treatment with anisomycin. It seems unlikely that this is due to changes in TFIIIB 
subunit levels, which would be expected to take longer than 30 minutes to 
achieve and impact Pol III-mediated transcription. A possibility, not excluded by 
the Zhong study, is that JNK has a direct effect on Pol III-mediated transcription 
i.e. it regulates Pol III-mediated transcription without the regulation of another 
gene as an intermediary. 
Further observations also support a more direct role for JNK in Pol III-mediated 
transcription. As described in Chapter 4, the paradigm JNK target, c-Jun, is 
present at many Pol III-transcribed genes. c-Jun requires phosphorylation at its 
N-terminus by JNK for full activation so if c-Jun does regulate Pol III 
transcription initiation it is reasonable to suppose that JNK activity may be 
required. Like c-Jun, STAT1 has also recently been identified at many Pol III-
transcribed genes (Oler et al., 2010). STAT1 is a transcription factor that has 
increased activity following its phosphorylation by JNK, however its function at 
Pol III-transcribed genes is so far undetermined. While investigating Elk1’s role in 
regulating TFIIIB expression, Zhong and colleagues also observed Elk1 at a 
tRNALeu gene (Zhong et al., 2011). Though it is unclear how widespread Elk1 
occupancy is at Pol III target genes, it provides another potential route for JNK 
regulation of Pol III-mediated transcription. c-Myc binds to and regulates the 
expression of Pol III target genes (Gomez-Roman et al., 2003). c-Myc is also 
phosphorylated by JNK, though whether this contributes to its activity at Pol III 
target genes has not been determined (Noguchi et al., 1999).  Further JNK 
targets may also be identified at Pol III target genes. The phosphorylation of any 
of these by JNK has the potential to influence Pol III activity. The relevance of 
the presence of JNK targets at Pol III genes on Pol III-mediated transcription 
remains to be determined.  
Alternatively, JNK could regulate Pol III-mediated transcription through 
phosphorylation of the Pol III machinery like its fellow MAPK, ERK. ERK can 
phosphorylate Brf1 following serum stimulation (Felton-Edkins et al., 2003). This 
phosphorylation promotes TFIIIB interaction with TFIIIC and Pol III and, thus, 
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activates Pol III-mediated transcription. ERK targets Ser145 on Brf1; however the 
authors found ERK activity only partially accounts for phosphorylation at this site 
suggesting another kinase may be involved. Alternatively, Bdp1 and TBP have 
also been shown to undergo modifications that alter their activity (Hu et al., 
2004). JNK has some precedent for phosphorylating polymerase-associated 
transcription factors. It can phosphorylate TIF-IA, reducing TIF-IA’s ability to 
recruit Pol I to 45S rRNA genes and, therefore, causing reduced rRNA levels 
(Mayer et al., 2005).  
JNK has recently been identified as a histone modifier in a study analysing the 
role of JNK in neuronal development (Tiwari et al., 2011). It binds at a variety of 
genes in mouse ES cells, mouse neuronal progenitors and terminally 
differentiated neurons. Treatment of terminally differentiated neurons with JNK 
inhibitor SP600125 resulted in reduced expression of JNK-bound genes and 
reduced phosphorylation at Serine 10 of histone H3 present at these genes. The 
authors show that JNK can carry out this phosphorylation. Histone H3 Ser10 
phosphorylation is associated with active gene transcription at Pol II and Pol III 
transcribed genes (Sawicka and Seiser, 2012, Zhong et al., 2013a). Therefore, 
another potential route by which JNK could regulate tRNA expression is through 
direct modification of the chromatin environment at tRNA genes. 
The experiments in this chapter were primarily carried out in the osteosarcoma 
cell line U2OS. In Chapter 4, I showed that c-Jun and c-Fos are associated with 
Pol III machinery in these cells (Figure 4.5, Figure 4.8). U2OS have active JNK 
under normal growth conditions (Figure 5.1). Indeed, bone cancers often have 
increased JNK activity and this is associated with tumour progression (Eferl and 
Wagner, 2003). The presence of active JNK in U2OS means that the function of 
JNK can be investigated through inhibition of basal activity, without prior 
activation by a JNK stimulant such as anisomycin or UV. This has been done in 
the literature previously in HCT116 cells which also contain active JNK (Aguilera 
et al., 2011). 
One of the primary difficulties when studying JNK is to differentiate between 
the function of JNK1, JNK2 and JNK3 (and their different isoforms). JNK3 is not 
considered here as its expression is limited to the brain, heart and testis. While 
initially considered to be redundant, it is now well demonstrated that JNK1 and 
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JNK2 have independent functions (Bode and Dong, 2007). Indeed, as described 
above, JNK1 and JNK2 appear to have opposing effects in regulating the 
expression of TFIIIB (Zhong and Johnson, 2009). In the results section below, I 
refer to JNK as a singular for ease of description and because I have not 
attempted to distinguish the effects of the different JNK proteins and isoforms. 
My main tool is the JNK inhibitor SP600125 which has been measured to inhibit 
both proteins equally in vitro (Bennett et al., 2001, Bain et al., 2003). As such, 
the overall effect of JNKs on Pol III-mediated transcription will be determined. 
Given further time, this study would be extended to determine the role of the 
individual JNKs.  
The objectives of the experiments carried out in this chapter were to determine 
if JNK kinases may regulate tRNA expression by phosphorylating a target to be 
recruited to or already at the tRNA gene. It was necessary to differentiate 
between these effects and JNK’s effect on Pol III machinery levels, as already 
established by Zhong and Johnson. In particular, I aimed to establish whether 
the c-Jun present at tRNA genes, as described in Chapter 4, played a functional 
role at these genes.  
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5.2 Results 
5.2.1 JNK inhibition causes reduction in tRNA levels 
Previous studies have shown that JNK is able to regulate Pol III-mediated 
transcription by modulating the expression of TBP, Brf1 and Bdp1 (Zhong and 
Johnson, 2009). Influenced by the observation that c-Jun and several other JNK 
targets can be found at tRNA genes, I decided to explore whether JNK may have 
a more direct role in regulating tRNA expression. As this effect would be 
mediated by protein phosphorylation I hypothesise it would occur with much 
faster kinetics than an effect that requires protein synthesis. A reversible, ATP-
competitive JNK inhibitor, SP600125, was employed to observe the effect of JNK 
inhibition on Pol III products before the change in TFIIIB levels occurred.  
U2OS were primarily used for these studies as they have a functional JNK 
pathway that is active under normal growth conditions. As seen in Figure 5.1, a 
reduction in phosphorylation of c-Jun at the JNK target site Serine 63 was 
observed following treatment with 20μM SP600125 for 15 minutes, when 
compared to the DMSO-treated control. After 60 minutes of treatment, a 
reduction in c-Jun mRNA was also detected (Figure 5.2). This was as expected 
following the reduction in transcriptionally active c-Jun (i.e. phosphorylated c-
Jun) as c-Jun acts in a positive feedback loop to promote transcription of the c-
Jun gene (Angel et al., 1988). There is no detectable difference in c-Jun protein 
levels after 60 minutes of treatment (Figure 5.1). 
 
Figure 5.1  JNK inhibitor, SP600125, reduces c-Jun phosphorylation (Ser63) in U2OS 
Analysis by western blot of c-Jun and phospho-c-Jun(Ser63) protein levels in U2OS 
following treatment with 20µM SP600125 or DMSO. Cells were harvested at 15, 30 and 
60 minutes post-treatment. HSP70 used as a loading control. 
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A significant reduction in tRNA levels was observed within 15 minutes of addition 
of the JNK inhibitor, as measured by RT-qPCR (Figure 5.2). Reduced c-Jun 
phosphorylation by this time point allows for the possibility that c-Jun is the JNK 
target involved in this effect. Following one hour of treatment, the tRNA levels 
had decreased further to 50-60% compared to those in the DMSO-treated cells. 
This rapid effect did not occur through changes in levels of TBP and Brf1 
subunits as these remained unchanged during the treatment (Figure 5.3). 
Changes in TBP and Brf1 mRNA levels were also not observed in this short time 
course (Figure 5.2).  
  
Figure 5.2  Short treatment with SP600125 significantly reduces tRNA levels, while 
TFIIIB subunit mRNA levels remain unchanged 
Analysis by RT-qPCR of tRNALeu, tRNATyr, tRNAIle, Brf1 mRNA, TBP mRNA and c-Jun mRNA 
levels in U2OS following treatment with 20µM SP600125 or DMSO. Cells were harvested 
at 15, 30 and 60 minutes post-treatment. The expression was normalised to ARPP P0 
mRNA levels. *p<0.05, **p<0.01, ***p<0.001 n=3 
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Figure 5.3  TFIIIB subunit protein levels remain unchanged after short JNK inhibitor 
treatment 
Analysis by western blot of Brf1 and TBP protein levels in U2OS following treatment with 
20µM SP600125 or DMSO. Cells were harvested 15, 30 and 60 minutes post-treatment. 
HSP70 used as a loading control. 
 
To determine if JNK can regulate TFIIIB subunit expression levels in U2OS, as 
demonstrated previously by Zhong and colleagues in MEF and Huh-7 
(hepatocellular carcinoma cell line) cells, a longer treatment was carried out. 
Protein lysates and RNA were harvested after 9 hours treatment with 20μM 
SP600125. This treatment resulted in a reduction in phospho-c-Jun and total c-
Jun protein levels (Figure 5.4). c-Jun mRNA levels were also significantly 
reduced following treatment (Figure 5.5). tRNA levels were significantly 
reduced, to a similar level to that seen after 60 minutes treatment (Figure 5.5, 
Figure 5.2) TBP and Bdp1 mRNA levels were reduced compared to the control 
samples; however Brf1 mRNA levels did not differ between DMSO and SP600125 
treated cells. Preliminary western blot findings suggest both TBP and Brf1 
protein levels remain unchanged (Figure 5.4), suggesting the mechanism 
described by Zhong and Johnson may not occur in U2OS. 
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Figure 5.4  Longer treatment with SP600125 reduces total c-Jun levels 
Analysis by western blot of c-Jun, phospho-c-Jun(Ser63), TBP and Brf1 protein levels in 
U2OS following treatment with 20µM SP600125 or DMSO. Cells were harvested 9 hours 
post-treatment. HSP70 used as a loading control. 
 
 
 
Figure 5.5  Longer treatment with SP600125 significantly reduces tRNA levels and 
TFIIIB subunit mRNA levels 
Analysis by RT-qPCR of tRNALeu, tRNAi
Met, Brf1 mRNA, TBP mRNA and c-Jun mRNA levels 
in U2OS following treatment with 20µM SP600125 or DMSO. Cells were harvested 9 hours 
post-treatment. The expression was normalised to ARPP P0 mRNA levels. *p<0.05, 
***p<0.001 n=3 
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5.2.2 Anisomycin treatment results in increased tRNA levels 
Based on the above results, we hypothesised that the activation of JNK would 
cause a rapid increase in tRNA levels. To examine whether this was the case, 
tRNA levels were measured by RT-qPCR following treatment with anisomycin, a 
known activator of JNK activity. A treatment curve indicated that 30 minutes of 
treatment with 100nM anisomycin was sufficient to activate JNK, as phospho-c-
Jun(Ser63) and phospho-JNK levels rose above background with this treatment 
(Figure 5.6). The p-JNK antibody detects the phosphorylated forms of the 54kDa 
and 46kDa isoforms of JNK. These are the top two bands visible in the blot. A 
third band also appears to increase following anisomycin treatment; however its 
identity is unknown (Figure 5.7a).  
 
Figure 5.6  Determining the concentration of anisomycin required to induce JNK 
activity  
Analysis by western blot of phospho-JNK(Thr183/Tyr185) and phospho-c-Jun(Ser63) 
protein levels in U2OS following treatment with anisomycin at 1nM, 10nM, 100nM and 
200nM. Cells were harvested 30 and 60 minutes post-treatment.  HSP70 used as a 
loading control. 
Preliminary results show that c-Jun mRNA levels increased following 100nM 
anisomycin treatment for 30 minutes, indicative of increased c-Jun activity 
(Figure 5.7c). tRNATyr levels also increase with 100nM or 200nM of anisomycin 
(Figure 5.7c). Interestingly, tRNALeu levels do not appear to change.  Brf1 protein 
levels do not change with anisomycin treatment according to preliminary 
findings (Figure 5.7b). TBP levels appear to go down, however an upwards shift 
in the TBP band upon treatment suggests it may be undergoing modification. As 
the tRNA level changes seen after anisomycin treatment are not concordant with 
changes in TFIIIB subunit levels, it suggests that tRNA levels may be regulated 
via a different mechanism to the one described by Zhong and Johnson.  
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Figure 5.7  Anisomycin treatment may increase tRNA levels 
Analysis by western blot of a) JNK, phospho-JNK(Thr183/Tyr185), c-Jun and  phospho-c-
Jun(Ser63) protein levels and b) Brf1 and TBP protein levels in U2OS following treatment 
with anisomycin at 100nM and 200nM. Cells were harvested 30 minutes post-
treatment.  HSP70 used as a loading control. * indicates non-specific band. n=1 c) 
Analysis by RT-qPCR of tRNALeu, tRNATyr and c-Jun mRNA levels in U2OS following 
treatment with 100nM or 200nM anisomycin or DMSO. Cells were harvested 30 minutes 
post-treatment. The expression was normalised to ARPP P0 mRNA levels. n=2 
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5.2.3 Pol III occupancy is reduced at tRNA genes following 
SP600125 treatment 
To further examine what effect the JNK inhibitor SP600125 was having on tRNA 
genes, the occupancy of Pol III and the associated transcription machinery at 
tRNA genes were examined by chromatin immunoprecipitation (ChIP). Results 
from multiple experiments were difficult to combine due to differences in the 
percentage of input of chromatin associated with each antibody between 
experiments indicating an interexperimental difference in efficiency. However, 
Pol III occupancy reproducibly went down at tRNA genes following 60 minutes of 
treatment with 20μM SP600125 (see representative ChIP in Figure 5.8a). This 
corresponds with the reduction in tRNA levels that was determined by RT-qPCR 
(Figure 5.2) and, as Pol III occupancy is associated with gene activity, provides 
evidence that the reduction in tRNA levels is a transcriptional effect. Preliminary 
studies show reduced TBP and Brf1 occupancy at tRNA genes following SP600125 
treatment (Figure 5.8b). This would explain the reduction in Pol III occupancy, 
as TFIIIB recruits Pol III to tRNA genes.  
5.2.4 Examining histone occupancy and histone modification at 
tRNA genes following JNK inhibition 
As with Pol II-transcribed genes, histone occupancy and histone modification at 
Pol III-transcribed genes are associated with gene activity. Examination by 
chromatin immunoprecipitation showed that H3 occupancy increased upon 
SP600125 treatment (Figure 5.9). This is consistent with the movement of a 
nucleosome back into the gene from which it had previously been excluded. 
Preliminary findings also suggest an increase in the association of histone 
deacetylases 1 and 2 (HDAC1 and HDAC2) with tRNA genes upon JNK inhibition 
(Figure 5.9). This is also consistent with reduced gene activity. Histone 
acetylation itself appears to go down, but only slightly (Figure 5.9). Titration of 
the antibody should give us information as to whether this is a true reflection of 
the amount of acetylated histone at the tRNA genes at this time point. 
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Figure 5.8  SP600125 reduces Pol III and TFIIIB occupancy at tRNA genes 
Chromatin immunoprecipitation assays were carried out in U2OS cells with antibodies 
against  a) Pol III subunit, RPC155 (reduced Pol III occupancy at tRNA genes observed 
upon multiple experiments, representative data shown) and  b) TFIIIB subunits TBP and 
Brf1 (n=1) at tRNA loci following treatment with 20µM SP600125 for 1 hour. ChIP with 
TAFI48 used as a negative control. % input calculated: [(IP/input)x100] – [(TAFI48 
IP/input)x100]  
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Figure 5.9  SP600125 alters chromatin environment at tRNA genes 
Chromatin immunoprecipitation assay in U2OS cells with antibodies against histone H3, 
HDAC1, HDAC2, pan-acetylated  histone H3 and phospho-histone H3(Ser10) at tRNATyr, 
tRNAThr and tRNAVal loci following treatment with 20µM SP600125 for 1 hour. ChIP with 
TAFI48 used as a negative control. Acetyl Histone H3 and p-Histone H3 were normalised 
to H3 % input. % input calculated: [(IP/input)x100] – [(TAFI48 IP/input)x100] n=1 
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5.2.5 Reduction in tRNA levels may require c-Jun  
One possible mechanism by which JNK could be regulating tRNA transcription is 
through c-Jun, which is present at many tRNA genes (Raha et al., 2010). While c-
Jun was found to occupy tRNA genes in U2OS, the change in occupancy following 
SP600125 treatment was not reproducible. In some experiments it stayed the 
same, while in others c-Jun occupancy was reduced (data not shown). Levels of 
p-c-Jun did go down reproducibly, however the immunoprecipitation efficiency 
was very low with the anti-p-c-Jun antibody (data not shown). An alternative 
route to address whether c-Jun has a role in the rapid reduction in tRNA levels 
observed following JNK inhibitor treatment was, therefore, required. 
The effect of SP600125 treatment on c-Jun null mouse embryonic fibroblasts 
(MEFs) stably expressing c-Jun or an empty vector was examined. Like U2OS, 
these MEFs have some active JNK during normal growth as p-c-Jun levels are 
reduced 1 hour after the addition of 20μM SP600125 in c-Jun null MEFs that were 
stably expressing exogenous c-Jun (Figure 5.10a). Preliminary results show 
reduction in tRNAIle level is greater in c-Jun-expressing c-Jun null MEF than in c-
Jun null MEFs expressing the empty vector (Figure 5.10b). This suggests c-Jun 
may be required for reduced tRNA levels following JNK inhibition. Zhong and 
Johnson showed that JNK regulates TFIIIB levels in MEFs, however the finding 
above suggests the presence of an alternative JNK-dependent regulatory 
mechanism is not confined to U2OS (Zhong and Johnson, 2009).  
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Figure 5.10  SP600125 treatment of cells lacking c-Jun 
a) Analysis by western blot of c-Jun and phospho-c-Jun(Ser63/73) protein levels in c-Jun 
null MEFs stably expressing empty vector (EV) or c-Jun, following treatment with 20μM 
SP600125. Cells were harvested 1 hour post-treatment.  HSP70 used as a loading 
control. * indicates non-specific band. Arrow indicates specific band. N/A indicates 
samples that are not described in main text. b) Analysis by RT-qPCR of tRNAIle level in c-
Jun null MEFs stably expressing empty vector (EV) or c-Jun, following treatment with 
20μM SP600125. Cells were harvested 1 hour post-treatment. The expression was 
normalised to ARPP P0 mRNA levels. n=1 
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5.2.6 JNK inhibition does not reduce the phosphorylation of Brf1 
at Threonine 145 
In addition to regulating tRNA transcription through one of its known 
transcription factor targets, it is also possible that the regulation could occur 
through an unknown target of JNK. While in the process of carrying out the 
above experiments, I began to investigate this possibility. ERK phosphorylates 
Brf1 at Thr145 increasing its ability to occupy tRNA genes (Felton-Edkins et al., 
2003). However, this site is also phosphorylated by an unknown kinase. Given 
that JNK and ERK have several shared substrates, JNK is a possible candidate for 
this unknown kinase. Protein lysates from SP600125-treated and control-treated 
U2OS were subjected to western blot analysis using an antibody specific to Brf1 
phosphorylated at the Thr145 site. A band was identified at the correct size for 
Brf1 in the phospho-Brf1 blot, however the intensity of this band did not 
decrease following JNK inhibitor treatment (Figure 5.11). This suggests JNK does 
not phosphorylate this site in U2OS under normal growth conditions. It remains 
possible that JNK can directly target a component of the Pol III machinery.  
 
 
Figure 5.11  SP600125 does not decrease phosphorylation of Brf1 at Thr145 
Analysis by western blot of Brf1 and phospho-Brf1(Thr145) protein levels in U2OS 
following treatment with 20µM SP600125 or DMSO. Cells were harvested at 15, 30 and 
60 minutes post-treatment. Actin used as a loading control. 
 
 
 
Chapter 5: Regulation of Pol III-mediated transcription by JNKs   
120 
 
To investigate if JNK could interact with a component of the Pol III machinery, I 
carried out some preliminary co-immunoprecipitation experiments. I found that 
TBP and TFIIIC110 were both detectable following JNK immunoprecipitation from 
HeLa nuclear extract (Figure 5.12). In addition to suggesting the possibility of a 
phosphorylation target for JNK in the Pol III machinery, it also suggests that JNK 
may be present at tRNA genes.  
 
 
Figure 5.12  JNK interacts with TFIIIC and TFIIIB subunits 
Analysis by western blot for TFIIIC110 and TBP in precipitated material from 
immunoprecipitation with an anti-JNK1/3 antibody in HeLa nuclear extract. 
Immunoprecipitation with IgG serves as a negative control. 
 
5.2.7 JNK is present at tRNA genes 
A recent study identified the presence of JNK at a wide range of genes in 
differentiating mouse neurons where it plays a functional role regulating their 
transcription (Tiwari et al., 2011). This study did not describe whether JNK was 
found at tRNA genes; however we used the publically available dataset from this 
study to examine this and found JNK present at tRNA genes (Figure 5.13a). The 
number of genes occupied by JNK reduces during neuronal differentiation. JNK 
was found at 188 of 433 tRNA genes in embryonic stem cells, 140 in neural 
progenitors and 138 in terminally differentiated neurons. The tRNA genes 
occupied also alters between cell types (Figure 5.13b).  
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Figure 5.13  JNK occupies tRNA genes in mice 
a) Graph showing JNK occupancy at tRNA genes in mouse embryonic stem cells (ES), 
neuronal progenitors (NP) and terminally differentiated neurons (TN). ChIP-seq data 
mined from Tiwari et al. 2011 using tRNAs annotated in mm7 mouse genome. b) Venn 
diagram to show overlap in JNK occupancy at tRNA genes in the three cell types. Total 
number of tRNAs occupied by JNK in each cell line is displayed in brackets.  
 
Following these findings, we examined whether JNK was present at tRNA genes 
in U2OS. Preliminary findings suggest that JNK is indeed present here, which, 
once it can be confirmed, will be especially interesting as it will be, as far as we 
are aware, the first observation of JNK on the chromatin of human cells (Figure 
5.14a). Interestingly, JNK appears to be present at lower levels at an inactive 
tRNALeu gene. For Pol II target genes, JNK occupancy is associated with NF-Y 
binding and the presence of NF-Y binding motifs (CCAAT) nearby (Tiwari et al., 
2011). Analysis of motif incidence was carried out for CCAAT near tRNA genes in 
the human genome and 477 CCAAT motifs were identified within 1kb up- and 
downstream of tRNAs (analysis carried out by Ann Hedley). To determine if 
CCAAT sites were enriched at tRNA genes compared to elsewhere in the genome, 
the number of CCAAT motifs in randomly selected genome stretches of the same 
length as the tRNA windows was analysed. CCAAT was not enriched at tRNA 
genes (Figure 5.14b). JNK may be recruited to tRNA genes by an alternative 
method.     
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Figure 5.14  JNK appears to occupy tRNA genes in U2OS  
a) Chromatin immunoprecipitation in U2OS cells with antibody against JNK1 and JNK3 at 
tRNA loci. ChIP with TAFI48 used as a negative control. % input calculated: 
[(IP/input)x100] – [(TAFI48 IP/input)x100] JNK observed at tRNA genes in multiple ChIP 
experiments. Representative data shown. b) The incidence of the NF-Y binding motif 
CCAAT was analysed 250bp and 1000bp up and downstream of tRNAs in the human 
genome (labelled ‘tRNAs’). The incidence of this motif was also examined in 10 batches 
of 623 sequences the same length as the tRNAs (tRNA length -/+ 250bp or 1000bp) and 
from the same chromosomes but selected at random within the chromosome. The mean 
number of CCAAT motifs within these sequences is displayed (labelled ‘genome’).  
 
Tiwari and colleagues found that JNK could phosphorylate histone H3 at Ser10. 
My preliminary results indicate that phospho-histone H3 (Ser10) reduces at tRNA 
genes following 60 minutes of JNK inhibition (Figure 5.9). Phosphorylation of 
histone H3 at serine 10, though recently identified as a chromatin mark 
associated with active genes, is typically a marker of mitosis. Cell cycle analysis 
by flow cytometry showed no difference in the cell cycle profile between 
treatments (Figure 5.15) suggesting the reduced H3Ser10 phosphorylation is not 
due to a reduced number of mitotic cells.  
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Figure 5.15  SP600125 does not alter cell cycle profile 
Following 20µM SP600125 treatment, U2OS cells were fixed and DNA stained with 
propidium iodide. Cell cycle distribution was determined by flow cytometry. n=3 
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5.2.8 Alternative JNK inhibitor, JNK-IN-8, reduces tRNA levels 
Though widely used, SP600125 has been shown to have off-target effects at the 
concentrations required for efficient JNK inhibition in a cellular context (Bain et 
al., 2003). To test whether SP600125’s effect on tRNA levels was a JNK-specific 
effect, an alternative JNK inhibitor, JNK-IN-8, was used (Zhang et al., 2012). The 
recommended dosage for JNK inhibition using this inhibitor is 1μM for 3 hours in 
HEK293-ILR cells (human embryonic kidney cells stably expressing Interleukin 
Receptor 1) (Zhang et al., 2012). A time course in U2OS cells showed that the 
inhibitor binds to JNK after only 15 minutes, visible as an upward shift in the JNK 
bands (Figure 5.16).   
c-Jun mRNA levels were reduced after 1 hour with 1μM JNK-IN-8 (Figure 5.17b). 
However, tRNALeu levels remained unchanged with 1μM JNK-IN-8, even after 8 
hours, despite clear effects on c-Jun phosphorylation by JNK-IN-8 (Figure 5.17a). 
This suggests that c-Jun dephosphorylation at Serine 63 cannot account for the 
reduced tRNA expression seen following SP600125 treatment. Interestingly, 
reduced p-JNK and p-c-Jun levels were only detectable after 2 hours of JNK-IN-8 
treatment (Figure 5.16). With 20μM SP600125, reduced phosphorylation of c-Jun 
at Serine 63/73 is detectable after 15 minutes of treatment (Figure 5.1). The 
concentration of JNK-IN-8 was, therefore, increased to see if tRNA levels were 
susceptible to JNK-IN-8 treatment at higher levels, despite the possibility that 
this might increase chances of non-specific effects. 1 hour of treatment with 
20μM JNK-IN-8 resulted in tRNALeu repression (Figure 5.17b). JNK-IN-8 treatment 
does not appear to repress tRNA expression with the same kinetics as SP600125 
treatment, however further examination of tRNA genes is required.  
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Figure 5.16  JNK inhibitor, JNK-IN-8, reduces phospho-c-Jun (Ser63) levels in U2OS 
Analysis by western blot of JNK, phospho-JNK(Thr183/Tyr185) and phospho-c-Jun(Ser63) 
protein levels in U2OS following treatment with 1µM JNK-IN-8 or DMSO. Cells were 
harvested 15, 30, 60, 120 and 180 minutes post-treatment. HSP70 used as a loading 
control. 
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Figure 5.17  Treatment with alternative JNK inhibitor, JNK-IN-8, decreases in tRNA 
levels 
a) Analysis by western blot of c-Jun and phospho-c-Jun(Ser63) protein levels in U2OS 
following treatment with JNK-IN-8 at 1µM, 10µM, 20µM 30µM or DMSO. Cells were 
harvested 1, 3 and 8 hours post-treatment. HSP70 used as a loading control. # indicates 
c-Jun band visible from previous antibody probe. b) Analysis by RT-qPCR of tRNALeu and 
c-Jun mRNA levels in U2OS following treatment with JNK-IN-8 at 1µM, 10µM, 20µM 30µM 
or DMSO. Cells were harvested 1, 3 and 8 hours post-treatment. The expression was 
normalised to ARPP P0 mRNA levels. n=3 with exception of 20μM treatment where n=2 
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5.3 Discussion 
JNK has been shown to regulate Pol III-mediated transcription through regulation 
of the expression of TFIIIB, the basal transcription factor that recruits Pol III to 
its target genes (Zhong and Johnson, 2009). However, additional evidence hinted 
that this may not be the sole mechanism by which JNK modulates transcription 
by this polymerase. This is supported by findings described in this chapter. It is 
not unprecedented for a single factor to regulate Pol III-mediated transcription 
at multiple levels. For example, ERK has been shown to induce Brf1 activity by 
both phosphorylating it and inducing its transcription (Felton-Edkins et al., 2003, 
Goodfellow et al., 2006). c-Myc induces Brf1 expression and promotes Pol III-
mediated transcription through binding to TFIIIB (Sansom et al., 2007, Gomez-
Roman et al., 2003). 
Regulation of transcription at multiple levels may ensure both fast and sustained 
response to cellular conditions. The positive feedback loop of c-Jun provides an 
example of this (Angel et al., 1988). Phosphorylation of c-Jun increases its 
ability to activate its target genes. These genes include the gene encoding c-
Jun, thus c-Jun protein level will increase and so the response is sustained 
beyond the initial stimulus. The kinetics of this feedback loop are illustrated in 
Figure 5.1 and Figure 5.2, where reduced phosphorylation of c-Jun is evident 15 
minutes after addition of JNK inhibitor SP600125, yet a significant reduction in 
c-Jun mRNA level is not detected until 45 minutes later. At this timepoint, c-Jun 
protein level has not yet reduced.  
Treatment of U2OS cells with SP600125 resulted in a dramatic and rapid 
reduction in levels of all of the tRNAs examined. It would be interesting to look 
at whether it has a similar effect on other Pol III target genes, such as 7SL and 
U6. Determining if it is a specific effect on some genes, or a global effect on Pol 
III-mediated transcription as a whole, would provide mechanistic insight. A 
specific effect would occur if JNK is acting through its targets at tRNA genes, for 
example c-Jun is only at a proportion of genes being transcribed by Pol III (Raha 
et al., 2010). However, if the Pol III machinery is targeted a more general effect 
would be expected.  
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Alternatively, reduced tRNA levels may be due to increased tRNA degradation. A 
specific tRNA degradation pathway has not been defined in humans, however, in 
yeast the rapid tRNA degradation (RTD) pathway contributes to tRNA levels 
(Wichtowska et al., 2013). However, the preliminary ChIP assays carried out 
indicate reduced Pol III at tRNA genes, suggesting that reduced tRNA levels are 
due to reduced expression (Figure 5.8). Pol III occupancy is considered to be a 
readout of active transcription. This coincides with reduced TFIIIB occupancy 
and increased histone H3 occupancy (Figure 5.8b, Figure 5.9). As nucleosomes 
are excluded from actively transcribed tRNA genes (White, 2002, Wang et al., 
2012), an increase in histone H3 is indicative of reduced tRNA gene activity. 
Given more time, nuclear run-on assays could be carried out in order to confirm 
that reduced tRNA levels are indeed the result of reduced transcription. 
During the short course of JNK inhibitor treatment reduced TFIIIB levels were not 
detected (see Figure 5.3). This suggests that JNK is regulating Pol III-mediated 
transcription by a mechanism independent of that published by Zhong and 
Johnson in 2009. However, it cannot be ruled out that JNK is regulating Pol III 
activity via alteration of the transcription and/or translation of another Pol II-
transcribed gene. Secondary effects such as this can usually be ruled out if the 
same treatment outcome occurs in the presence of a protein synthesis inhibitor. 
However, as Pol III products are central to protein synthesis, inhibiting protein 
synthesis could alter Pol III-mediated transcription by other routes. Given the 
high speed with which tRNA levels were reduced (15min), faster than target 
genes that are known to be directly regulated by JNK (c-Jun, TBP and Brf1), it is 
more likely that the reduction in tRNA transcription is a primary effect of JNK 
inhibition rather than a secondary effect resulting from changes in expression of 
other target genes. 
Anisomycin (188nM) results in increased expression of a tRNA reporter in mouse 
embryonic fibroblasts after 30 minutes of treatment (Zhong and Johnson, 2009). 
Preliminary experiments suggest 30 minutes treatment with anisomycin can also 
increase endogenous tRNA levels in U2OS (Figure 5.7c). This was not due to 
increased TFIIIB levels as TBP and Brf1 levels did not increase (Figure 5.7b). 
Zhong and Johnson did not examine TFIIIB levels following anisomycin 
treatment. However, they did find the increase in tRNA level was JNK 
dependent. It will be interesting to determine if this is also true in U2OS. 
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To investigate if JNK can mediate changes in TFIIIB levels in U2OS cells, a longer 
treatment with JNK inhibitor was carried out (Figure 5.4 and Figure 5.5). After 9 
hours, tRNA levels were repressed to a similar degree as that seen after one 
hour. However, while Bdp1 and TBP mRNA levels were reduced, Brf1 mRNA and 
TBP and Brf1 protein levels appeared to be the same as in the untreated cells. 
This suggests JNK may not be able to regulate their expression in U2OS cells. It 
would be interesting to investigate if Elk1 is found at TBP and Brf1 genes in 
U2OS, as Zhong et al. attribute JNK’s ability to regulate their expression to Elk1 
(Zhong and Johnson, 2009).  
 Multiple JNK-targeted transcription factors have been identified at Pol III-
transcribed genes, yet, for the majority of them, their function there remains an 
enigma (Raha et al., 2010, Oler et al., 2010). These targets are all 
transcriptionally activated by JNK, thus JNK inhibition should result in the 
reduced expression of their target genes. They, therefore, have the potential to 
cause the change seen in tRNA gene expression. As described in Chapter 4, c-Jun 
is one of these transcription factors. The preliminary data in Figure 5.10 suggests 
c-Jun may contribute to JNK-dependent regulation of tRNA expression. It is 
unclear whether c-Jun occupancy changes at tRNA genes in U2OS following 
SP600125 treatment, as ChIP assays did not give reproducible results (data not 
shown). However, p-c-Jun(Ser63/73) occupancy was reproducibly reduced 
following treatment (data not shown). Preliminary co-immunoprecipitation 
assays described in Chapter 4 suggest that c-Jun’s association with TFIIIC does 
not change following JNK inhibitor treatment (Figure 4.10). This suggests that c-
Jun may remain at tRNA genes and, if it regulates gene expression, 
phosphorylation of c-Jun rather than its occupancy may mediate this regulation.   
Though c-Jun has long been known to regulate the expression of the genes it 
binds at, the first detailed evidence for the mechanism by which this occurs was 
published by Aguilera et al. in 2011. They showed that, when bound at target 
genes, unphosphorylated c-Jun interacts with Mbd3, a component of the 
nucleosome remodelling and histone deacetylation (NuRD) complex (Aguilera et 
al., 2011). Mbd3 is required for the recruitment of the histone deacetylase, 
HDAC1, which can then deacetylate histones at the target gene resulting in 
reduced transcription. The preliminary ChIP in Figure 5.9 shows reduced HDAC1 
and HDAC2 occupancy at tRNA genes following JNK inhibition. This coincides 
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with a possible increase in unphosphorylated c-Jun occupancy, as suggested by 
the reduced phospho-c-Jun(Ser63/73) occupancy (data not shown) and 
unchanged association between c-Jun and TFIIIC (Figure 4.10). These 
observations support the possibility that tRNA genes might be regulated by the c-
Jun-dependent model described by Aguilera and colleagues. Further analysis, 
including examining the occupancy of Mbd3 at tRNA genes, should be carried 
out. Certainly, it has been shown that reduced histone acetylation is associated 
with reduced activity of Pol III target genes (Barski et al., 2010, Oler et al., 
2010). However, it is currently unclear if this is a cause of the reduced 
transcription or a consequence (White, 2011). 
An alternative route by which JNK may directly regulate tRNA expression is 
through the phosphorylation of the Pol III machinery. Phosphorylation of TFIIIB 
has been shown to alter its recruitment to Pol III target genes (Hu et al., 2004, 
Fairley et al., 2003, Felton-Edkins et al., 2003, Fairley et al., 2012). While JNK 
does not appear to contribute to phosphorylation of Brf1 at Thr145, this does not 
rule out the possibility that JNK phosphorylates another site on the Pol III 
machinery. This could be examined by a mass spectrometry approach. 
The identification of JNK at many protein-coding genes in ES cells highlighted a 
further route by which JNK can regulate gene expression (Tiwari et al., 2011). 
The majority of genes bound by JNK were characteristic of the JNK signalling 
response, encoding proteins involved, for example, in gene expression and the 
cell cycle. So JNK may potentially regulate many pathways via its activity on the 
chromatin. Using published ChIP-seq data from this study, we identified JNK at 
many tRNA genes in mouse embryonic stem (ES) cells, neural progenitor (NP) 
cells and terminally differentiated neurons (Figure 5.13). While Pol III-mediated 
transcription has not been followed through neuron differentiation, it has been 
examined in mouse ES cells (Carrière et al., 2012). Pol III occupancy was found 
at 284 of the 433 tRNA genes shown in the mouse genome (Genomic tRNA 
database). This suggests 66% of tRNA genes in ES cells are expressed. Preliminary 
ChIP data suggests JNK may be present at tRNA genes in U2OS (Figure 5.14a). 
JNK occupancy of tRNA genes in human cells is further supported by co-
immunoprecipitation experiments showing association of JNK with TFIIIC and TBP 
in HeLa nuclear extract (Figure 5.12). Given more time, it would be interesting 
to examine whether the Pol II genes bound by JNK in murine cells are also bound 
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by JNK in U2OS. Given the speed of sequencing, this may be most easily 
approached by further ChIP-seq experiments which would also provide a more 
global view of JNK at tRNA genes and other Pol III target genes in U2OS. 
How JNK is recruited to tRNA genes is unclear. In mouse ES cells, JNK occupancy 
at protein-coding genes was associated with occupancy of the transcription 
factor NF-Y at these genes (Tiwari et al., 2011). Tiwari and colleagues found 
that JNK-bound genes were enriched for the NF-Y binding motif CCAAT. We 
found no enrichment of CCAAT sites near tRNA genes in the human genome 
(Figure 5.14b). Though not enriched, 477 were identified 1kb up- and 
downstream of tRNAs in the human genome. Therefore, JNK may still be 
recruited to tRNA genes via this route. Alternatively, JNK could be recruited by 
another factor occupying Pol III target genes. 
 As JNK appears to bind at tRNA genes, this is a potential mechanism through 
which the reduction in tRNA expression following JNK inhibitor treatment could 
be mediated. SP600125 resulted in reduced expression of some JNK-occupied 
genes (Tiwari et al., 2011). This was associated with reduced phosphorylation of 
histone H3 at serine 10, a modification that can be mediated by JNK in vitro 
(Tiwari et al., 2011). Interestingly, preliminary data suggests phospho-histone 
H3Ser10 occupancy goes down at tRNA genes in U2OS following JNK inhibitor 
treatment (unlike H3 itself, which goes up) (Figure 5.9). In addition to its 
association with active gene expression, H3Ser10 phosphorylation is a mitotic 
marker (Sawicka and Seiser, 2012). SP600125 does not cause a visible change in 
cell cycle profile according to cell cycle analysis (Figure 5.15). However, given 
that the experiment was only carried out over 1 hour, further analysis is 
required to conclude whether this change in H3Ser10 phosphorylation is 
associated with reduced gene expression rather than a reduced number of cells 
in mitosis. Since carrying out these experiments, a study has been published 
showing phospho-H3Ser10 occupancy at Brf1, tRNALeu and 5S genes in mouse 
hepatocytes (Zhong et al., 2013a). This occupancy increases following treatment 
with the chemical carcinogen diethylnitrosamine (DEN) and contributes to the 
increase in Pol III-mediated transcription that is observed. The mechanism of 
this contribution remains undetermined. However, based on the data above and 
the observation that JNK activity contributes to DEN-induced tumour 
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carcinogenesis (Hui et al., 2008), JNK is a good candidate for the kinase involved 
in mediating the phosphorylation of Histone H3 that is observed.       
I have not examined if JNK can directly regulate tRNA transcription via 
phosphorylation of its other targets. JNK phosphorylation stabilises p53, thus JNK 
inhibition should result in reduced p53 levels (Buschmann et al., 2001). As p53 is 
a negative regulator of Pol III activity, this would be expected to result in 
increased tRNA levels (Chesnokov et al., 1996, Cairns and White, 1998). As this 
does not occur, p53 is unlikely to contribute to the reduced tRNA levels 
observed. However, STAT1, ATF2 and c-Myc all bind Pol III target genes and all 
exhibit increased transactivational activity upon JNK-mediated phosphorylation 
(Oler et al., 2010, Felton-Edkins et al., 2006, Raha et al., 2010). Interestingly, 
STAT1 occupies a large proportion of active tRNA genes in HeLa cells. Of 278 Pol 
III-occupied sites (of which 227 are tRNA genes) in these cells, 161 have STAT1 
bound in interferon-γ –induced HeLa cells (Oler et al., 2010, Rozowsky et al., 
2009). However, It remains to be determined if the increased transactivational 
activity of these JNK targets following JNK activation alters Pol III target gene 
expression. 
Small molecule kinase inhibitors are useful tools, however they can cause off-
target effects (Bain et al., 2003). The use of inhibitors was necessary for this 
study in order to examine tRNA levels independently of JNK-dependent changes 
in TFIIIB levels. SP600125 is the only JNK inhibitor used widely in the literature. 
Concentrations used range from 5-50μM (Mayer et al., 2005, Aguilera et al., 
2011), however non-specific inhibitory activity has been described at these 
concentrations (Bain et al., 2003, Fabian et al., 2005). An alternative JNK 
inhibitor, JNK-IN-8, became available during the course of this project (Zhang et 
al., 2012). Treatment with the recommended dose (for HEK293 cells), 1μM, did 
not result in the rapid reduction of tRNA levels seen with SP600125 treatment in 
U2OS cells (Figure 5.17). This was despite the fact that JNK appears to be 
inhibited, as determined by reduced p-JNK levels and a mobility shift in JNK. At 
higher JNK-IN-8 concentrations (20 μM), tRNA levels were reduced after 1 hour 
treatment. There are several possible reasons why 1μM JNK-IN-8 treatment does 
not result in same effect on tRNA levels as SP600125 and higher concentrations 
of JNK-IN-8. Firstly, a certain level of inhibition of JNK may be required to 
reduce tRNA levels and this is not met with 1μM JNK-IN-8. It would be interesting 
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to examine whether lower concentrations of SP600125 result in similar kinetics 
to 1μM JNK-IN-8 treatment, just as higher concentrations of JNK-IN-8 (20-30μM) 
result in a similar effect to 20μM SP600125. Secondly, only one set of tRNA 
primers has been used to examine tRNA levels following JNK-IN-8 treatment so 
far and this tRNA is unlikely to be representative of all tRNAs. Finally, SP600125 
and JNK-IN-8 may both be having off-target effects at 20μM and it is this 
unknown target that is reducing tRNA levels.  
The off-target effects of JNK inhibitors have been examined to some extent by 
kinase assays. Two studies of JNK-IN-8 suggest that this inhibitor inhibits JNKs 
specifically at 1μM when compared to all other kinases examined (Zhang et al., 
2012, International Centre for Kinase Profiling). The possible off-target effects 
of JNK-IN-8 at higher concentrations have not been examined. The inhibitory 
effect of SP600125 has been examined by kinase assay at 1μM and 10μM 
(International Centre for Kinase Profiling, Bain et al., 2003). At both 
concentrations, the activity of multiple kinases (in addition to JNKs) was 
inhibited by 50% or more. I examined the published literature on these kinases to 
see if they might account for the changes in tRNA levels and other effects I had 
observed upon SP600125 treatment. While no particular kinase stood out as the 
most likely candidate, several possible candidates were present. In both studies, 
CK1 was inhibited more than JNK itself. While CK1 has not been shown to 
regulate Pol III-mediated transcription, a putative phosphorylation target site for 
CK1 has been identified on Maf1 using prediction software (Rollins et al., 2007). 
Maf1 is a repressor of Pol III-mediated transcription and phosphorylation of Maf1 
prevents this repressive activity (Moir and Willis, 2013). If CK1 could 
phosphorylate Maf1, inhibition of CK1 by SP600125 would result in reduced Maf1 
phosphorylation and could account to the decrease in tRNA levels seen. Another 
kinase inhibited to a greater degree than JNK was Aurora B (International Centre 
for Kinase Profiling). While a role for Aurora B in regulating Pol III-mediated 
transcription is undetermined, inhibition of this kinase could account for the 
decrease in phospho-Histone H3(Ser10) that was observed upon SP600125 
treatment (Figure 5.9), as Aurora B can phosphorylate this site (Goto et al., 
2002).  AMPK and DYRK2 were also inhibited to a greater degree than JNK 
according to kinase assays (Bain et al., 2003, International Centre for Kinase 
Profiling). These kinases both have the potential to regulate Pol III-mediated 
Chapter 5: Regulation of Pol III-mediated transcription by JNKs   
134 
 
transcription indirectly, AMPK through the upregulation of Maf1 activity by 
inhibiting mTORC1 and DYRK2 through the negative regulation of c-Jun and c-
Myc (Gwinn et al., 2008, Taira et al., 2012). These kinases can therefore be 
described as negative regulators of Pol III-mediated transcription and their 
inhibition by SP600125 would likely result in an increase rather than a decrease 
of tRNA levels. Thus, they are unlikely to account for the outcome of SP600125 
treatment observed. CK2 and ERK can both positively regulate Pol III-mediated 
transcription through the phosphorylation of TFIIIB (Johnston et al., 2002, 
Felton-Edkins et al., 2003). These kinases are not inhibited to the same degree 
as JNK upon SP600125 treatment, however 10μM SP600125 does reduce their 
activity to 55-65% of the control treatment (Bain et al., 2003). It is therefore 
possible that inhibition of either of these kinases could account for the reduced 
tRNA levels and Pol III recruitment at tRNA genes that was observed upon 
treatment with 20μM SP600125 in U2OS (Figure 5.1, Figure 5.8). Clearly further 
examination is required to determine the kinase responsible for reduced Pol III-
mediated transcription observed upon SP600125 treatment. Carrying out the 
treatment in JNK1/JNK2 double null cells would confirm whether JNK inhibition 
was required.  
A reductionist approach using in vitro experiments may prove very useful for 
examining the various possibilities described in this chapter. Such techniques 
were not originally considered as they have been overshadowed by new 
technologies and have been criticised for their ‘non-physiological’ conditions. 
For example, in in vitro transcription (IVT) assays genes are not in their normal 
chromosome environment and it has become apparent that the regulation of a 
gene is often influenced by the surrounding chromatin. However, benefits 
include the ability to control the environment. For example, using IVT, the 
ability of JNK targets to regulate Pol III-mediated transcription could be 
examined without possible JNK-induced changes in TFIIIB levels. JNK occupancy 
at tRNA genes and the potential phosphorylation of the Pol III machinery could 
also be examined using in vitro approaches. 
As described above, several observations point to the possibility that JNK can 
regulate Pol III-mediated transcription by a mechanism independent of its ability 
to modulate TFIIIB subunit expression. In this chapter, I have demonstrated that 
JNK inhibitor treatment can result in a dramatic reduction in tRNA levels and 
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this appears to be mediated by reduced transcription of the tRNA genes. It will 
be interesting to examine whether this observation is also applicable at other 
Pol III target genes. Multiple routes by which JNK may modulate tRNA expression 
have been identified and examined (Figure 5.18). JNK-mediated upregulation of 
Pol III-mediated transcription could contribute to the cell’s response to 
mitogenic stimuli, as Pol III products are required for growth and proliferation. 
As JNK also has an important role in mediating the response of a cell to stress, it 
may also be able to contribute to repression of Pol III-mediated transcription 
that is frequently observed following stress. These contrasting effects could 
arise from differences between JNK1 and JNK2 activity. Indeed, it has been 
demonstrated that JNK1 and JNK2 have opposing effects on the regulation of 
TFIIIB subunit expression (Zhong et al., 2007, Zhong and Johnson, 2009). 
Undoubtedly, the role of the JNK family in the regulation of Pol III-mediated 
transcription warrants further examination.  
 
Figure 5.18 Model for regulation of Pol III-mediated transcription by JNK 
JNK has been shown to regulate Pol III-mediated transcription indirectly by modulating 
the expression of TFIIIB subunits, TBP and Brf1, in (Zhong and Johnson, 2009) (on blue 
background). Possible routes of direct regulation by JNK include (a) the phosphorylation 
of a component of the Pol III machinery, altering its recruitment to/activity at Pol III 
target gene, (b) direct binding of JNK to Pol III target genes and modification of 
chromatin, altering gene environment and (c) phosphorylation of a JNK substrate that 
has been identified to bind at Pol III target genes, such as c-Jun or Elk1.  
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6 Final Discussion 
Transcription by RNA Polymerase III in humans is subject to regulation by many 
factors including p53, RB, c-Myc, ERK, Maf1, CK2 and JNKs (Chesnokov et al., 
1996, Cairns and White, 1998, White et al., 1996, Gomez-Roman et al., 2003, 
Felton-Edkins et al., 2003, Reina et al., 2006, Ghavidel and Schultz, 2001, 
Johnston et al., 2002, Zhong and Johnson, 2009). These factors share the 
common feature of being regulated in response to stress and nutrient 
availability, times when the cell undergoes changes in proliferation rate. Having 
multiple regulators advocates the importance of the regulation of Pol III-
mediated transcription in response to the cell’s environment. Pol III produces 5S 
rRNA and tRNAs, essential components of the translation machinery. Other Pol III 
products essential for cellular function include U6 snRNA, which is required for 
mRNA splicing, H1, which facilitates the processing of the 5’ end of pre-tRNAs, 
and MRP RNA, which is essential for rRNA processing. These RNAs share a 
common purpose: they are all essential for protein synthesis and, as a 
consequence, cell growth. In order to maintain cellular size and use energy 
efficiently, cell growth is tightly regulated in response to the proliferation state 
of the cell. Tight regulation of Pol III-mediated transcription is part of this cell 
growth regulation. 
In this thesis, the contribution of p53, AP-1 and JNKs to the regulation of Pol III-
mediated transcription has been examined.  In Chapter Three, it is 
demonstrated that repression of Pol III activity is not a universal response to p53 
induction. Indeed, doxorubicin treatment results in a robust induction of p53 
and, independently of p53, a significant repression of Pol III-mediated 
transcription. In light of the published literature, this suggests that p53 may only 
repress Pol III-mediated transcription in response to oncogenic stress, when p53 
is induced by ARF (Morton et al., 2007). In Chapter Four, the occupancy of c-Jun 
and c-Fos, which together constitute a form of the transcription factor AP-1, at 
tRNA genes is shown to be associated with occupancy of Pol III, suggesting they 
may positively regulate Pol III-mediated transcription. c-Jun N-terminal kinases 
(JNKs) are key regulators of c-Jun, inducing c-Jun transactivational activity by 
phosphorylation of its transactivation domain. In Chapter 5, JNK is demonstrated 
to be able to regulate the transcription of Pol III target genes independently of 
its previously published ability to regulate TFIIIB expression (Zhong and Johnson, 
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2009). Various potential routes by which this may occur are identified. JNK 
occupies multiple tRNA genes and may regulate tRNA expression by the 
phosphorylation of the Pol III pre-initiation complex or by modifying the 
chromatin environment, making it more conducive to transcription. In addition, 
it could regulate tRNA expression through phosphorylation of c-Jun or one of 
several other JNK targets that occupy tRNA genes.  
This study highlights the multiple levels at which Pol III-mediated transcription is 
regulated. JNKs regulate the expression of TFIIIB subunits, altering the level of 
Pol III machinery available (Zhong and Johnson, 2009). p53 alters Pol III-specific 
transcription factor availability by an alternative route; sequestering TFIIIB away 
from Pol III target genes (Cairns and White, 1998, Crighton et al., 2003). ERK, a 
MAPK family member like JNK, phosphorylates TFIIIB, promoting the recruitment 
of TFIIIB to the target promoter (Felton-Edkins et al., 2003). The binding of 
regulators at Pol III target genes, where they can repress or promote Pol III 
activity, is a further mechanism of regulation. The association of c-Jun and c-Fos 
with active tRNA genes suggests they may contribute to regulation at this level. 
These different levels of regulation are represented diagrammatically in Figure 
6.1. Further routes of regulation that may also influence the quantity of Pol III 
products in the cell include regulating the stability and degradation of Pol III 
machinery at the mRNA and protein level and of the Pol III products themselves. 
The regulation of Pol III-mediated transcription will also include feedback loops. 
For example, 5S rRNA can regulate p53 activity (Donati et al., 2013). 
Interestingly, a single regulator can act at multiple levels of regulation. For 
example, c-Myc regulates Brf1 expression and also recruits histone 
acetyltransferase activity to enhance Pol III recruitment to target genes (Gomez-
Roman et al., 2003, Kenneth et al., 2007). In Chapter Five, it is demonstrated 
that JNK, also, may act at multiple levels. Multiple levels of regulation ensure 
that the levels of Pol III products in the cell can be regulated rapidly and then 
maintained over a longer period of time if required. They also ensure that the 
cell makes efficient use of resources and they allow the integration of signals 
from multiple signalling pathways. The amount of tRNA, 5S rRNA and the other 
Pol III products in the cell is the outcome of the combination of these multiple 
regulatory routes.  
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Figure 6.1  The multiple levels of regulation of Pol III-mediated transcription 
The diagram above represents some of the routes by which Pol III-mediated 
transcription can be regulated. These are divided into three groups: a) the regulation of 
expression of the Pol III-specific transcription factors TFIIIB and TFIIIC (encoded by Pol 
II-transcribed genes), b) modification, sequestration and degradation of Pol III-specific 
transcription factors and c) regulator binding at Pol III target genes and altering 
expression by promoting/inhibiting recruitment of Pol III-specific transcription factors or 
modification of chromatin environment. TF = transcription factor. Feedback loops and 
the regulation of mRNA for Pol III-TF subunits may also contribute to Pol III-mediated 
transcription. 
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The regulation of tRNA expression has been the main focus of this thesis, 
primarily because tRNAs are the subject of most studies exploring the role of 
p53, AP-1 and JNK on Pol III-mediated transcription in human cells (Crighton et 
al., 2003, Morton et al., 2007, Zhong and Johnson, 2009, Zhong et al., 2011, 
Zhong et al., 2013b). However, as noted above, Pol III-mediated transcription 
produces many other non-coding RNAs that are equally important for cellular 
function (Dieci et al., 2007). A degree of coordination is expected between the 
regulation of all genes transcribed by Pol III as many Pol III regulators target the 
Pol III-specific transcription factors (Marshall and White, 2008). This will have a 
global impact on the formation of pre-initiation complexes at Pol III target genes 
(White, 2008). However, recent genome-wide studies of transcription factor 
binding have identified Pol II-associated transcription factors, including c-Jun, c-
Fos, STAT1, c-Myc and Ets1, at Pol III target genes in human cells (Raha et al., 
2010, Oler et al., 2010). These have the potential to contribute to the 
expression of the genes they occupy and, as they are only present at a 
proportion of Pol III-bound genes, may contribute to differential expression of 
Pol III target genes (Dittmar et al., 2006, White, 2011). By employing RNA-seq 
analysis, future studies will gain a more global view of Pol III product levels and 
how these change in different cellular contexts. In combination with ChIP-seq 
analysis, this will contribute significantly to our understanding of the regulation 
of Pol III-mediated transcription. 
Several known regulators of Pol III-mediated transcription can also regulate Pol I-
mediated transcription, including RB, c-Myc and p53  [reviewed in (White, 
2008)]. Coordinated regulation is beneficial to the cell as 45S rRNA and 5S rRNA 
are required in equimolar quantities for ribosome biogenesis (Phillips and 
McConkey, 1976). p53 represses Pol III-mediated transcription by binding to 
TFIIIB and sequestering it away from Pol III target genes (Chesnokov et al., 1996, 
Cairns and White, 1998, Crighton et al., 2003). Similarly, p53 represses Pol I-
mediated transcription by binding to SL1 (like TFIIIB, the TBP-containing 
transcription factor) and preventing its recruitment to the promoter of the rRNA 
gene (Zhai and Comai, 2000). JNK2 can phosphorylate TIF-IA, impairing TIF-IA’s 
recruitment to rRNA genes where it is required to promote Pol I recruitment 
(Mayer et al., 2005). JNKs may also directly regulate Pol III-mediated 
transcription, as demonstrated in Chapter Five, and indirect regulation has 
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already been shown (Zhong and Johnson, 2009). JNK2 has a negative effect on 
TFIIIB subunit expression (Zhong and Johnson, 2009). Conversely, JNK1 can 
positively regulate TFIIIB expression (Zhong and Johnson, 2009). As JNK2 has a 
negative effect on both Pol I and Pol III activity, it will be interesting to examine 
if JNK1 has a positive effect on Pol I-mediated transcription. JNKs are activated 
by both mitogens and stress stimuli and the differences in the activity of JNK1 
and JNK2 could contribute to the altered levels of Pol III and Pol I activity that 
occur following these stimuli (increased following mitogenic stimuli and 
decreased following stress).  As demonstrated in Chapter Four, the binding of c-
Jun and c-Fos at active Pol III target genes indicates that they may have a 
positive influence of Pol III-mediated transcription. Whether they can regulate 
Pol I-mediated transcription has not been shown. However, c-Jun contributes 
directly to rRNA processing by binding to the RNA helicase DDX21 and promoting 
its translocation to the nucleolus, the site of Pol I-mediated transcription and 
rRNA processing  (Holmström et al., 2008). Exploring the coordinated regulation 
of Pol I- and Pol III-mediated transcription will provide further insight into the 
control of ribosome biogenesis and cell growth. 
The regulation of Pol III-mediated transcription by oncogenes and tumour-
suppressor proteins has been the subject of intense study over the past decade. 
Pol III products and Pol III-specific transcription factors have been found 
upregulated in many tumours compared to untransformed tissue (Winter et al., 
2000, Chen et al., 1997, Zhao et al., 2004, Hong et al., 2010).  Higher levels of 
protein synthesis are required to sustain the increased growth and proliferation 
of a cancer cell. However, it remains to be determined if Pol III product 
overexpression has transformation potential. p53, AP-1 and JNK all have the 
potential to contribute to the increased Pol III-mediated transcription observed 
in tumours. Wild type tumour suppressor function of p53 is estimated to be lost 
in over 80% of human tumours (Lozano and Elledge, 2000). Several common 
cancer-derived mutants of p53 can no longer repress Pol III-mediated 
transcription in vitro (Stein et al., 2002a). On the other hand, AP-1 and JNK both 
have pro-tumorigenic activity, contributing to tumour development in a variety 
of tissues (see Sections 1.6.3 and 1.7.3). It will be interesting to examine 
whether their association with active Pol III-mediated transcription may be a 
factor of this contribution.     
Chapter 6: Final Discussion   
141 
 
In conclusion, it is evident that many pathways converge to regulate Pol III-
mediated transcription in mammalian cells. This ensures that cellular levels of 
Pol III products meet the cell’s requirements, while efficiency is maintained.  In 
this thesis, I have demonstrated that p53 contributes to the regulation of Pol III-
mediated transcription in a stress-specific manner. I also show that AP-1 and JNK 
both have the potential to directly activate Pol III-mediated transcription. This is 
in accord with their known pro-proliferative functions, as cell growth is a 
prerequisite for successful proliferation. In particular, this thesis demonstrates 
the complexity of the regulation of Pol III-mediated transcription and highlights 
many directions for future study. 
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